[
    {
        "study_id": 1,
        "nct_id": "NCT01706250",
        "studyTitle": "U0289-401: An Evaluator Blinded, 8 Week, Split-Face Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and PROACTIV in Subjects with Acne",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Acne Vulgaris"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3,
        "nct_id": "NCT01381536",
        "studyTitle": "GSK1550188, A randomised, single-blind, placebo controlled, dose ascending, single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic of GSK1550188 in Japanese subjects with Systemic Lupus Erythematosus (SLE)",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Systemic Lupus Erythematosus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4,
        "nct_id": "NCT00688519",
        "studyTitle": "A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety and Efficacy of Emulsion Formulation U0267, versus Vehicle in Subjects with Plaque-type Psoriasis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Psoriasis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 8,
        "nct_id": "NCT01015638",
        "studyTitle": "Two-week Study to Determine and Compare the Tolerance and Irritation Potential of Duac\u00ae Topical Gel (clindamycin 1% and benzoyl peroxide 5%) to ACANYA\u2122 Gel (clindamycin phosphate 1.2% and benzoyl peroxide 2.5%) Topical Acne Medications",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Acne Vulgaris"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 9,
        "nct_id": "NCT00964223",
        "studyTitle": "A single-blind, randomized, comparative split-face study evaluating the tolerability of clindamycin and benzoyl peroxide gel to benzoyl peroxide/adapalene gel in the treatment of acne vulgaris.",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Acne Vulgaris"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 10,
        "nct_id": "NCT01016977",
        "studyTitle": "A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of Tazorac Cream when used in Combination with Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Acne Vulgaris"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 11,
        "nct_id": "NCT00776919",
        "studyTitle": "A Phase 3 Multicenter, Randomized, Double-Blind, Active And Vehicle-Controlled Study Of The Safety And Efficacy Of A Clindamycin / Benzoyl Peroxide Gel Versus Clindamycin Gel Versus Benzoyl Peroxide Gel Versus Vehicle Gel In Subjects With Acne Vulgaris",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Acne Vulgaris"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 12,
        "nct_id": "NCT01139580",
        "studyTitle": "A Multicenter, Randomized, Double-Blind Study of the Safety and Efficacy of Calcipotriene Foam, 0.005%, Versus Vehicle Foam In The Treatment Of Moderate Plaque-Type Scalp And Body Psoriasis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Psoriasis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 13,
        "nct_id": "NCT00508365",
        "studyTitle": "A study to evaluate the potential incidence of orthostatic hypotension in elderly hypertensive patients following administration of a combination of carvedilol CR and lisinopril",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Hypertension"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 14,
        "nct_id": "NCT00624065",
        "studyTitle": "COR111096, A Randomized, Double-Blind, Active-Controlled, Parallel Group, Multicenter Study Comparing the Proportion of Subjects with Stage 1 or 2 Essential Hypertension Who Achieve Target Blood Pressure While Receiving Either carvedilol CR + lisinopril or lisinopril Monotherapy",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hypertension"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16,
        "nct_id": "NCT00440128",
        "studyTitle": "A Phase I, Open-Label, Randomized, Two Period Crossover Study to Investigate the Effects of GW679769 on the Pharmacokinetics of Docetaxel in Subjects with Cancer",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Nausea and Vomiting",
            "Chemotherapy-Induced"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19,
        "nct_id": "NCT00887484",
        "studyTitle": "A single-blind, randomized, comparative pilot study evaluating the tolerability of two topical combination therapies in the treatment of acne vulgaris",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Acne Vulgaris"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20,
        "nct_id": "NCT01323673",
        "studyTitle": "Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Dermatitis",
            "Chronic"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 33,
        "nct_id": "NCT00682643",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110mcg in Adults and Adolescents 12 Years of Age and Older with Perennial Allergic Rhinitis",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Rhinitis",
            "Allergic",
            "Perennial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 34,
        "nct_id": "NCT00730756",
        "studyTitle": "A Pilot, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of Once-daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110 mcg for 4 Weeks in Adults and Adolescents with Irritant (Non-Allergic) Rhinitis",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Rhinitis",
            "Allergic",
            "Perennial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 35,
        "nct_id": "NCT00539006",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone Propionate Nasal Spray in Adult Subjects with Seasonal Allergic Rhinitis",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Rhinitis",
            "Allergic",
            "Perennial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 36,
        "nct_id": "NCT00519636",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone Propionate Nasal Spray in Adult Subjects with Seasonal Allergic Rhinitis",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Rhinitis",
            "Allergic",
            "Perennial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 37,
        "nct_id": "NCT00502775",
        "studyTitle": "A Comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the treatment of seasonal allergic rhinitis",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Rhinitis",
            "Allergic",
            "Seasonal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 39,
        "nct_id": "NCT00848965",
        "studyTitle": "A randomised, double-blind, placebo-controlled, 4-period, incomplete block, crossover study to assess the dose-response curve of intranasal fluticasone propionate (25, 50, 100 and 200 g, once daily for 8 days) in the Vienna Challenge Chamber for the purpose of investigating the sensitivity of the model when evaluating glucocorticosteroids",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Rhinitis",
            "Allergic",
            "Perennial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 40,
        "nct_id": "NCT00452699",
        "studyTitle": "A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects with Asthma",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 41,
        "nct_id": "NCT00452348",
        "studyTitle": "A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects with Asthma",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 42,
        "nct_id": "NCT01192178",
        "studyTitle": "A Randomized, Double-Blind, Parallel Group study of ADVAIR\u2122 DISKUS\u2122 100/50 and FLOVENT\u2122DISKUS\u2122 100, both twice daily, in a Pediatric Population during the Fall Viral Season.",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 43,
        "nct_id": "NCT00784550",
        "studyTitle": "A Randomized, Double-Blind, Parallel-Group, 24-Week Study to Evaluate the Efficacy and Safety of ADVAIR DISKUS (Fluticasone Propionate/Salmeterol Combination Product 250/50mcg Inhalation Powder) BID Plus Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder 18mcg) QD Versus Spiriva QD Plus Placebo DISKUS BID in Subjects with Chronic Obstructive Pulmonary Disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 44,
        "nct_id": "NCT00633217",
        "studyTitle": "A Randomized, Double-Blind, Double-Dummy, Parallel Group 12-Week Comparison of the Efficacy and Safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg twice-daily with Fluticasone Propionate/Salmeterol DISKUS 250/50mcg twice-daily in subjects with COPD",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 45,
        "nct_id": "NCT00857766",
        "studyTitle": "A Randomized, Double-Blind, Parallel-Group, 16-Week Study to Evaluate the Effect of Fluticasone Propionate/Salmeterol DISKUS\u00ae 250/50mcg BID and Placebo on Arterial Stiffness in Subjects with Chronic Obstructive Pulmonary Disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 46,
        "nct_id": "NCT01124422",
        "studyTitle": "A study of fluticasone propionate/salmeterol DISKUS combination product 250/50 mcg twice daily plus tiotropium 18 mcg daily versus placebo DISKUS twice daily plus tiotropium 18 mcg daily on exercise time and physiological parameters in subjects with Chronic Obstructive Pulmonary Disease",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 49,
        "nct_id": "NCT00981409",
        "studyTitle": "Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Pulmonary Thromboembolism (PE)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Embolism",
            "Pulmonary"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 50,
        "nct_id": "NCT00911157",
        "studyTitle": "Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Deep Vein Thrombosis (DVT)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Thrombosis",
            "Venous"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 53,
        "nct_id": "NCT00579982",
        "studyTitle": "An Open-Label Trial Measuring Satisfaction and Convenience of Two Formulations of Lamotrigine in Subjects with a Mood Disorder",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Mood Disorders"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 54,
        "nct_id": "NCT00516139",
        "studyTitle": "Lamotrigine Extended-Release in Elderly Patients with Epilepsy",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Epilepsy"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 55,
        "nct_id": "NCT00550407",
        "studyTitle": "Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Bipolar Disorder"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 56,
        "nct_id": "NCT00566020",
        "studyTitle": "Study SCA106052, a clinical evaluation of BW430C (lamotrigine) in bipolar I disorder\u2013 Long-term extension study (extension of study SCA104779 (NCT00550407))",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Bipolar Disorder"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 74,
        "nct_id": "NCT00435045",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Forced Titration Study to Assess the Efficacy and Safety of Omacor, Co-Administered with Open-Label Atorvastatin Therapy, in Hypertriglyceridemic Subjects",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hypertriglyceridemia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 82,
        "nct_id": "NCT00812812",
        "studyTitle": "A randomised, double-blind, placebo controlled, parallel group , flexible dose study to evaluate the efficacy and safety of Paxil\u00ae Tablets in children and adolescents with Major Depressive Disorder<Post-marketing clinical study>",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Depressive Disorder"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 101,
        "nct_id": "NCT00539994",
        "studyTitle": "Randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of Retapamulin ointment, 1% applied twice daily for 3 or 5 days to the anterior nares of healthy adult subjects nasally colonized with Staphylococcus aureus",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Bacterial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 103,
        "nct_id": "NCT00684177",
        "studyTitle": "A Randomized, Double-Blind, Multicenter, Placebo-controlled, Phase III Superiority Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adult and Pediatric Subjects with SITL",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Skin Infections",
            "Bacterial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 104,
        "nct_id": "NCT00852540",
        "studyTitle": "A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus aureus",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Skin Infections",
            "Bacterial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 105,
        "nct_id": "NCT01480609",
        "studyTitle": "An open label, single-dose, fixed sequence, two treatment period study to assess the effect of haemodialysis on the pharmacokinetics of ezogabine/retigabine and the n-acetyl metabolite of ezogabine/retigabine (NAMR).",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Epilepsy"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 110,
        "nct_id": "NCT00823836",
        "studyTitle": "Clinical Evaluation of ropinirole PR/XR Tablet for Adjunctive Therapy to L-dopa in subjects with advanced Parkinson\u2019s disease",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Parkinson Disease"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 112,
        "nct_id": "NCT00996944",
        "studyTitle": "Clinical evaluation of ropinirole IR (immediate release) tablets in patients who are diagnosed with symptomatic restless legs syndrome (RLS) associated with Chronic kidney disease (CKD) managed with haemodialysis (including haemofiltration and haemodiafiltration)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Restless Legs Syndrome"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 113,
        "nct_id": "NCT00530790",
        "studyTitle": "Clinical Evaluation of Ropinirole CR-RLS Tablets in Restless Legs Syndrome-Open-Label, Uncontrolled Study. Classification: Clinical Pharmacology, Exploratory",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Restless Legs Syndrome"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 121,
        "nct_id": "NCT01812408",
        "studyTitle": "A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET\u00ae (Sumatriptan + Naproxen Sodium) vs. Butalbital-containing Combination Medications for the Acute Treatment of Migraine when administered during the Moderate-Severe Migraine Pain, 1 of 2",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Migraine Disorders"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 122,
        "nct_id": "NCT00599157",
        "studyTitle": "A Crossover, Randomized, Double-blind, Double-dummy, Placebo-controlled Study to Evaluate the Efficacy of TREXIMET\u00ae/Sumatriptan + Naproxen Sodium vs. Butalbital-containing Combination Medications for the Acute Treatment of Migraine when administered during Moderate-Severe Migraine Pain, 2 of 2",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Migraine Disorders"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 123,
        "nct_id": "NCT00792636",
        "studyTitle": "Assessment of the effect of sumatriptan and naproxen sodium combination tablet, sumatriptan tablet, and naproxen sodium tablet treatment on blood pressure when administered intermittently for six months for the acute treatment of migraine attacks, with or without aura, in adults",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Migraine Disorders"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 124,
        "nct_id": "NCT01017146",
        "studyTitle": "A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects with Acne Vulgaris",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Acne Vulgaris"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 125,
        "nct_id": "NCT01017120",
        "studyTitle": "A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects with Acne Vulgaris",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Acne Vulgaris"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 132,
        "nct_id": "NCT00492544",
        "studyTitle": "Evaluation of the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV vaccine 580299 when administered as a 3-dose schedule in healthy Japanese pre-adolescent and adolescent female subjects.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 141,
        "nct_id": "NCT00473668",
        "studyTitle": "Non-inferiority of one formulation of GSK Biologicals' DTPw-HBV/Hib to 2 formulations of GSK Biologicals' DTPw-HBV/Hib with respect to the immune response to the PRP antigen, when administered to healthy infants at 6, 10, 14 weeks of age",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 146,
        "nct_id": "NCT00406562",
        "studyTitle": "Open, booster vaccination study to assess safety and reactogenicity of GSK Biologicals\u2019 dTpa vaccine (Boostrix) when administered to healthy chinese children 6-8 years of age.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Acellular pertussis; Diphtheria; Tetanus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 148,
        "nct_id": "NCT00548171",
        "studyTitle": "Evaluation of GSK Biologicals\u2019 dTpa booster vaccine in adults, given 10 years after previous dTpa boosting.",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Acellular pertussis; Diphtheria; Tetanus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 150,
        "nct_id": "NCT00835237",
        "studyTitle": "Evaluation of GSK Biologicals\u2019 Boostrix\u00ae vaccine when compared with Decavac\u2122 in adults aged 65 years or older.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Acellular pertussis; Diphtheria; Tetanus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 153,
        "nct_id": "NCT00412854",
        "studyTitle": "Phase IIIb, multicentre study to assess safety & immunogenicity of GSK Biologicals\u2019 combined DTPa/Hib (Infanrix/Hib) vaccine vs separate administration of DTPa (Infanrix) & Hib (Hiberix) vaccines in healthy infants 3,4,&5 months of age as compared with the separate administration of DTPa and Hib vaccines at different injection sites.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Acellular pertussis; Diphtheria; Tetanus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 157,
        "nct_id": "NCT00693706",
        "studyTitle": "Safety and immunogenicity study of GSK Biologicals\u2019 cell culture-based influenza virus vaccine 1388442A compared with US licensed TIV in healthy adults",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 158,
        "nct_id": "NCT00771615",
        "studyTitle": "A trial to evaluate the safety & immunogenicity of investigational influenza vaccine GSK1557484A in adults 18-64 yrs of age",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 161,
        "nct_id": "NCT01114620",
        "studyTitle": "Immunogenicity and safety study of GSK Biologicals\u2019 influenza vaccine Arepanrix\u2122 (GSK2340274A) in adults 65 years of age or older",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 162,
        "nct_id": "NCT00985088",
        "studyTitle": "A study to evaluate the safety and immunogenicity of A/California/7/2009 (H1N1)v-like vaccines GSK2340273A and GSK2340274A in adults aged 18 years and older",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 166,
        "nct_id": "NCT00979602",
        "studyTitle": "A study to evaluate the safety, immunogenicity, and relative efficacy of A/California/7/2009 (H1N1)v-like vaccines GSK2340274A and GSK2340273A in adults aged 18 years and older",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 167,
        "nct_id": "NCT01059617",
        "studyTitle": "A study to evaluate immune responses following A/California/7/2009 (H1N1)v-like virus vaccination given 4 months following seasonal influenza vaccination in adults 19 to 40 years of age",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 168,
        "nct_id": "NCT00989612",
        "studyTitle": "Immunogenicity and safety study of GSK Biologicals\u2019 influenza candidate vaccine GSK2340274A",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 172,
        "nct_id": "NCT00985673",
        "studyTitle": "A study to evaluate the safety and immunogenicity of an A/California/7/2009 (H1N1)v-like vaccine GSK2340274A or GSK2340273A co-administered with trivalent inactivated seasonal influenza vaccine in adults 19 to 40 years of age.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 180,
        "nct_id": "NCT01001169",
        "studyTitle": "Safety and immunogenicity study of GSK Biologicals\u2019 pandemic influenza (H1N1) candidate vaccine (GSK2340274A) in Japanese children aged 6 months to 17 years",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 186,
        "nct_id": "NCT00449670",
        "studyTitle": "Assess the consistency of the immunogenicity of a GlaxoSmithKline Biologicals' pandemic influenza vaccine (GSK1562902A) in adults aged between 18 and 60 years",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 187,
        "nct_id": "NCT00616928",
        "studyTitle": "A trial to evaluate the safety and immunogenicity of an investigational vaccination regimen in adults aged \u226518 years",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 188,
        "nct_id": "NCT00719043",
        "studyTitle": "A trial to evaluate the safety and immunogenicity of monovalent H5N1 vaccine in adults >=18 yrs of age",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 189,
        "nct_id": "NCT00742885",
        "studyTitle": "Immunogenicity and safety of GSK Biologicals\u2019 (pre-) pandemic influenza candidate vaccine GSK 1557484A.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 191,
        "nct_id": "NCT00510874",
        "studyTitle": "A Phase I/II, Observer-Blind, Randomized, Active-Controlled Trial to Evaluate the Safety and Immunogenicity of a Two-Dose Series of GSK Biologicals' Candidate Influenza Vaccine GSK 1557484A Antigens With or Without Adjuvant",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 192,
        "nct_id": "NCT00652743",
        "studyTitle": "Immunogenicity of GSK Biologicals\u2019 pandemic influenza vaccine (GSK1562902A) at different boosting vaccination schedules",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 193,
        "nct_id": "NCT00695669",
        "studyTitle": "A trial to evaluate the immunogenicity of accelerated primary vaccination with monovalent A/Indonesia/5/05 (H5N1) vaccine antigen in association with AS03 adjuvant in adults aged 18-64.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 194,
        "nct_id": "NCT00812981",
        "studyTitle": "Non-inferiority study of GSK Biologicals\u2019 Pandemic influenza vaccine 1562902A.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 198,
        "nct_id": "NCT00456625",
        "studyTitle": "To Evaluate Immune Response to a Hepatitis B Vaccine (Engerix\u2122-B ) Challenge Dose in Healthy Subjects Who Received GSK Biologicals' Hepatitis B Vaccine (Engerix\u2122-B ) Approximately 20 Years Ago as Primary Vaccination at 0, 1, 2 and 12 Months.",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 203,
        "nct_id": "NCT00485732",
        "studyTitle": "A phase IIIb, double-blind, randomized, controlled study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals\u2019 HPV-16/18 L1 VLP AS04 vaccine, administered intramuscularly in healthy female subjects aged 15 \u2013 25 years",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 204,
        "nct_id": "NCT00549900",
        "studyTitle": "Safety and immunogenicity study of the HPV vaccine (GSK-580299) in healthy, Chinese, female subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 206,
        "nct_id": "NCT00423046",
        "studyTitle": "Phase IIIb, Observer-blind Study to Compare Immunogenicity of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Versus Gardasil\u00ae [Quadrivalent Human Papillomavirus (HPV-6,11,16,18 L1 VLP) Recombinant Vaccine Merck & Co., Inc.]",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 208,
        "nct_id": "NCT00546078",
        "studyTitle": "Safety and immunogenicity study of an additional dose of HPV vaccine (580299) in young, adult women in North America.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 212,
        "nct_id": "NCT00811798",
        "studyTitle": "Safety study of GSK Biologicals\u2019 human papillomavirus vaccine (GSK-580299) in healthy female subjects.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 233,
        "nct_id": "NCT00505453",
        "studyTitle": "A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral\u00ae Trivalent Split Virion Influenza Vaccine (2007 \u2013 2008 Season) in Adults Ranging in Age from 18 to 60 Years and 61 Years and Over",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 234,
        "nct_id": "NCT00718120",
        "studyTitle": "Immunogenicity and safety study of a single injection of GSK Biologicals' Trivalent Split virion Influenza vaccine Fluviral\u00ae (2008 - 2009 Season) in adults aged 18 to 60 years and over 60 years.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 235,
        "nct_id": "NCT01153685",
        "studyTitle": "Immunogenicity and safety study of GSK Biologicals\u2019 (GSK1536489A) Trivalent Split Virion Influenza Vaccine Fluviral\u00ae (2010 - 2011 Season) in adults aged 18 to 60 years and over 60 years.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 236,
        "nct_id": "NCT00586469",
        "studyTitle": "Observer-blind, Post-Marketing Study to Compare the Safety and Immunogenicity of Fluviral\u00ae Trivalent Split Virion Influenza Vaccine (2007-2008 Season) Made With New vs. Aged Bulk Material, in Adults Ranging in Age from 18 to 60 Years",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 237,
        "nct_id": "NCT00929331",
        "studyTitle": "Immunogenicity and safety study of GSK Biologicals\u2019 Trivalent Split Virion Influenza Vaccine Fluviral\u00ae (2009 - 2010 Season) in adults aged 18 to 60 years and over 60 years.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 278,
        "nct_id": "NCT01162590",
        "studyTitle": "Reactogenicity and safety of a single dose of GlaxoSmithKline (GSK) Biologicals\u2019 human rotavirus (HRV) vaccine (444563) in healthy adults",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Rotavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 296,
        "nct_id": "NCT01132443",
        "studyTitle": "A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin from Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects with Acne Vulgaris",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Acne Vulgaris"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 299,
        "nct_id": "NCT00612105",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study to Evaluate the Efficacy of Maximally Tolerated Doses of Retigabine vs. Placebo in Reducing the Pain Associated with Post-Herpetic Neuralgia",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Neuralgia",
            "Postherpetic"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 300,
        "nct_id": "NCT00502593",
        "studyTitle": "A phase II, randomized, open, controlled study to evaluate the safety and immunogenicity of different formulations of a pandemic influenza vaccine candidate (split virus formulation adjuvanted with AS03) given following a two-administration schedule (21 days apart) in children between 3 and 9 years of age.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 301,
        "nct_id": "NCT00502593",
        "studyTitle": "A phase II, randomized, open, controlled study to evaluate the safety and immunogenicity of different formulations of a pandemic influenza vaccine candidate (split virus formulation adjuvanted with AS03) given following a two-administration schedule (21 days apart) in children between 3 and 9 years of age.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 303,
        "nct_id": "NCT00652743",
        "studyTitle": "Immunogenicity of GSK Biologicals\u2019 pandemic influenza vaccine (GSK1562902A) at different boosting vaccination schedules",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 304,
        "nct_id": "NCT00652743",
        "studyTitle": "Immunogenicity of GSK Biologicals\u2019 pandemic influenza vaccine (GSK1562902A) at different boosting vaccination schedules",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 305,
        "nct_id": "NCT00652743",
        "studyTitle": "Immunogenicity of GSK Biologicals\u2019 pandemic influenza vaccine (GSK1562902A) at different boosting vaccination schedules",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 306,
        "nct_id": "NCT00586612",
        "studyTitle": "Immunogenicity & safety study in preterm & full-term infants of GSK Biologicals' Hib-MenC vaccine, Menitorix\u2122 co-administered with Infanrix\u2122 penta & Prevenar\u2122 at 2, 4, 6 months & as a booster with Infanrix\u2122 IPV & Prevenar\u2122 at 16-18 months",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Haemophilus influenzae type b; Neisseria Meningitidis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 312,
        "nct_id": "NCT00511823",
        "studyTitle": "An Open-Label, Three-Part, Two Period, Single Sequence Study to Assess the Pharmacokinetic Interaction Between Repeat Doses of Oral Casopitant and Repeat Oral Doses of Dolasetron, Granisetron or Rosiglitazone When Co-Administered in Healthy Adult Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Nausea and Vomiting",
            "Chemotherapy-Induced"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 314,
        "nct_id": "NCT00453687",
        "studyTitle": "A single-centre, randomized, double-blind placebo-controlled, dose-ascending, cross-over study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705, formulated with the excipient magnesium stearate, in healthy volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 319,
        "nct_id": "NCT00811356",
        "studyTitle": "A Single-Blind, Placebo-Controlled, Randomized First Time in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Dose Escalation of GSK932121 in Healthy Adult Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Malaria"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 322,
        "nct_id": "NCT01607086",
        "studyTitle": "A randomised, double-blind study in healthy volunteers to compare the properties and characteristics of an investigational formulation of lamotrigine with placebo",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Mental Disorders"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 323,
        "nct_id": "NCT00627575",
        "studyTitle": "An open-label, two-cohort study to assess the effect of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Epilepsy"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 324,
        "nct_id": "NCT00605371",
        "studyTitle": "A pivotal single-dose, randomised, parallel-group, open-label study to demonstrate bioequivalence of 250mg lamotrigine XR relative to 200mg + 50mg lamotrigine XR and to demonstrate lack of food effect on 250mg lamotrigine XR in healthy male and female volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Epilepsy"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 327,
        "nct_id": "NCT00551564",
        "studyTitle": "A Single-Center, Non-Randomized, Open-Label, Comparative Study to Assess the Utility of Novel Technologies and Biomarkers as Methods for Measuring Human Pharmacodynamic Response to 8 Weeks of Administration of Rosiglitazone Maleate 4mg BID in Healthy Normal or Overweight Controls, Healthy Obese Subjects and Subjects with Type 2 Diabetes Mellitus (T2DM)",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 328,
        "nct_id": "NCT01112787",
        "studyTitle": "A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Cumulative Irritation Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Acne Vulgaris"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 329,
        "nct_id": "NCT01114841",
        "studyTitle": "A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Contact Sensitization Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Acne Vulgaris"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 330,
        "nct_id": "NCT01115322",
        "studyTitle": "A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled Study To Evaluate The Phototoxic Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Acne Vulgaris"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 331,
        "nct_id": "NCT01119651",
        "studyTitle": "A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Photoallergic Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Acne Vulgaris"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 337,
        "nct_id": "NCT00352963",
        "studyTitle": "Study to assess immunogenicity and reactogenicity of three doses of GSK Bio\u2019s combined Hib-MenC vaccine co-admind with GSK Bio\u2019s DTPa-HBV-IPV vaccine and of two doses of Baxters meningococcal C conjugate vaccine co-admind with GSK Bio\u2019s DTPa-HBV-IPV/Hib vaccine",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 338,
        "nct_id": "NCT00379977",
        "studyTitle": "Open, primary vaccination study to assess safety and reactogenicity of GSK Biologicals\u2019 DTPa/Hib vaccine when administered to healthy chinese infants at 3, 4 and 5 months of age.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Tetanus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 349,
        "nct_id": "NCT01457547",
        "studyTitle": "Study to assess and compare the immunogenicity and reactogenicity of GlaxoSmithKline Biologicals\u2019 DTPa-HBV-IPV/Hib vaccine (INFANRIX\u2122 HEXA) and Aventis Pasteur MSD\u2019s DTPa-HBV-IPV-Hib vaccine (HEXAVAC\u2122) given at 3, 5 and 11-12 months of age",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 364,
        "nct_id": "NCT00908115",
        "studyTitle": "Evaluation of safety and efficacy through Post Market Surveillance for Infanrix\u2122, the DTaP mixed vaccine",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Acellular pertussis; Diphtheria; Tetanus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 368,
        "nct_id": "NCT00148941",
        "studyTitle": "Safety, immunogenicity&consistency of 3 manufacturing lots of DTaP-IPV vaccine vs separate injections of GSK Biologicals' DTaP + Aventis Pasteur's IPV admd as booster doses to healthy children 4-6 yrs, each co-admd with Merck's MMR vaccine",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Acellular pertussis; Diphtheria; Tetanus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 369,
        "nct_id": "NCT00056407",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Neoplasms",
            "Prostate"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 370,
        "nct_id": "NCT00090103",
        "studyTitle": "A randomized, double-blind, parallel group study to investigate the efficacy and safety of treatment with dutasteride (0.5mg) and tamsulosin (0.4mg), administered once daily for 4 years, alone and combination, on the improvement of symptoms and clinical outcome in men with moderate to severe symptomatic benign prostatic hyperplasia",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Prostatic Hyperplasia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 371,
        "nct_id": "NCT00363311",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men who are Candidates for or Undergoing Expectant Management",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Neoplasms",
            "Prostate"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 373,
        "nct_id": "NCT00522678",
        "studyTitle": "A randomised, double blind, placebo controlled, parallel group, 14 day repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled GW685698X containing magnesium stearate in healthy subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 376,
        "nct_id": "NCT00625196",
        "studyTitle": "A randomised, double-blind, placebo-controlled, four-way crossover study to compare the pharmacodynamics and pharmacokinetics of GW685698X and GW642444M when administered separately and in combination as a single dose from a novel dry powder device in healthy japanese subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 377,
        "nct_id": "NCT00444509",
        "studyTitle": "A randomised, double blind, two-way crossover study, to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of a single inhaled administration of GW685698X (800?g) with and without magnesium stearate, in mild/moderate asthmatic patients.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 382,
        "nct_id": "NCT00972673",
        "studyTitle": "Phase I study of GW685698X-A randomized, double blind, placebo controlled, parallel-group, repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled dose from a novel dry powder device in healthy Japanese male subjects.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 387,
        "nct_id": "NCT01000597",
        "studyTitle": "An open-label, randomised, two-way crossover study, to evaluate and compare the pharmacokinetics of fluticasone furoate, administered from a novel dry powder device (repeat dose) and intravenously (single dose), in healthy Caucasian, Japanese, Korean and Chinese subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 388,
        "nct_id": "NCT01299558",
        "studyTitle": "An open-label, non-randomised, three-way crossover, single dose study to determine the absolute bioavailability of fluticasone furoate (FF)/GW642444 Inhalation Powder, in healthy subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 399,
        "nct_id": "NCT00346749",
        "studyTitle": "A Randomized, Double-Blind, Parallel-Group, 12-Week Study to Evaluate the Anti-Inflammatory Effect of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg BID Compared with Salmeterol DISKUS 50mcg Twice Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 401,
        "nct_id": "NCT00479739",
        "studyTitle": "Randomised, double-blind, double-dummy, 52-week, parallel group study of a standard dosing regimen with salmeterol/fluticasone propionate50/250 twice daily Diskus versus a symptom-driven, variable dosing regimen with formoterol/budesonide combination 4.5/160 in adult asthmatics",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 402,
        "nct_id": "NCT01324362",
        "studyTitle": "A multicenter, randomized, double-blind, parallel group, 40-week comparison of asthma control using bronchial hyperresponsiveness as an additional guide to long-term treatment in adolescents and adults receiving either fluticasone propionate/sameterol DISKUS twice daily or fluticasone propionate DISKUS twice daily (or placebo twice daily if asymptomatic)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 403,
        "nct_id": "NCT00920543",
        "studyTitle": "A multicenter, randomized, double-blind, parallel group, 40-week comparison of asthma control using bronchial hyperresponsiveness as an additional guide to long-term treatment in adolescents and adults receiving either fluticasone propionate/salmeterol DISKUS twice daily or fluticasone propionate DISKUS twice daily (or placebo BID if asymptomatic)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 404,
        "nct_id": "NCT00169546",
        "studyTitle": "Randomised, double-blind parallel group study to assess the bronchodilative and bronchoprotective properties of SERETIDE DISKUS \u00ae inhlaer 50/100mcg twice daily vs. FLIXOTIDE\u00ae inhaler 200mcg twice daily.",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 406,
        "nct_id": "NCT00370591",
        "studyTitle": "Randomised, double blind, parallel group study to assess the bronchodilative and bronchoprotective properties of SERETIDE DISKUS\u00ae inhaler 50/100 mcg twice daily vs FLIXOTIDE\u00ae inhaler 200 mcg twice daily",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 411,
        "nct_id": "NCT00369993",
        "studyTitle": "A randomised, open label, five-way crossover study to assess the systemic exposure of fluticasone propionate and salmeterol from SERETIDE/ADVAIR 250HFA MDI alone and with AeroChamber-Max spacer and VOLUMATIC both in their washed and unwashed states in adult subjects with mild or intermittent asthma",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 412,
        "nct_id": "NCT00400608",
        "studyTitle": "A repeat-dose, open-label, randomized, incomplete block design in pediatric subjects with asthma, ages 4 - 11 years, to compare systemic exposure and pharmacodynamics of fluticasone propionate and salmeterol following Advair HFA 45/21mcg (2 inhalations), ADVAIR\u00ae HFA 45/21mcg (2 inhalations) with Aerochamber Plus Spacer and Advair Diskus 100/50 twice daily",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 413,
        "nct_id": "NCT00920959",
        "studyTitle": "A stratified, randomized, double-blind, placebo-controlled, parallel-group, 12 week trial evaluating the safety and efficacy of fluticasone propionate/salmeterol DISKUS combination product 100/50mcg once daily versus fluticasone propionate DISKUS 100mcg once daily and placebo in symptomatic pediatric subjects (4-11 years) with asthma",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 414,
        "nct_id": "NCT00115492",
        "studyTitle": "A Randomized, Double-Blind, Parallel Group, 52-Week Study to Compare the Effect of Fluticasone Propionate/Salmeterol Diskus Combination Product 250/50mcg Twice Daily with Salmeterol Diskus 50mcg Twice Daily on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 416,
        "nct_id": "NCT00268216",
        "studyTitle": "A multicentre, randomised, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of salmeterol/fluticasone propionate (SERETIDE\u00ae inhaler) 50/500mcg BD, salmeterol 50mcg BD and fluticasone propionate 500mcg BD, all delivered via the DISKUS\u00ae/ACCUHALER\u00ae inhaler, on mortality and morbidity of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 417,
        "nct_id": "NCT00268177",
        "studyTitle": "A 13-week, double-blind, parallel group, multi-centre study to compare the bronchial anti-inflammatory activity of the combination of salmeterol/fluticasone propionate 50/500mcg twice daily compared with placebo twice daily in patients with Chronic Obstructive Pulmonary Disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 419,
        "nct_id": "NCT00355342",
        "studyTitle": "A Randomized, Double-Blind, Parallel-Group Clinical Trial Evaluating the Effect of the fluticasone propionate/salmeterol Combination Product 250/50mcg twice daily via DISKUS\u00ae inhaler versus salmeterol 50mcg twice daily via DISKUS\u00ae inhaler on Bone Mineral Density in Subjects with Chronic Obstructive Pulmonary Disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 420,
        "nct_id": "NCT00144911",
        "studyTitle": "A Randomized, Double-Blind, Parallel Group, 52-Week Study to Compare the Effect of Fluticasone Propionate/Salmeterol DISKUS\u00ae inhaler Combination Product 250/50mcg twice daily with Salmeterol DISKUS\u00ae inhaler 50mcg twice daily on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 422,
        "nct_id": "NCT00118716",
        "studyTitle": "A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS\u00ae inhaler Combination Product 100/50mcg Twice Daily versus Fluticasone Propionate DISKUS\u00ae inhaler 100mcg Twice Daily in Pediatric and Adolescent Subjects with Activity-Induced Bronchospasm",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Bronchospasm"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 423,
        "nct_id": "NCT00118690",
        "studyTitle": "A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS\u00ae inhaler Combination Product 100/50mcg Twice Daily versus Fluticasone Propionate DISKUS\u00ae inhaler 100mcg Twice Daily in Pediatric and Adolescent Subjects with Activity-Induced Bronchospasm",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Bronchospasm"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 424,
        "nct_id": "NCT00102765",
        "studyTitle": "A Multicenter, Randomized, Double-Blind, Parallel Group, 52-Week Comparison of Asthma Control and Measures of Airway Inflammation in Subjects of African Descent Receiving Fluticasone Propionate/Salmeterol 100/50mcg DISKUS\u00ae Inhaler Twice Daily or Fluticasone Propionate 100mcg DISKUS\u00ae Inhaler Twice Daily Alone.",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 433,
        "nct_id": "NCT01466322",
        "studyTitle": "An open-label, randomised, crossover study to assess the relative bioavailability of different 2mg formulations of GSK2018682(S1P1 agonist) in healthy volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Multiple Sclerosis",
            "Relapsing-Remitting"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 436,
        "nct_id": "NCT00338351",
        "studyTitle": "To assess reactogenicity and immunogenicity of GSK Biologicals\u2019 10-valent pneumococcal conjugate vaccine, when co-administered with GSK Biologicals\u2019 DTPa-HBV-IPV/Hib vaccine (Infanrix\u2122 hexa) at 2, 4 and 6 months of age.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Streptococcal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 438,
        "nct_id": "NCT00343915",
        "studyTitle": "Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix\u2122-B and 3-dose preservative-free Engerix\u2122-B vaccines in subjects aged 11-15 yrs",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 439,
        "nct_id": "NCT00343915",
        "studyTitle": "Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix\u2122-B and 3-dose preservative-free Engerix\u2122-B vaccines in subjects aged 11-15 yrs",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 440,
        "nct_id": "NCT00343915",
        "studyTitle": "Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix\u2122-B and 3-dose preservative-free Engerix\u2122-B vaccines in subjects aged 11-15 yrs",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 443,
        "nct_id": "NCT00343915",
        "studyTitle": "Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix\u2122-B and 3-dose preservative-free Engerix\u2122-B vaccines in subjects aged 11-15 yrs",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 447,
        "nct_id": "NCT00329576",
        "studyTitle": "Evaluate the anti-HBs antibody persistence, in subjects who received GSK Biologicals\u2019 preservative-free or thiomersal-free Engerix\u2122-B or Engerix\u2122-B containing thiomersal, approximately 5 to 6 yrs earlier",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 454,
        "nct_id": "NCT00880477",
        "studyTitle": "Immunogenicity and safety of GSK Biological\u2019s DTPa-HBV-IPV/Hib vaccine or DTPa-IPV/Hib co-administered with HBV vaccine as primary and booster vaccination in healthy infants born to hepatitis B surface antigen negative mothers",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 455,
        "nct_id": "NCT00366366",
        "studyTitle": "Phase III, open, randomised immunogenicity and reactogenicity study to assess the interchangeability between GSK Bios' DTPa-HBV-IPV/Hib and DTPa-IPV/Hib + HBV at 3rd dose of primary vac. course in children who received HBV vac. at birth and one month of age and DTPa-IPV/Hib vac at 3-4 Mth of age",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 475,
        "nct_id": "NCT00279045",
        "studyTitle": "A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients with Drug-Naive, Recently Diagnosed Type 2 Diabetes Mellitus",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 476,
        "nct_id": "NCT00500955",
        "studyTitle": "A Study to Evaluate the Efficacy of Rosiglitazone (BRL-049653) on Reduction of Microalbuminuria in Subjects with Type 2 Diabetes Mellitus",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 478,
        "nct_id": "NCT00379769",
        "studyTitle": "A long term, open label, randomised study in patients with type 2 diabetes, comparing the combination of rosiglitazone and either metformin or sulfonylurea with metformin plus sulfonylurea on cardiovascular endpoints and glycaemia",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 482,
        "nct_id": "NCT00306644",
        "studyTitle": "Effect of rosiglitazone and placebo on carotid intima media thickness in patients with insulin resistance syndrome and/or type 2 diabetes",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 484,
        "nct_id": "NCT00306696",
        "studyTitle": "A Randomised study Examining the Effect of Different Diuretics on Fluid Balance in Diabetics Treated with Avandia",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 485,
        "nct_id": "NCT00329225",
        "studyTitle": "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Control, Clinical Evaluation of Insulin Plus Rosiglitazone (2mg and 4mg) Compared to Insulin Plus Placebo for 24 Weeks in Subjects with Type 2 Diabetes Mellitus Who are Inadequately Controlled on Insulin",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 489,
        "nct_id": "NCT00422955",
        "studyTitle": "A 16-week, randomised, double-blind, placebo-controlled, single-centre study to investigate fluid retention in insulin-treated subjects with type 2 diabetes mellitus and varying degrees of autonomic neuropathy when administered rosiglitazone 4mg twice daily",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Neuropathy",
            "Diabetic"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 507,
        "nct_id": "NCT00318630",
        "studyTitle": "A randomised double-blind two-period crossover study to investigate the effect of treatment with repeat doses of a PPAR gamma agonist on the allergen-induced late asthmatic response in subjects with mild asthma compared with repeat doses of placebo.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 510,
        "nct_id": "NCT00140673",
        "studyTitle": "A placebo-controlled, multi-country & multi-center study to assess the efficacy, safety & immunogenicity of 2 doses of GSK Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine in healthy infants",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Rotavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 514,
        "nct_id": "NCT01019603",
        "studyTitle": "A Single-Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects with Acne Vulgaris",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Acne Vulgaris"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 522,
        "nct_id": "NCT01072149",
        "studyTitle": "A three-way incomplete block crossover study to investigate the 24-hour pulmonary function of three dosage strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder vs. Placebo, in subjects with Chronic Obstructive Pulmonary Disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 526,
        "nct_id": "NCT00980200",
        "studyTitle": "A multi-center, randomized, double-blind, placebo-controlled, five period cross-over study to evaluate the efficacy and safety of selected doses and dose intervals of GW642444 administered via a novel dry powder inhaler (NDPI) in subjects \u226518 years of age with persistent asthma",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1276,
        "nct_id": "NCT00883909",
        "studyTitle": "ARI103094-Follow-Up Study for REDUCE Study Subjects",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Neoplasms",
            "Prostate"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1277,
        "nct_id": "NCT00538057",
        "studyTitle": "A randomised, double-blind, placebo-controlled, four-way crossover study to compare the pharmacodynamics and pharmacokinetics of GW685698X and GW642444M when administered separately and in combination as a single dose from a novel dry powder device in healthy subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1281,
        "nct_id": "NCT01583036",
        "studyTitle": "An interaction study to assess the effect of the ezogabine/retigabine and the main metabolite NAMR on the pharmacokinetics of digoxin in healthy volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Epilepsy"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1284,
        "nct_id": "NCT00383903",
        "studyTitle": "A phase II, randomized, double-blind, placebo-controlled study of safety, reactogenicity and immunogenicity of 2 or 3 doses of GSK Biologicals\u2019 oral live attenuated human rotavirus vaccine at 10E6.5 CCID50 viral concentration in healthy infants (approximately 5-10 weeks old) in the Republic of South Africa",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Rotavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1289,
        "nct_id": "NCT00197210",
        "studyTitle": "A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine in healthy infants",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Rotavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1290,
        "nct_id": "NCT00329745",
        "studyTitle": "A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Rotavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1291,
        "nct_id": "NCT00197210",
        "studyTitle": "A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine in healthy infants",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Rotavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1292,
        "nct_id": "NCT00329745",
        "studyTitle": "A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Rotavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1293,
        "nct_id": "NCT00757770",
        "studyTitle": "Study to assess the clinical consistency of three production lots of GSK Biologicals\u2019 HRV vaccine in terms of immunogenicity and safety when given to healthy infants at 2 and 4 months of age",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Rotavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1295,
        "nct_id": "NCT00420316",
        "studyTitle": "To assess long-term efficacy & safety of subjects approximately 3 years after priming with 2 doses of GlaxoSmithKline (GSK) Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in the primary vaccination study (102247).",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Rotavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1297,
        "nct_id": "NCT00241644",
        "studyTitle": "Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Rotavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1298,
        "nct_id": "NCT00169455",
        "studyTitle": "Study to assess the immunogenicity, reactogenicity and safety of GlaxoSmithKline Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine following a 0, 2 month schedule, in healthy infants previously uninfected with human rotavirus",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Rotavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1302,
        "nct_id": "NCT00345956",
        "studyTitle": "A placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Vietnam",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Rotavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1303,
        "nct_id": "NCT00363545",
        "studyTitle": "A study to assess the immunogenicity, reactogenicity and safety of 2 different formulations of GSK Biologicals' live attenuated HRV vaccine, given as a two-dose primary vaccination, in healthy infants previously uninfected with HRV",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Rotavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1372,
        "nct_id": "NCT00549198",
        "studyTitle": "Study of Once-Daily Abacavir/Lamivudine versus Tenofovir/Emtricitabine, Administered with Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus I"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1373,
        "nct_id": "NCT00244712",
        "studyTitle": "A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination with KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus I"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1374,
        "nct_id": "NCT00044577",
        "studyTitle": "A phase III, randomized, open-label, parallel, multicenter study to evaluate treatment with fixed-dose combination of abacavir/lamivudine (600mg/300mg) once-daily versus abacavir (300mg) twice-daily and lamivudine (300mg) once-daily in combination with tenofovir once-daily and a new PI or NNRTI for 48 weeks in ART-experienced HIV-1 infected patients",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus I"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1375,
        "nct_id": "NCT00340080",
        "studyTitle": "A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1376,
        "nct_id": "NCT01102972",
        "studyTitle": "A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying from a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1377,
        "nct_id": "NCT00046176",
        "studyTitle": "A Phase III, 48-Week, Open-Label, Randomized, Multicenter Study of the Safety and Efficacy of the Abacavir/Lamivudine Fixed-Dose Combination Tablet Administered QD Versus Abacavir + Lamivudine Administered BID in Combination with a PI or NNRTI in Antiretroviral Experienced Patients.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus I"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1378,
        "nct_id": "NCT00053638",
        "studyTitle": "A phase III, randomized, open-label, multicenter study of the safety and efficacy of efavirenz versus tenofovir when administered in combination with the abacavir/lamivudine fixed-dose combination tablet as a once-daily regimen in antiretroviral-naive HIV-1 infected subjects.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus I"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1379,
        "nct_id": "NCT00043888",
        "studyTitle": "A Phase IIIb/IV, Randomized, Open Label, Multicenter, Pilot Trial to Explore the Safety and Tolerability of GW433908 +/- Ritonavir (1400mg twice daily or 700mg/100mg twice daily) When Used in Combination with a Zidovudine-containing Regimen (TRIZIVIR or COMBIVIR twice daily) Over a 24 Week Period in Antiretroviral Therapy Naive HIV-1 Infected Subjects.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1380,
        "nct_id": "NCT00038506",
        "studyTitle": "A phase IV, open-label, multicenter study of treatment with TRIZIVIR (abacavir 300mg/lamivudine 150mg/zidovudine 300mg) twice daily and tenofovir 300mg once-daily for 48 weeks in HIV-infected subjects experiencing early virologic failure (ZIAGEN Intensification Protocol)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus I"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1381,
        "nct_id": "NCT00082394",
        "studyTitle": "A Phase IV Randomized, Multicenter, Open-Label Study to Compare the Safety, Tolerability and Efficacy of Trizivir (abacavir 300mg, lamivudine 150mg, and zidovudine 300mg) BID vs Combivir (lamivudine 150mg and zidovudine 300mg) BID plus atazanavir 400mg QD in Antiretroviral Naive HIV-1 Infected Subjects over 48 Weeks",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1382,
        "nct_id": "NCT01231516",
        "studyTitle": "A Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered with an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Na\u00efve, Antiretroviral-Experienced Adults",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1383,
        "nct_id": "NCT00708110",
        "studyTitle": "A Phase 2a, Multicenter, Randomized, Parallel, Double-Blind, Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1349572 Monotherapy Versus Placebo Over 10 days in HIV-1 Infected Adults (ING111521)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1384,
        "nct_id": "NCT00951015",
        "studyTitle": "A Phase IIb study to select a once daily dose of GSK1349572 administered with either abacavir/lamivudine or tenofovir/emtricitabine in HIV-1 infected antiretroviral therapy naive adult subjects",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1385,
        "nct_id": "NCT01328041",
        "studyTitle": "A Phase III study to demonstrate the antiviral activity and safety of dolutegravir in HIV-1 infected adult subjects with treatment failure on an integrase inhibitor containing regimen.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1386,
        "nct_id": "NCT00950859",
        "studyTitle": "A pilot study to assess the antiviral activity of GSK1349572 containing regimen in antiretroviral therapy (ART)-experienced, HIV-1-infected adult subjects with raltegravir resistance",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1387,
        "nct_id": "NCT01227824",
        "studyTitle": "A randomized, double blind study of the safety and efficacy of GSK1349572 50mg once daily to raltegravir 400mg twice daily both administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral therapy naive adult subjects",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus I"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1388,
        "nct_id": "NCT01263015",
        "studyTitle": "A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus I"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1389,
        "nct_id": "NCT00296504",
        "studyTitle": "An Open-Label Phase III Study to Assess the Long Term Safety Profile of GW433908 Containing Regimens in HIV-1 Infected Subjects",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1390,
        "nct_id": "NCT00094523",
        "studyTitle": "A phase IIIB/IV, open-label, multi-center trial to evaluate the safety, tolerability, and efficiency of HIV-1 infected subjects switching their current protease-inhibitor therapies for a fosamprenavir therapy over 48 weeks",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus I"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1391,
        "nct_id": "NCT00085943",
        "studyTitle": "A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 (700mg BID) plus ritonavir (100mg BID) Versus Lopinavir/ritonavir (400mg/100mg BID) when Administered in Combination with the Abacavir/Lamivudine (600mg/300mg) Fixed-Dose Combination Tablet QD in Antiretroviral-Naive HIV-1 Infected Adults Over 48 Weeks",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1392,
        "nct_id": "NCT00450580",
        "studyTitle": "Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir, Administered with Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Adult Subjects.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus I"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1393,
        "nct_id": "NCT00363142",
        "studyTitle": "A Phase IIIB, randomized, open-label, parallel group, multi-center, non-inferiority, 24-week study to evaluate the safety, efficacy and tolerability of switching from a 200mg ritonavir-boosted regimen of LEXIVA (700mg/100mg BID or 1400mg/200mg QD) to a once-daily, 100mg ritonavir-boosted regimen of LEXIVA (1400mg/100mg QD)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1394,
        "nct_id": "NCT00144833",
        "studyTitle": "A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor regimen of Fosamprenavir/Lopinavir/Ritonavir 1400mg/533mg/133mg Twice Daily and an Increased Dosage Regimen of FPV/RTV 1400mg/100mg BID Versus the Standard Dosage Regimen of FPV/RTV 700mg/100mg BID for 24 Weeks in Multiple-PI Experienced, HIV-infected Adults Experiencing Virological Failure",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1398,
        "nct_id": "NCT00440947",
        "studyTitle": "Safety and Efficacy of an Initial Regimen of Atazanavir (ATV) + Ritonavir (/r) + the Abacavir/Lamivudine Fixed-Dose Combination Tablet (ABC/3TC FDC) for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FDC or Maintenance of the Initial Regimen for an Additional 48 weeks in Antiretroviral-Naive HIV-1 Infected HLA-B*5701 Negative Subjects followed by an Optional 60-Week Treatment Extension Phase",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus I"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1400,
        "nct_id": "NCT00827112",
        "studyTitle": "A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1401,
        "nct_id": "NCT00634959",
        "studyTitle": "Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1402,
        "nct_id": "NCT00098748",
        "studyTitle": "Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects",
        "overallStatus": "",
        "phase": "Phase 2/Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1403,
        "nct_id": "NCT00098722",
        "studyTitle": "Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects",
        "overallStatus": "",
        "phase": "Phase 2/Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1404,
        "nct_id": "NCT00098306",
        "studyTitle": "Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects",
        "overallStatus": "",
        "phase": "Phase 2/Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1405,
        "nct_id": "NCT00643643",
        "studyTitle": "Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1406,
        "nct_id": "NCT00098293",
        "studyTitle": "Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1416,
        "nct_id": "NCT00410384",
        "studyTitle": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 76-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B\u2122), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Systemic Lupus Erythematosus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1417,
        "nct_id": "NCT00424476",
        "studyTitle": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Wk Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B\u2122), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Systemic Lupus Erythematosus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1420,
        "nct_id": "NCT00282295",
        "studyTitle": "Safety & immunogenicity of a booster dose of dTPa vaccine (Boostrix\u00ae) co-admnd. with Aventis Pasteur\u2019s meningococcal (serogroups A, C, Y and W-135) polysaccharide vaccine (Menactra\u2122) vs admn. of either vaccine alone in healthy adolescents",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Acellular pertussis; Diphtheria; Tetanus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1421,
        "nct_id": "NCT00263679",
        "studyTitle": "A phase III, double-blinded, randomized, multicenter, clinical study to assess the safety and immunogenicity of GSK Biologicals' Tdap 0.3 mg candidate vaccine when given as a booster dose to healthy school children and adolescents (9-13 years of age), previously vaccinated with a 5th consecutive dose of acellular pertussis-containing vaccine, in studies APV-118 or APV-120",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Acellular pertussis; Diphtheria; Tetanus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1422,
        "nct_id": "NCT01294605",
        "studyTitle": "Double-blind, randomized, phase III clinical trial to evaluate the immunogenicity and reactogenicity of three consecutive doses of dTpa, or of dTpa-IPV followed by two doses of Td vaccine , and compared to three consecutive doses of Td vaccine administered to healthy adults in a 0,1,6-month schedule",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Acellular pertussis; Diphtheria; Tetanus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1423,
        "nct_id": "NCT00544271",
        "studyTitle": "Phase IIIb study to evaluate immunogenicity, antibody persistency and reactogenicity of DTPa - INFANRIX and dTpa - BOOSTRIX vaccines administered to healthy children previously primed with 3 doses of DTPa vaccine compared to placebo (HAVRIX\u00aeJUNIOR)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Acellular pertussis; Diphtheria; Tetanus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1429,
        "nct_id": "NCT00537654",
        "studyTitle": "An Open-Label, Randomized, Single Dose Three-Period Partial Crossover Study to Determine the Bioequivalence and Food Effect of a Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5mg/0.4mg) Compared to Concomitant Dosing of AVODART\u2122 0.5mg and Flomax 0.4mg Commercial Capsules in Healthy Male Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Prostatic Hyperplasia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1430,
        "nct_id": "NCT00609596",
        "studyTitle": "An open label, randomized, repeat dose, 3 period crossover study to determine the bioequivalence of 3 different formulations of tamsulosin at steady state in healthy male volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Prostatic Hyperplasia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1442,
        "nct_id": "NCT00370097",
        "studyTitle": "PD of Hydrofluoroalkane propellant of inhaled fluticasone propionate following administration in pediatric subjects 6-12 months of age with asthma",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1472,
        "nct_id": "NCT00400855",
        "studyTitle": "A randomised, double-blind, placebo-controlled, incomplete block, 4-period crossover, study to investigate the effects of 5-day repeat inhaled doses of fluticasone propionate (BID, 50-2000 mcg) on airway responsiveness to adenosine 5-monophosphate (AMP) challenge when delivered after the last dose in mild asthmatic subjects.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1473,
        "nct_id": "NCT00503009",
        "studyTitle": "An exploratory study to evaluate the response of salmeterol plus fluticasone propionate vs fluticasone propionate alone to experimental nasal inoculation with rhinovirus",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1509,
        "nct_id": "NCT00196937",
        "studyTitle": "Phase 3, open, age-stratified study to assess immunogenicity and safety of GSK Biologicals' HPV-16/18 vaccine administered intramuscularly according to 3-dose schedule (0,1,6 months) in healthy female subjects aged 15 - 55 years and long term follow-up",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1510,
        "nct_id": "NCT00196937",
        "studyTitle": "Phase 3, open, age-stratified study to assess immunogenicity and safety of GSK Biologicals' HPV-16/18 vaccine administered intramuscularly according to 3-dose schedule (0,1,6 months) in healthy female subjects aged 15 - 55 years and long term follow-up",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1511,
        "nct_id": "NCT00345878",
        "studyTitle": "Phase 3, open, age-stratified study to assess immunogenicity and safety of GSK Biologicals' HPV-16/18 vaccine administered intramuscularly according to 3-dose schedule (0,1,6 months) in healthy female subjects aged 15 - 55 years and long term follow-up",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1512,
        "nct_id": "NCT00306241",
        "studyTitle": "A phase III, double-blind, randomized, controlled study to evaluate immunogenicity and safety of GSK Biologicals\u2019 HPV-16/18 L1 VLP AS04 vaccine, administered intramuscularly (0, 1, 6 month schedule) in healthy females aged 18 \u2013 35 years",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1514,
        "nct_id": "NCT00344032",
        "studyTitle": "Phase IIIb, double-blind, randomized, controlled study to evaluate the immunogenicity and safety of GSK Biologicals\u2019 HPV-16/18 VLP/AS04 vaccine administered intramuscularly at 0, 1, 6 months in healthy Indian female subjects aged 18\u201335 yrs",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1516,
        "nct_id": "NCT00316693",
        "studyTitle": "A phase II study to assess the efficacy, immunogenicity and safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 (Cervarix TM) vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy Japanese female subjects aged 20 - 25 years.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1521,
        "nct_id": "NCT00337818",
        "studyTitle": "Immunogenicity: 3 consecutive lots of GSK Biologicals\u2019 HPV-16/18 vaccine administered intramuscularly at 0,1,6 month schedule in healthy females aged 10\u201325 years and demonstrate non-inferiority of candidate HPV vaccine manufactured by modified production process",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1522,
        "nct_id": "NCT00337818",
        "studyTitle": "Immunogenicity: 3 consecutive lots of GSK Biologicals\u2019 HPV-16/18 vaccine administered intramuscularly at 0,1,6 month schedule in healthy females aged 10\u201325 years and demonstrate non-inferiority of candidate HPV vaccine manufactured by modified production process",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1523,
        "nct_id": "NCT00369824",
        "studyTitle": "A randomized, open study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals\u2019 HPV vaccine Co-administered intramuscularly with Boostrix\u00ae and/or Menactra\u2122 in healthy female subjects aged 11\u201318 years",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1525,
        "nct_id": "NCT00456807",
        "studyTitle": "Complementary testing to further evaluate the immunogenicity of a GSK Biologicals\u2019 HPV vaccine (580299) in healthy female subjects aged over 26 years enrolled in study 104820.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1527,
        "nct_id": "NCT00120848",
        "studyTitle": "Study of the efficacy of candidate HPV 16/18 VLP vaccine in the prevention of HPV-16 and/or HPV-18 cervical infection in adolescent & young adult women in North America and Brazil vaccinated in primary study 580299/001",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1534,
        "nct_id": "NCT00731393",
        "studyTitle": "To determine the immunogenicity and reactogenicity of a thiomersal free trivalent influenza split vaccine 2003/2004 or of GSK Biologicals\u2019 standard formulation Influsplit SSW\u00ae/Fluarix\u2122 2003/2004 in children aged from 6 months until 6 years",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1536,
        "nct_id": "NCT00306995",
        "studyTitle": "A phase III, open, randomized, multicenter, comparative vaccination study to evaluate the immunogenicity and reactogenicity of various formulations of a monovalent candidate pandemic influenza A vaccine in individuals over 60 years of age",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1537,
        "nct_id": "NCT00197288",
        "studyTitle": "A phase III, observer-blind, randomized study to evaluate the immunogenicity and safety of Fluarix\u2122 (GlaxoSmithKline Biologicals) compared with Fluzone\u00ae (Aventis Pasteur) administered intramuscularly in adults 18 years and older in the U.S.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1540,
        "nct_id": "NCT00383123",
        "studyTitle": "A phase III, single-blind, randomized study to evaluate the immunogenicity and safety of Fluarix\u00ae (GSK Biologicals) compared with Fluzone\u00ae (Aventis Pasteur/Sanofi) administered intramuscularly in children (6 months and older)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1542,
        "nct_id": "NCT00380211",
        "studyTitle": "A Randomized, Double-Blind Trial Evaluating the Safety and Immunogenicity of an Influenza Vaccine with reduced Preservative (FluLaval\u2122 TR) and a Standard Influenza Vaccine (Fluarix\u00ae) in subjects between 18-60 and Over 60 Years of Age.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1549,
        "nct_id": "NCT00144846",
        "studyTitle": "A Randomized, Double-Blind, Parallel-group, Multi-Center Study of Albuterol Sulfate HFA Inhalation Aerosol Delivered Cumulatively with a valved holding chamber and an attached facemask in subjects between birth to 23 months of age with acute wheezing due to obstructive airways disease",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1551,
        "nct_id": "NCT01013974",
        "studyTitle": "Phase I study of GSK573719 -A randomized, double blind, placebo controlled, dose ascending, single and repeat dose study to investigate the safety, tolerability, and pharmacokinetics of inhaled dose of GSK573719 from a novel dry powder device in healthy Japanese male subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1553,
        "nct_id": "NCT01039675",
        "studyTitle": "Safety, tolerability, pharmacokinetics and pharmacodynamics of the combination of GSK573719 and GW642444 in subjects with COPD",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1554,
        "nct_id": "NCT00976144",
        "studyTitle": "A single centre, randomised, placebo-controlled, four-way cross over study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK573719 and GW642444 as monotherapies and concurrently in healthy Japanese subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1611,
        "nct_id": "NCT00980005",
        "studyTitle": "Immunogenicity & safety study of GSK Biologicals\u2019 thimerosal-free trivalent influenza vaccine (TIV) versus a licensed comparator in children",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1612,
        "nct_id": "NCT00938158",
        "studyTitle": "An adaptive design study for the assessment of the pharmacokinetics of albiglutide in subjects with normal renal function and subjects with moderate-to-severe renal impairment and hemodialysis.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1639,
        "nct_id": "NCT00067444",
        "studyTitle": "Assessment of Paxil CR, 12.5 and 25 mg/day in treating elderly patients with major depression",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Depressive Disorder",
            "Major"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1643,
        "nct_id": "NCT01353768",
        "studyTitle": "Medical Record Review and Data Abstraction for Pediatric, Adolescent and Pregnant Patients treated with IV zanamivir in the Relenza Compassionate Use Program",
        "overallStatus": "",
        "phase": NaN,
        "studyType": "",
        "conditions": [
            "Infections",
            "Respiratory Tract"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1657,
        "nct_id": "NCT00354536",
        "studyTitle": "A single-blinded randomized, placebo-controlled, staggered-parallel, escalating-dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous injections of GSK 716155 in Subjects with type 2 Diabetes Mellitus",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1658,
        "nct_id": "NCT00537719",
        "studyTitle": "A Single-Blind, Randomized, Placebo-Controlled Study in Healthy Men and Women to Determine the Effect of Single Subcutaneous Injections of GSK716155 on Gastric Emptying Time for Solid and Liquid Components of a Meal",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1660,
        "nct_id": "NCT01077505",
        "studyTitle": "An open-label study to evaluate the pharmacokinetics of an oral contraceptive containing Norethindrone and Ethinyl Estradiol when co-administered with GSK716155 in healthy adult female subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1661,
        "nct_id": "NCT01406262",
        "studyTitle": "A Randomized, Double-blind, Parallel, Nested Crossover Study to Investigate the Effect of Albiglutide on Cardiac Repolarization (corrected QT Interval) Compared With Placebo in Healthy Male and Female Subjects: A Thorough ECG Study Employing Placebo, Albiglutide, and a Positive Control (Moxifloxacin)",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1662,
        "nct_id": "NCT01147718",
        "studyTitle": "An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Digoxin When Coadministered With Albiglutide in Healthy Adult Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1663,
        "nct_id": "NCT01147731",
        "studyTitle": "An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Warfarin When Coadministered With Albiglutide in Healthy Adult Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1665,
        "nct_id": "NCT00394030",
        "studyTitle": "An Open-Label, Randomized, Multi-Site Study to Assess the Pharmacokinetics of Single Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered at Three Different Injection Sites in Adult Male and Female Subjects with Type 2 Diabetes and of Single Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered in the Abdomen of Healthy, Normal Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1675,
        "nct_id": "NCT00354965",
        "studyTitle": "A study to determine PK profiles of AUGMENTIN XR in adolescents weight at least 40 kg receiving Augmentin XR BID for 10 days",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Respiratory Tract"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1689,
        "nct_id": "NCT00347360",
        "studyTitle": "A Randomized, Double-Blind, Double-Dummy, Parallel Group, Factorial Design Trial to Assess the Efficacy and Safety of up to Six Weeks Treatment with 20mg, 40mg, or 80mg QD Doses of Carvedilol Controlled Release Formulation (COREG\u2122 CR) or 10mg, 20mg, or 40mg QD doses of Lisinopril (Zestril) or a Combination of One of the Doses of Each Medication",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hypertension"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1692,
        "nct_id": "NCT00062790",
        "studyTitle": "Effects of Dutasteride on Intraprostatic Dihydrotestosterone (DHT) Levels",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Prostatic Hyperplasia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1693,
        "nct_id": "NCT00470834",
        "studyTitle": "A Randomized Double-Blind Parallel Group Study Comparing Casodex (or generic equivalent) 50mg plus Placebo to Casodex (or generic equivalent) 50mg plus dutasteride 3.5mg Administered for 18 months to Men with Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Neoplasms",
            "Prostate"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1708,
        "nct_id": "NCT00103454",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Perennial Allergic Rhinitis (PAR)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Rhinitis",
            "Allergic",
            "Perennial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1709,
        "nct_id": "NCT00116818",
        "studyTitle": "A randomized, double-blind, parallel group, placebo and active (prednisone) controlled, 6-week study of the\r\n\u00a0effect of fluticasone furoate aqueous nasal spray 100mcg QD on the hypothalamic pituitary adrenocortical (HPA) axis\r\n\u00a0in adolescents and adults 12 to 65 years of age with perennial allergic rhinitis (PAR)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Rhinitis",
            "Allergic",
            "Perennial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1710,
        "nct_id": "NCT00115622",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 14 days in Adult and Adolescent Subjects with Seasonal Allergic Rhinitis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Rhinitis",
            "Allergic",
            "Seasonal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1713,
        "nct_id": "NCT01287065",
        "studyTitle": "A randomised, repeat-dose, placebo-controlled, double-blind study to evaluate and compare the efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder, when administered either in the morning or in the evening, in male and female asthmatic subjects",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1720,
        "nct_id": "NCT00346775",
        "studyTitle": "A Randomized, Single-Blind, Cross-Over, Multicenter Study to Validate the Preference Module of the Experience with Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q) Administered to Adult Subjects with Seasonal Allergic Rhinitis during a Three-week Cross-over Study",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Rhinitis",
            "Allergic",
            "Perennial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1729,
        "nct_id": "NCT01332292",
        "studyTitle": "A randomized, double-blind, placebo-controlled, two-way crossover 14-day study to investigate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat dose inhaled fluticasone furoate 100ug (micrograms) in children aged 5-11 years with persistent asthma",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1730,
        "nct_id": "NCT00118729",
        "studyTitle": "A Randomized, Double Blind, Placebo-Controlled, Single-Dose, Parallel-Group Study to Evaluate the Onset of Action of a Single Dose of Intranasal GW685698X Aqueous Nasal Spray 100mcg in Adolescent and Adult Subjects (12 years of age and older) with Seasonal Allergic Rhinitis Exposed to Ragweed Pollen in an Allergen Challenge Chamber",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Rhinitis",
            "Allergic",
            "Seasonal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1733,
        "nct_id": "NCT00116883",
        "studyTitle": "A randomized, double-blind, parallel group, placebo controlled, 6-week study of the effect of GW685698X aqueous nasal spray 100mcg QD on the hypothalamic pituitary adrenocortical (HPA) axis in children 2 to 11 years of age with perennial allergic rhinitis (PAR).",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Rhinitis",
            "Allergic",
            "Perennial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1734,
        "nct_id": "NCT00197262",
        "studyTitle": "See Detailed Description",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Rhinitis",
            "Allergic",
            "Seasonal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1735,
        "nct_id": "NCT00107757",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg and 100mcg for 2 Weeks in Pediatric Subjects Ages 2 to <12 Years with Seasonal Allergic Rhinitis (SAR)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Rhinitis",
            "Allergic",
            "Perennial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1741,
        "nct_id": "NCT00064428",
        "studyTitle": "An International Randomized Study Evaluating the Efficacy and Safety of Fondaparinux Versus Control Therapy in a Broad Range of Patients With ST Segment Elevation Acute Myocardial Infarction.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Thromboembolism"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1742,
        "nct_id": "NCT00038961",
        "studyTitle": "A multicenter, randomized, double-blind, parallel group trial to demonstrate the efficacy of fondaparinux sodium in association with Intermittent Pneumatic Compression (IPC) versus IPC used alone for the prevention of venous thromboembolic events in subjects at increased risk undergoing major abdomi",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Thromboembolism"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1743,
        "nct_id": "NCT00139815",
        "studyTitle": "An international, randomized, double-blind study evaluating the efficacy and safety of fondaparinux versus enoxaparin in the acute treatment of unstable angina/non ST-segment elevation MI acute coronary syndromes",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Thromboembolism"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1745,
        "nct_id": "NCT00976820",
        "studyTitle": "A study to evaluate the safety and immunogenicity of A/California/7/2009 (H1N1)v-like vaccines GSK2340274A and GSK2340273A in children 6 months to less than 9 years of age",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1746,
        "nct_id": "NCT01416571",
        "studyTitle": "Immunogenicity and safety study of GSK Biologicals\u2019 monovalent pandemic H5N1 vaccine 1557484A in adults aged 18 \u2013 64 years",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1748,
        "nct_id": "NCT01061541",
        "studyTitle": "A phase II, double-blind, randomized study to compare the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals\u2019 Tritanrix\u2122-HepB/Hib2.5 to GSK Biologicals\u2019 Tritanrix\u2122-HepB/Hiberix\u2122 when administered as a three-dose primary vaccination course to healthy infants at 6, 10 and 14 weeks of age. A dose of unconjugated Hib vaccine (plain PRP booster) will be administered at the age of 10 months to 50% of the subjects",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Haemophilus influenzae type b"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1750,
        "nct_id": "NCT00127855",
        "studyTitle": "A phase II, open (partially double-blind), randomised, controlled, multicentre, primary vaccination study to evaluate the immunogenicity (including immune memory), reactogenicity and safety of three different formulations of the GSK Biologicals\u2019 combined Haemophilus influenzae type b-meningococcal serogroups CY conjugate vaccine given concomitantly with Infanrix\u00ae penta and Prevenar\u00ae, versus ActHIB\u00ae and Meningitec\u00ae given concomitantly with Infanrix\u00ae penta and versus ActHIB\u00ae given concomitantly with Infanrix\u00ae penta and Prevenar\u00ae in infants according to a 2-4-6 month schedule.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Haemophilus influenzae type b; Neisseria Meningitidis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1752,
        "nct_id": "NCT00129116",
        "studyTitle": "A phase II, open (partially double-blind), randomised, controlled, multicentre, primary vaccination study to evaluate the immunogenicity, reactogenicity and safety of three different formulations of GSK Biologicals\u2019 combined Haemophilus influenzae type b-meningococcal serogroups C and Y- conjugate vaccine and one formulation of GSK Biologicals\u2019 Haemophilus influenzae type b-meningococcal serogroup C conjugate vaccine each given concomitantly with InfanrixTM penta, versus MeningitecTM, given concomitantly with InfanrixTM hexa in infants according to a 2-3-4 month schedule",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Haemophilus influenzae type b; Neisseria Meningitidis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1753,
        "nct_id": "NCT00129129",
        "studyTitle": "Evaluate Immuno and Safety of GSKBiologicals' HibMenCYTT vs Licensed Hib Conjugate Vaccine, Each Coadministered With Pediarix\u00ae and Prevnar\u00ae, in Healthy Infants. An Exploratory Control Group Will Receive Licensed Menomune\u00ae at 3 to 5 years",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Haemophilus influenzae type b; Neisseria Meningitidis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1754,
        "nct_id": "NCT00129129",
        "studyTitle": "Evaluate Immuno and Safety of GSKBiologicals' HibMenCYTT vs Licensed Hib Conjugate Vaccine, Each Coadministered With Pediarix\u00ae and Prevnar\u00ae, in Healthy Infants. An Exploratory Control Group Will Receive Licensed Menomune\u00ae at 3 to 5 years",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Haemophilus influenzae type b; Neisseria Meningitidis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1755,
        "nct_id": "NCT00134719",
        "studyTitle": "A multicentre primary & booster vaccination study of GSK Biologicals' Hib-MenCY-TT conjugate vaccine vs ActHIB\u00ae & MenC conjugate licensed vaccine when given according to the 2-4-6 month schedule to healthy infants with booster dose at 12 to 15 months",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Haemophilus influenzae type b; Neisseria Meningitidis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1756,
        "nct_id": "NCT00134719",
        "studyTitle": "A multicentre primary & booster vaccination study of GSK Biologicals' Hib-MenCY-TT conjugate vaccine vs ActHIB\u00ae & MenC conjugate licensed vaccine when given according to the 2-4-6 month schedule to healthy infants with booster dose at 12 to 15 months",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Haemophilus influenzae type b; Neisseria Meningitidis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1758,
        "nct_id": "NCT00289783",
        "studyTitle": "A phase III, randomized, multinational study, double-blinded for the immunogenicity and consistency evaluation of 3 Hib-MenCY-TT vaccine lots and single-blinded and controlled for the evaluation of safety and immunogenicity of GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (Hib-MenCY-TT) compared to monovalent Hib vaccine in healthy infants at 2, 4, 6, and 12 to 15 months of age.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Haemophilus influenzae type b; Neisseria Meningitidis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1760,
        "nct_id": "NCT00359983",
        "studyTitle": "A study to evaluate the long-term antibody persistence at 1, 3 & 5 years after the administration of a fourth dose of Hib-MenCY-TT Vaccine compared to ActHIB in subjects boosted in a previous study.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Haemophilus influenzae type b; Neisseria Meningitidis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1766,
        "nct_id": "NCT00327184",
        "studyTitle": "Study to demonstrate non-inferiority of GSK Biologicals\u2019 Hib-MenC given with Infanrix\u2122 penta versus NeisVac-C\u2122 given with Infanrix\u2122 hexa at 3, 5 months of age and persistence prior to a Hib-MenC booster at 11 months and immunogenicity of the booster",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Haemophilus influenzae type b; Neisseria Meningitidis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1770,
        "nct_id": "NCT00603252",
        "studyTitle": "Evaluate the effect of risk factors that influence the immunogenicity of GSK Biologicals Twinrix compared to hepatitis A and hepatitis B vaccines given separately and to show the non-inferiority between the vaccines in adults",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A; Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1776,
        "nct_id": "NCT00289757",
        "studyTitle": "Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1777,
        "nct_id": "NCT00289757",
        "studyTitle": "Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1778,
        "nct_id": "NCT00289757",
        "studyTitle": "Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1779,
        "nct_id": "NCT00289757",
        "studyTitle": "Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1780,
        "nct_id": "NCT00289757",
        "studyTitle": "Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1781,
        "nct_id": "NCT00289757",
        "studyTitle": "Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1782,
        "nct_id": "NCT00289757",
        "studyTitle": "Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1783,
        "nct_id": "NCT00289757",
        "studyTitle": "Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1784,
        "nct_id": "NCT00289757",
        "studyTitle": "Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1785,
        "nct_id": "NCT00291876",
        "studyTitle": "Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1786,
        "nct_id": "NCT00291876",
        "studyTitle": "Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1787,
        "nct_id": "NCT00291876",
        "studyTitle": "Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1788,
        "nct_id": "NCT00291876",
        "studyTitle": "Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1789,
        "nct_id": "NCT00291876",
        "studyTitle": "Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1790,
        "nct_id": "NCT00291876",
        "studyTitle": "Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1791,
        "nct_id": "NCT00291876",
        "studyTitle": "Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1792,
        "nct_id": "NCT00291876",
        "studyTitle": "Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1793,
        "nct_id": "NCT00291876",
        "studyTitle": "Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1798,
        "nct_id": "NCT00778895",
        "studyTitle": "Clinical study in children, 6 months to 3 years of age, to assess the immunogenicity and safety of two dose levels of thimerosal-free Fluviral\u00ae vaccine, using a licensed influenza virus vaccine, Vaxigrip\u00ae as the control",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1805,
        "nct_id": "NCT00410371",
        "studyTitle": "An open-label, randomised, single-dose, parallel-group study to evaluate the pharmacokinetic characteristics, safety and tolerability of up to two formulations (with different taste masking approaches) of an orally disintegrating tablet (ODT) of lamotrigine at 25mg and 200mg versus the immediate release (IR) lamotrigine in healthy subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Mental Disorders"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1806,
        "nct_id": "NCT00274677",
        "studyTitle": "A Multicenter, Double-Blind, Placebo-Controlled, Fixed-Dose, 8-Week Evaluation of the Efficacy and Safety of Lamotrigine in the Treatment of Depression in Patients with Type II Bipolar Disorder",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Bipolar Disorder"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1807,
        "nct_id": "NCT00056277",
        "studyTitle": "Double blind placebo controlled study of lamictal in acute bipolar depression",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Bipolar Disorder"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1813,
        "nct_id": "NCT00355082",
        "studyTitle": "A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Epilepsy",
            "Partial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1814,
        "nct_id": "NCT00043901",
        "studyTitle": "A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Evaluation of Lamotrigine Adjunctive Therapy in Subjects wtih Primary Generalized Tonic-Clonic Seizures",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Epilepsy",
            "Tonic-Clonic"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1815,
        "nct_id": "NCT00264615",
        "studyTitle": "An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine when Switching Patients with Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Epilepsy"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1816,
        "nct_id": "NCT00043875",
        "studyTitle": "A Double-Blind, Placebo-Controlled, Add-On Clinical Trial of the Safety, Pharmacokinetics and Efficacy of Lamictal in Pediatric Age Subjects (1-24 months)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Epilepsy"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1817,
        "nct_id": "NCT00044278",
        "studyTitle": "An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive subjects (1-24 months of age)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Epilepsy"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1821,
        "nct_id": "NCT00067938",
        "studyTitle": "Lamictal for use in treatment of Bipolar Disorder In Adults. A Practical Clinical Assessment of Tolerability and Clinical Effectiveness.",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Bipolar Disorder"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1823,
        "nct_id": "NCT00043914",
        "studyTitle": "A Multicenter, Open-Label Conversion of Valproate Monotherapy to Lamotrigine Monotherapy in Patients with Epilepsy",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Epilepsy"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1828,
        "nct_id": "NCT00144872",
        "studyTitle": "An Open-label Evaluation of LAMICTAL (lamotrigine) Monotherapy for the Treatment of Newly-diagnosed Typical Absence Seizures in Children and Adolescents",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Seizure",
            "Absence"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1829,
        "nct_id": "NCT00086593",
        "studyTitle": "A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of a Flexible Dose of Lamotrigine Compared to Placebo as an Adjunctive Therapy to an Atypical Antipsychotic Agent(s) in Subjects with Schizophrenia",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Schizophrenia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1830,
        "nct_id": "NCT00071747",
        "studyTitle": "A Multi-Center, Double blind, Placebo-controlled, Randomized, Parallel Group Evaluation of the Efficacy of a Flexible Dose of Lamotrigine versus Placebo As Add-On Therapy In Schizophrenia",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Schizophrenia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1882,
        "nct_id": "NCT00225862",
        "studyTitle": "A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Restless Legs Syndrome"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1887,
        "nct_id": "NCT00381472",
        "studyTitle": "A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment with Ropinirole CR as Adjunctive Therapy in Patients with Parkinson's Disease who are not Optimally Controlled on L-dopa",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Parkinson Disease"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1893,
        "nct_id": "NCT00650104",
        "studyTitle": "101468/196: A Long-Term, Open-Label Continuation Study of Once Daily Administration of Ropinirole CR Tablets to Patients with Parkinson's Disease who Completed the Previous Ropinirole CR Studies 167 or 164",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Parkinson Disease"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1899,
        "nct_id": "NCT00197080",
        "studyTitle": "A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole XR (Extended Release) in Patients with Restless Legs Syndrome",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Restless Legs Syndrome"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1900,
        "nct_id": "NCT00355641",
        "studyTitle": "A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients with Restless Legs Syndrome (RLS)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Restless Legs Syndrome"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1904,
        "nct_id": "NCT00363727",
        "studyTitle": "A two year Phase IIIb randomised, multicenter, double-blind, SINEMET controlled, parallel group, flexible dose study, to assess the effectiveness of controlled release ropinirole add-on therapy to L-dopa at increasing the time to onset of dyskinesia in Parkinson's disease subjects.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Parkinson Disease"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1906,
        "nct_id": "NCT00363857",
        "studyTitle": "A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Restless Legs Syndrome"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1907,
        "nct_id": "NCT00140712",
        "studyTitle": "An open label, single dose, dose rising, multi-centre study to assess the tolerability and pharmacokinetics of Ropinirole Immediate Release in adolescent patients with RLS.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Restless Legs Syndrome"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1913,
        "nct_id": "NCT00373542",
        "studyTitle": "A 12-Week, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Flexible Dose Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome (RLS) in RLS Patients with Sleep Disturbance and Periodic Limb Movements (PLM) During Sleep",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Restless Legs Syndrome"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1929,
        "nct_id": "NCT01372410",
        "studyTitle": "A randomized, double blind, placebo controlled, incomplete block, crossover, dose ranging study to evaluate the dose response of GSK573719 administered once or twice daily over 7 days in patients with Chronic Obstructive Pulmonary Disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1934,
        "nct_id": "NCT00158860",
        "studyTitle": "An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Herpes Genitalis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1935,
        "nct_id": "NCT00297206",
        "studyTitle": "An open-label, single-dose, multicenter, pharmacokinetic, safety and tolerability study of valaciclovir oral suspension in infants and children.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Herpes Simplex"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1943,
        "nct_id": "NCT00116844",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Way Crossover Study to Investigate the Effect of VALTREX 1g Once Daily for 60 Days on Viral Shedding in HSV-2 Seropositive Subjects with No Previous History of Symptomatic Genital Herpes Infection.",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Infections",
            "Herpesviridae"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1944,
        "nct_id": "NCT00306293",
        "studyTitle": "The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed with Genital Herpes Infection",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Herpes Labialis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1948,
        "nct_id": "NCT01244984",
        "studyTitle": "A Long-term Study to Evaluate the Safety and Tolerability of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and FF Inhalation Powder in Japanese Subjects with asthma",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1988,
        "nct_id": "NCT00358813",
        "studyTitle": "An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in Subjects with Renal Impairment",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Vomiting"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1989,
        "nct_id": "NCT00359177",
        "studyTitle": "An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in subjects with Hepatic Impairment",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Vomiting"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1998,
        "nct_id": "NCT00197041",
        "studyTitle": "A study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals\u2019 candidate malaria vaccine RTS,S/AS02A, administered intramuscularly according to a 0, 1 and 2 month vaccination schedule in toddlers and children aged 1 to 4 years in a malaria-endemic region of Mozambique.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Malaria"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 1999,
        "nct_id": "NCT00323622",
        "studyTitle": "An open study for a 2-year period to confirm the safety and immunogenicity of the candidate malaria vaccine RTS,S/AS02A in Mozambican children aged 1 to 4 years at the time of first vaccine dose.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Malaria"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2000,
        "nct_id": "NCT01449929",
        "studyTitle": "A Phase IIIb, randomized, open-label study of the safety and efficacy of GSK1349572 (dolutegravir, DTG) 50 mg once daily compared to darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily each administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral na\u00efve adult subjects",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus I"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2072,
        "nct_id": "NCT00404378",
        "studyTitle": "An open-label, two period, fixed sequence study of healthy subjects to assess the effect of repeat oral dosing of ketoconazole on the pharmacokinetics of a single oral dose of [GW679769]",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Nausea and Vomiting",
            "Chemotherapy-Induced"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2073,
        "nct_id": "NCT00404274",
        "studyTitle": "An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Steady-State Warfarin when Co-administered with Repeat Doses of Casopitant [GW679769] in Healthy Adult Subjects.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Nausea and Vomiting",
            "Chemotherapy-Induced"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2074,
        "nct_id": "NCT00460707",
        "studyTitle": "A Phase I, Randomized, Double-Blind Study to Assess the Effects of Repeat Oral Dosing of Ketoconazole on the Pharmacokinetics of Repeat Oral Dosing of Casopitant [GW679769] in Healthy Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Nausea and Vomiting",
            "Chemotherapy-Induced"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2153,
        "nct_id": "NCT00228917",
        "studyTitle": "Assess reactogenicity & safety of a booster of either Tritanrix\u2122-HepB/Hib-MenAC or Tritanrix\u2122-HepB/Hiberix\u2122 given (single-blind) at 15-18 (Philippines)/15-24 mths (Thailand) & a dose of Mencevax\u2122 ACWY at 24-30 mths (open label)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2154,
        "nct_id": "NCT00228917",
        "studyTitle": "Assess reactogenicity & safety of a booster of either Tritanrix\u2122-HepB/Hib-MenAC or Tritanrix\u2122-HepB/Hiberix\u2122 given (single-blind) at 15-18 (Philippines)/15-24 mths (Thailand) & a dose of Mencevax\u2122 ACWY at 24-30 mths (open label)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2155,
        "nct_id": "NCT00612105",
        "studyTitle": "Study to evaluate immunogenicity, reactogenicity and safety of an investigational vaccination regimen as compared to extemporaneously mixed GlaxoSmithKline Biological\u2019s Hiberix and Tritanrix-HepB vaccines, when administered intramuscularly in infants at 6, 10 and 14 weeks of age",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2156,
        "nct_id": "NCT00136604",
        "studyTitle": "Assess immunogenicity, safety & reactogenicity of a 4th dose of GSK Biologicals\u2019 Tritanrix\u2122-HepB/Hib-MenAC at 15-24 m & of a dose of Mencevax\u2122 ACWY at 24-30 m in subjects primed with 3 doses of Tritanrix\u2122-HepB/Hib-MenAC",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2157,
        "nct_id": "NCT00197275",
        "studyTitle": "Demonstrate lot-to-lot consistency of final production method of GSK Biologicals' Hib-MenAC vaccine mixed extemporaneously with Tritanrix\u2122-HepB & demonstrate its non-inferiority vs Tritanrix\u2122-HepB/Hiberix\u2122 in healthy infants at 2, 4 and 6 months",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2160,
        "nct_id": "NCT00332566",
        "studyTitle": "Immunogenicity, Reactogenicity & Safety of a Booster Dose of GSK Biologicals\u2019 DTPw-HBV/Hib Kft Vaccine Vs GSK Biologicals\u2019 DTPw-HBV/Hib Vaccine, in Infants Who Received a 3-Dose Primary Vaccination Course With the Same Vaccines.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2168,
        "nct_id": "NCT00397215",
        "studyTitle": "Evaluate immunogenicity & safety of a single or double-dose of the pandemic influenza candidate vaccine (GSK1562902A) given following a two-administration schedule (21 days apart) in adults over 60 yrs",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2169,
        "nct_id": "NCT00397215",
        "studyTitle": "Evaluate immunogenicity & safety of a single or double-dose of the pandemic influenza candidate vaccine (GSK1562902A) given following a two-administration schedule (21 days apart) in adults over 60 yrs",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2170,
        "nct_id": "NCT00397215",
        "studyTitle": "Evaluate immunogenicity & safety of a single or double-dose of the pandemic influenza candidate vaccine (GSK1562902A) given following a two-administration schedule (21 days apart) in adults over 60 yrs",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2171,
        "nct_id": "NCT00322335",
        "studyTitle": "Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix\u2122 Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Haemophilus influenzae type b; Neisseria Meningitidis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2172,
        "nct_id": "NCT00322335",
        "studyTitle": "Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix\u2122 Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Haemophilus influenzae type b; Neisseria Meningitidis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2173,
        "nct_id": "NCT00322335",
        "studyTitle": "Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix\u2122 Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Haemophilus influenzae type b; Neisseria Meningitidis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2174,
        "nct_id": "NCT00322335",
        "studyTitle": "Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix\u2122 Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Haemophilus influenzae type b; Neisseria Meningitidis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2175,
        "nct_id": "NCT00289731",
        "studyTitle": "Evaluate the Effect of Several Risk Factors That Are Likely to Influence the Immunogenicity of GSK Biologicals\u2019 Combined Hepatitis A & B Vaccine, vs Separately Administered Monovalent Hepatitis A and Hepatitis B Vaccines",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A; Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2176,
        "nct_id": "NCT00289731",
        "studyTitle": "Evaluate the Effect of Several Risk Factors That Are Likely to Influence the Immunogenicity of GSK Biologicals\u2019 Combined Hepatitis A & B Vaccine, vs Separately Administered Monovalent Hepatitis A and Hepatitis B Vaccines",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A; Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2177,
        "nct_id": "NCT00289731",
        "studyTitle": "Evaluate the Effect of Several Risk Factors That Are Likely to Influence the Immunogenicity of GSK Biologicals\u2019 Combined Hepatitis A & B Vaccine, vs Separately Administered Monovalent Hepatitis A and Hepatitis B Vaccines",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A; Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2178,
        "nct_id": "NCT00289731",
        "studyTitle": "Evaluate the Effect of Several Risk Factors That Are Likely to Influence the Immunogenicity of GSK Biologicals\u2019 Combined Hepatitis A & B Vaccine, vs Separately Administered Monovalent Hepatitis A and Hepatitis B Vaccines",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A; Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2179,
        "nct_id": "NCT00197171",
        "studyTitle": "Evaluate the persistence of immune response of GSK Biologicals\u2019 TWINRIX\u2122 ADULT, administered according to 0,6 month schedule and 0,12 month schedule, in volunteers aged 12-15 years inclusive at the time of first vaccine dose",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatitis A; Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2180,
        "nct_id": "NCT00197171",
        "studyTitle": "Evaluate the persistence of immune response of GSK Biologicals\u2019 TWINRIX\u2122 ADULT, administered according to 0,6 month schedule and 0,12 month schedule, in volunteers aged 12-15 years inclusive at the time of first vaccine dose",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatitis A; Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2181,
        "nct_id": "NCT00289770",
        "studyTitle": "A double blind randomised, comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals\u2019 combined hepatitis A - hepatitis B vaccine when administered in healthy adults",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatitis A; Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2182,
        "nct_id": "NCT00289770",
        "studyTitle": "A double blind randomised, comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals\u2019 combined hepatitis A - hepatitis B vaccine when administered in healthy adults",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatitis A; Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2183,
        "nct_id": "NCT00289770",
        "studyTitle": "A double blind randomised, comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals\u2019 combined hepatitis A - hepatitis B vaccine when administered in healthy adults",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatitis A; Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2184,
        "nct_id": "NCT00289770",
        "studyTitle": "A double blind randomised, comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals\u2019 combined hepatitis A - hepatitis B vaccine when administered in healthy adults",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatitis A; Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2185,
        "nct_id": "NCT00289770",
        "studyTitle": "A double blind randomised, comparative study of the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals\u2019 combined hepatitis A - hepatitis B vaccine when administered in healthy adults",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatitis A; Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2186,
        "nct_id": "NCT00289718",
        "studyTitle": "Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatitis A; Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2187,
        "nct_id": "NCT00289718",
        "studyTitle": "Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatitis A; Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2188,
        "nct_id": "NCT00289718",
        "studyTitle": "Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatitis A; Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2190,
        "nct_id": "NCT00289718",
        "studyTitle": "Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatitis A; Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2192,
        "nct_id": "NCT00291876",
        "studyTitle": "Double-blind randomized study to evaluate the immunogenicity and reactogenicity of two different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 12 month schedule in healthy adult volunteers",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2193,
        "nct_id": "NCT00289757",
        "studyTitle": "Double-blind, randomized study to evaluate the immunogenicity and reactogenicity of three different lots of GlaxoSmithKline Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per mL and injected according to a 0, 6 month schedule in healthy adult subjects",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2194,
        "nct_id": "NCT00240500",
        "studyTitle": "Long-Term Follow Up Study at Years 16-20, to Evaluate the Persistence of Immune Response of GlaxoSmithKline Biologicals' Hepatitis B Vaccine in Newborns of HBeAg+ and HBsAg+ Mothers",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2198,
        "nct_id": "NCT00586339",
        "studyTitle": "Evaluation of the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV vaccine 580299 (Cervarix TM) in adult human immunodeficiency virus (HIV) infected female subjects",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2199,
        "nct_id": "NCT00518336",
        "studyTitle": "Follow-up study to evaluate the long-term efficacy of a HPV vaccine (580299) in healthy young adult women in Brazil",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2200,
        "nct_id": "NCT00518336",
        "studyTitle": "Follow-up study to evaluate the long-term efficacy of a HPV vaccine (580299) in healthy young adult women in Brazil",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2201,
        "nct_id": "NCT00518336",
        "studyTitle": "Follow-up study to evaluate the long-term efficacy of a HPV vaccine (580299) in healthy young adult women in Brazil",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2205,
        "nct_id": "NCT00136604",
        "studyTitle": "A phase III, multicentre booster vaccination study to assess the immunogenicity, safety and reactogenicity of a dose of Mencevax\u2122 ACWY at 24 to 30 months of age in subjects primed with an investigational vaccination regimen in study 100480 and boosted at 15 to 24 months of age in study 104727.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Meningococcal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2206,
        "nct_id": "NCT00317109",
        "studyTitle": "Booster Vaccination Study to Assess Safety & Reactogenicity of a Dose of DTPw-HBV/Hib Vaccine and to Assess the Immunogenicity, Safety & Reactogenicity of a Dose of Mencevax\u2122 ACW in Subjects Primed in Study 759346/007",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Meningococcal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2207,
        "nct_id": "NCT00291343",
        "studyTitle": "Booster Vaccination Study to Assess Immunogenicity & Safety of a Dose of GSK Biologicals' Mencevax\u2122 ACWY & 1/5th of a Dose of Mencevax\u2122 ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Meningococcal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2208,
        "nct_id": "NCT00291343",
        "studyTitle": "Booster Vaccination Study to Assess Immunogenicity & Safety of a Dose of GSK Biologicals' Mencevax\u2122 ACWY & 1/5th of a Dose of Mencevax\u2122 ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Meningococcal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2225,
        "nct_id": "NCT01264939",
        "studyTitle": "A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic Idiopathic Urticaria (CIU)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2414,
        "nct_id": "NCT00518115",
        "studyTitle": "A 16-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Doses and Multiple Treatment Regimens of GSK716155, with Byetta as an Open Label Active Reference, in Subjects with Type 2 Diabetes Mellitus",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2419,
        "nct_id": "NCT00103922",
        "studyTitle": "A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO\u00ae (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2424,
        "nct_id": "NCT00812929",
        "studyTitle": "A multi-centre, randomized, double-blind, five-way crossover study evaluating the dose response and duration of action of GSK2190915 compared to placebo in subjects with mild asthma who experience exercise induced bronchoconstriction.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2429,
        "nct_id": "NCT01387217",
        "studyTitle": "A single-blind, placebo-controlled, two part study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of GSK2018682 in healthy volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Multiple Sclerosis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2430,
        "nct_id": "NCT01431937",
        "studyTitle": "A single-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat ascending doses of GSK2018682 (S1P1 agonist) in healthy volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Multiple Sclerosis",
            "Relapsing-Remitting"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2431,
        "nct_id": "NCT01462669",
        "studyTitle": "An open-label, randomized, single centre, 4-way crossover study to evaluate the pharmacokinetics of single oral doses of ezogabine/retigabine in healthy adult Taiwanese subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Epilepsy"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2444,
        "nct_id": "NCT00499707",
        "studyTitle": "A randomized, double-blind trial to evaluate the efficacy and safety of fixed dose rosiglitazone/metformin combination therapy compared to both rosiglitazone and metformin monotherapies in drug naive type 2 diabetes mellitus subjects",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2447,
        "nct_id": "NCT00069836",
        "studyTitle": "A 24 week, randomised, double blind, parallel study to compare the change in HbA1c with AVANDAMET\u00ae (8.0mg / 2.0g) plus insulin to placebo plus insulin, in subjects with type 2 diabetes starting insulin therapy",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2450,
        "nct_id": "NCT01424514",
        "studyTitle": "A randomised, double blind placebo controlled, 2 way cross over study in adults with non-allergic rhinits to evaluate the effect of once daily administration of intranasal SB-705498 12mg for two weeks and the response to a chamber challenge of cold dry air",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Rhinitis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2463,
        "nct_id": "NCT00373945",
        "studyTitle": "A Retrospective Case-Control Study to Estimate the Sensitivity and Specificity of a Pharmacogenetic Marker (HLA-B*5701) in Subjects With and Without Hypersensitivity to Abacavir",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus I"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2629,
        "nct_id": "NCT00689741",
        "studyTitle": "A double-blind, placebo-controlled, randomised study of the efficacy of an HPV-16/18 VLP vaccine in the prevention of HPV-16 and/or HPV-18 cervical infection in healthy adolescent and young adult women in North America and Brazil.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2749,
        "nct_id": "NCT00662909",
        "studyTitle": "A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects with Symptoms of Overactive Bladder.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Urinary Bladder",
            "Overactive"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2015-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2754,
        "nct_id": "NCT00317174",
        "studyTitle": "Assess immune persistence & memory by giving plain PRP,PSA & PSC (10 mths age), & immunogenicity & safety of a Tritanrix\u2122-HBV/Hib-MenAC/ Tritanrix\u2122-HBV/Hib2.5 booster (15-18 mths age) in previously primed subjects",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2755,
        "nct_id": "NCT00317161",
        "studyTitle": "Study to show lot-to-lot consistency of Hib-MenAC mixed with Tritanrix\u2122-HBV, its non-inferiority to Tritanrix\u2122-HBV/Hiberix\u2122 with or without Meningitec\u2122, and MenA response in 2, 4, 6 month infants with hepatitis B birth dose",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2756,
        "nct_id": "NCT00317187",
        "studyTitle": "Study to assess immunogenicity and non-inferiority of investigational vaccination regimen as compared to Tritanrix-HepB/Hiberix and as compared to Meningitec when administered to healthy infants",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2759,
        "nct_id": "NCT00406211",
        "studyTitle": "Follow-up to evaluate the the immunogenicity & safety of GSK Biologicals\u2019 MMRV vaccine given as a two-dose schedule in the second year of life, as compared to separate administration of GSK Biologicals\u2019 Priorix\u00ae & Varilrix\u00ae.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Measles; Mumps; Rubella; Varicella"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2766,
        "nct_id": "NCT00109330",
        "studyTitle": "A phase III, observer-blinded randomised, multi-centre clinical study of the safety, immunogenicity and consistency of three manufacturing lots of GSK Biologicals' candidate Tdap vaccine as compared to a US-licensed Td vaccine when given as a booster dose to healthy adolescents (10-18 years of age)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Acellular pertussis; Diphtheria; Tetanus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2770,
        "nct_id": "NCT01236040",
        "studyTitle": "Immunogenicity and safety study of GSK Biologicals\u2019 cell culture derived pandemic influenza vaccines GSK2590066A and GSK2592984A administered to healthy adults 18 - 49 years old",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2772,
        "nct_id": "NCT01440387",
        "studyTitle": "A Phase IIIA study of immunogenicity and safety of GSK Biologicals\u2019 quadrivalent split virion influenza vaccine FLU-Q-QIV in adults aged 18 years and older",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2776,
        "nct_id": "NCT01051661",
        "studyTitle": "A study to evaluate the safety and efficacy of A/California/7/2009 (H1N1)v-like vaccines GSK2340274A and GSK2340273A in children aged 6 months to less than 10 years of age",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2793,
        "nct_id": "NCT00383591",
        "studyTitle": "A phase III, clinical trial comparing the immunogenicity and safety of SmithKline Beecham Biologicals new adjuvanted hepatitis B vaccine to a double dose of Engerix\u2122-B, in pre-haemodialysis/haemodialysis patients (>=15 years of age)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2794,
        "nct_id": "NCT00779766",
        "studyTitle": "Efficacy, immunogenicity and safety of GlaxoSmithKline Biologicals\u2019 HPV GSK 580299 vaccine in healthy Chinese female subjects",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2795,
        "nct_id": "NCT00929526",
        "studyTitle": "Long-term extension study of the efficacy of the 580299 vaccine in the prevention of HPV-16 and/or HPV-18 associated cervical intraepithelial neoplasia (CIN) in Japanese women vaccinated in the primary vaccination study NCT00316693",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2800,
        "nct_id": "NCT00377585",
        "studyTitle": "A phase II/III, observer-blind, Multi-Country, Multi-Centre, randomized study to demonstrate the superiority in terms of immunogenicity of adjuvanted influenza vaccine administered in adults aged 50 years and older compared to Fluarix\u2122",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2802,
        "nct_id": "NCT00750360",
        "studyTitle": "Study to monitor the safety and reactogenicity of GlaxoSmithKline Biologicals\u2019 influenza split vaccine FLUARIX\u2122 administered according to the Prescribing Information in Korean subjects aged more than 6 months of age at the time of vaccination",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2820,
        "nct_id": "NCT00333723",
        "studyTitle": "A 24-Week Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of AVANDIA (8mg once daily) in Combination with Glyburide in African American and Hispanic Patients with Type 2 Diabetes Mellitus who are Inadequately Controlled on Glyburide Monotherapy",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2821,
        "nct_id": "NCT00501020",
        "studyTitle": "A 24-Week Randomized, Double-blind, Double-Dummy, Multicenter Study to Compare the Efficacy of AVANDIA when added to Submaximal Doses of Metformin and to Compare the Tolerability of the Combination to Metformin Monotherapy when Administered to Subjects with Type 2 Diabetes Mellitus",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2822,
        "nct_id": "NCT00044460",
        "studyTitle": "A 24-week Randomized, Double-Blind, Parallel-Group, Multicenter Study to Demonstrate the Efficacy and Safety of Two Different Rosiglitazone Dosing Regimens, 4mg OD and 8mg OD, in Poorly-Controlled Drug Naive Patients with Type 2 Diabetes Mellitus",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2824,
        "nct_id": "NCT00197132",
        "studyTitle": "A single-centre, randomised, double-blind, placebo controlled, two 12 week period, cross-over phase III study to investigate the effect of rosiglitazone 4mg bd on the vasodilator response to hyperinsulinaemia in obese insulin resistant subjects.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2937,
        "nct_id": "NCT01147692",
        "studyTitle": "An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Simvastatin When Coadministered With Albiglutide in Healthy Adult Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2938,
        "nct_id": "NCT01357889",
        "studyTitle": "A multidose study in subjects with type 2 diabetes mellitus to assess the pharmacokinetics and pharmacodynamics of albiglutide",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2949,
        "nct_id": "NCT00671216",
        "studyTitle": "A single centre, randomised, placebo-controlled, four-way cross over study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705 and GW642444 as monotherapies and in combination in healthy subjects.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2970,
        "nct_id": "NCT00232596",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/day) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Seizures"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 2971,
        "nct_id": "NCT00235755",
        "studyTitle": "Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Seizures"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3013,
        "nct_id": "NCT00989404",
        "studyTitle": "A Randomized, Placebo Controlled, 3-Way Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo 10mg Administered Twice Daily for 5 Days by a Rotahaler Compared to the Diskhaler in Healthy Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Influenza A Virus",
            "H1N1 Subtype"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3084,
        "nct_id": "NCT00289718",
        "studyTitle": "Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatitis A; Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2014-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3085,
        "nct_id": "NCT00040664",
        "studyTitle": "A 48 Week, Phase II, Open-label, Multi-Cohort, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GW433908/Ritonavir once daily and GW433908/Ritonavir BID when Administered to HIV-1 Infected, Antiretroviral Na\u00efve and Experienced, Pediatric Subjects 2 to 18 Years Old.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2015-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3086,
        "nct_id": "NCT00071760",
        "studyTitle": "A 48 week, Phase II, open-label, 2-cohort, multicenter study to evaluate the pharmacokinetics, safety, tolerability and antiviral activity of GW433908 and GW433908/RTV when administered to HIV-1 infected protease inhibitor (PI) naive and PI-experienced pediatric subjects aged 4 weeks to &lt;2 years.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2015-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3087,
        "nct_id": "NCT00089583",
        "studyTitle": "A 48 Week, Phase II, non-comparative, open-label, multi-cohort, multicenter study to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of GW433908/Ritonavir BID when administered to HIV-1 infected PI-Naive and experienced, Pediatric Subjects 2 to 18 years old and of GW433908 BID Administered to PI-Naive Pediatric subjects 2 to &lt;6 years old.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus I"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2015-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3127,
        "nct_id": "NCT01475734",
        "studyTitle": "A single-site, randomized, double-blind, placebo-controlled, parallel-group, stepped glucose clamp study to assess the effects of albiglutide on counter-regulatory hormone responses and recovery from hypoglycemia in subjects with Type 2 diabetes mellitus.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3128,
        "nct_id": "NCT00344006",
        "studyTitle": "A multi-centre, randomised, double-blind, double dummy study comparing the efficacy and safety of chlorproguanil-dapsone-artesunate versus artemether-lumefantrine in the treatment of acute uncomplicated Plasmodium falciparum malaria in children and adolescents in Africa.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Malaria",
            "Falciparum"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3129,
        "nct_id": "NCT00371735",
        "studyTitle": "A multi-centre, randomised, double-blind study to compare the efficacy and safety of chlorproguanil-dapsone-artesunate versus chlorproguanil-dapsone in the treatment of acute uncomplicated Plasmodium falciparum malaria in children, adolescents and adults in Africa.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Malaria",
            "Falciparum"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3131,
        "nct_id": "NCT00405080",
        "studyTitle": "An Open-Label, Two Period, Fixed Sequence Study of Healthy Subjects to Assess the Effect of Repeat Oral Dosing of [Rifampin] on the Pharmacokinetics of a Single Oral Dose of [GW679769]",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Nausea and Vomiting",
            "Chemotherapy-Induced"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3141,
        "nct_id": "NCT00984659",
        "studyTitle": "Validation of a New Shortness of Breath with Daily Activities Questionnaire in patients with Chronic Obstructive Pulmonary Disease",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3143,
        "nct_id": "NCT01031108",
        "studyTitle": "A Phase I, Randomized, Placebo-Controlled, Crossover Clinical Trial to Assess the Safety of Oral SRT2104 and its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects with Type 2 Diabetes Mellitus",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3156,
        "nct_id": "NCT00749359",
        "studyTitle": "An open-label, randomized, single dose, two-period crossover study to demonstrate bioequivalence between the controlled release paroxetine tablet (37.5 mg) manufactured at Cidra and Mississauga",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Depressive Disorder"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3157,
        "nct_id": "NCT01332513",
        "studyTitle": "An open label, randomised, repeat dose study to assess the pharmacokinetic performance of five ezogabine/retigabine modified release (MR) formulations at steady state compared to the immediate release (IR) formulation.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Epilepsy"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3161,
        "nct_id": "NCT00048204",
        "studyTitle": "An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Fixed-Dose Study Comparing the Efficacy and Safety of GW597599B or Paroxetine to Placebo in Moderately to Severely Depressed Patients with Major Depressive Disorder",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Depressive Disorder",
            "Major"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3215,
        "nct_id": "NCT01071850",
        "studyTitle": "A Phase 2, Double-Blind, Randomized, Placebo and Active-Controlled Dose-Finding Study to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of ASP1941 in Subjects with Type 2 Diabetes Mellitus",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3218,
        "nct_id": "NCT00826280",
        "studyTitle": "A Phase 3b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Caffeine Intake on Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) in Subjects Administered Regadenoson",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Myocardial Perfusion Imaging"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3222,
        "nct_id": "NCT00519467",
        "studyTitle": "An open, randomised, multi-centre dose-ranging phase II study to evaluate LAPDAP in combination with three different doses of artesunate.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Malaria"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3223,
        "nct_id": "NCT00879827",
        "studyTitle": "Immunogenicity and reactogenicity of GSK Biologicals\u2019 DTPa-HBV-IPV and Hib vaccines when administered concomitantly to healthy infants administered as a three-dose primary vaccination course at the age of 1.5, 3.5 and 6 months",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3227,
        "nct_id": "NCT00366366",
        "studyTitle": "An open clinical study to assess the immunogenicity and safety of GSK Bio\u2019s DTPa-HBV-IPV vaccine mixed in one syringe with Hib vaccine, as a primary vaccination course to pre-term infants(<37 weeks) at 2, 4 and 6 months of age in comparison with infants born after normal gestation period",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Acellular pertussis; Diphtheria; Hepatitis B; Poliomyelitis; Tetanus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3228,
        "nct_id": "NCT01457560",
        "studyTitle": "Study to assess the immunogenicity and reactogenicity of DTPa-HBV-IPV mixed with Hib vaccine in healthy infants, followed by a dose of the same vaccine administered simultaneously with one dose of oral polio vaccine (OPV)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3243,
        "nct_id": "NCT00290303",
        "studyTitle": "Study to show non-inferiority of Tritanrix\u2122-HepB/Hib-MenAC (+/- hepatitis B vaccine at birth) versus Tritanrix\u2122-HepB/Hiberix\u2122 without hepatitis B vacc. at birth for antibody response to all vaccine antigens given in healthy infants",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3247,
        "nct_id": "NCT00317122",
        "studyTitle": "Demonstrate non-inferiority of GSK Biologicals\u2019 Tritanrix\u2122-HepB/Hib-MenAC vs Tritanrix\u2122-HepB/Hiberix\u2122 with respect to anti-HBs immune response, when given to healthy infants at 6,10 & 14 weeks age, after a birth dose of hepatitis B vaccine",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3259,
        "nct_id": "NCT01277705",
        "studyTitle": "Assess immunogenicity, reactogenicity of GSK Biologicals\u2019-dTpa-IPV vaccine versus dTpa & IPV vaccines administered separately & compared with Aventis Pasteur MSD\u2019s Td-IPV vaccine when administered to healthy adolescents & adults",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Acellular pertussis; Diphtheria; Tetanus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3267,
        "nct_id": "NCT00742261",
        "studyTitle": "An Open-label, Randomized, Two-way Balanced Crossover Study to Investigate the Bioavailability of two forms ofGSK1363089 in Subjects with Solid Tumors",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Solid Tumours"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3268,
        "nct_id": "NCT00726323",
        "studyTitle": "A Phase 2 Study of the c-Met RTK Inhibitor GSK1363089 (Formerly XL880) in Subjects with Papillary Renal-Cell Carcinoma",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Carcinoma",
            "Renal Cell"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3272,
        "nct_id": "NCT01018017",
        "studyTitle": "A Phase IIa, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT2104 Capsules Administered for 28 Days to Subjects with Type 2 Diabetes Mellitus",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3273,
        "nct_id": "NCT00933062",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Phase I Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered as Single and Multiple Doses in the Fed State to Normal Healthy Male Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3274,
        "nct_id": "NCT00937326",
        "studyTitle": "A Phase II, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3275,
        "nct_id": "NCT00938275",
        "studyTitle": "A phase I randomized, open-label, clinical study to assess the effect of food and gender on the pharmacokinetics of SRT2104 administered as an oral suspension or capsule formulation to normal healthy volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3276,
        "nct_id": "NCT01014117",
        "studyTitle": "A Phase I study to evaluate single and multiple (seven) oral doses of SRT2104 on the endotoxin induced inflammatory response in healthy male subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Sepsis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3277,
        "nct_id": "NCT00964340",
        "studyTitle": "A Randomized, Placebo-Controlled, Double-Blind, Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral SRT2104 Capsules Administered to Healthy Elderly Subjects for 28 Days",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Atrophy",
            "Muscular"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3278,
        "nct_id": "NCT00920660",
        "studyTitle": "A randomised, double-blind, placebo-controlled, multi-way crossover study to assess the effects of single oral doses of SRT2104 and prednisolone on biomarkers in blood in healthy volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3279,
        "nct_id": "NCT01702493",
        "studyTitle": "A Phase 1, Open-Label, Randomized, Controlled, Four-Period Crossover Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Psoriasis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3302,
        "nct_id": "NCT00197249",
        "studyTitle": "A phase III, open, randomized, multicentric study to compare the reactogenicity and immunogenicity of GSK Bios\u2019 combined Vi polysaccharide typhoid vac and inactivated hepatitis A vac, to that elicited by GSK Bios\u2019 hepatitis A vac, admin singly or concomitantly with GSK Bios\u2019 Vi polysaccharide vac",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatitis A"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3303,
        "nct_id": "NCT00119743",
        "studyTitle": "Assess, in young children, the efficacy in preventing acute otitis media (AOM) of GSK Biologicals undecavalent pneumococcal-protein D conjugate vaccine, when administered as a three dose primary vaccination course during the first year of life with a booster dose in the second year of life.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Otitis Media"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3308,
        "nct_id": "NCT00429481",
        "studyTitle": "Study to assess efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Bio\u2019s oral live attenuated human rotavirus vaccine at different viral concentrations in healthy infants previously uninfected with human rotavirus and approximately 3 months of age",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Rotavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3309,
        "nct_id": "NCT00699764",
        "studyTitle": "Safety of SmithKline Beecham Biologicals' Herpes Simplex candidate vaccine (gD2t) with MPL & its efficacy to prevent genital herpes disease in HSV positive or negative consorts of subjects with genital herpes disease",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Herpes Simplex"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3312,
        "nct_id": "NCT00224484",
        "studyTitle": "A study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals' herpes simplex candidate vaccine (gD2\u2011AS04) in healthy HSV seronegative and seropositive female subjects aged 10-17 years.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Herpes Simplex"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3314,
        "nct_id": "NCT00224471",
        "studyTitle": "Study to Compare Immunogenicity & Safety of 3 comercial Lots of GlaxoSmithKline (GSK) Biologicals\u2019 herpes simplex candidate Vaccine in Healthy HSV-1 & -2 Seronegative (HSV 1-/2-) Females of 10\u201317 y & Vaccine Immunogenicity in Healthy HSV 1-/2- Females of 10\u201317 y With Healthy HSV 1-/2- Adult Females",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Herpes Simplex"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3316,
        "nct_id": "NCT01277042",
        "studyTitle": "Immunogenicity and safety study of GSK Biologicals\u2019 HPV vaccine (GSK 580299) in healthy adult Chinese female subjects",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3319,
        "nct_id": "NCT00693615",
        "studyTitle": "Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine against Human Papillomavirus Types 16 and 18, when Formulated with Aluminum Hydroxide, AS04, or without Adjuvant, in Healthy Adult Female Volunteers",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3320,
        "nct_id": "NCT00693966",
        "studyTitle": "A Phase II Double-Blind, Randomized, Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine Against Human Papillomavirus Types 16 and 18, in Healthy Adult Female Volunteers",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3326,
        "nct_id": "NCT00388440",
        "studyTitle": "Phase IV open study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK)Biologicals live attenuated Measles-Mumps-Rubella (MMR) vaccine when given to healthy children at the age of 12 to 18months in Singapore.",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Measles; Mumps; Rubella"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3335,
        "nct_id": "NCT00137917",
        "studyTitle": "A primary vaccination study to evaluate immunogenicity, safety & reactogenicity of 3 doses of GSK Biologicals/Finlay\u2019s meningococcal B candidate vaccine given intramuscularly using either 0-2-4 mth or 0-1-6 mth schedule to healthy subjects aged 12-18 yrs",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Meningococcal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3336,
        "nct_id": "NCT00135486",
        "studyTitle": "Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals\u2019 MenC-TT vaccine (2 formulations) given with Infanrix hexa\u00ae + GSK Biologicals\u2019 Hib MenC-TT vaccine (2 formulations) given with Infanrix penta\u00ae to infants in mths 3,4,5 of life",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Meningococcal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3337,
        "nct_id": "NCT00135564",
        "studyTitle": "Evaluate the persistence and immune memory induced by a primary vaccination course with GSK Biologicals\u2019 MenC-TT (1 formulation) & GSK Biologicals\u2019 Hib-MenC-TT (2 formulations) or Meningitec\u2122 in healthy toddlers aged 12-15 mths primed in study 711202/001",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Meningococcal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3347,
        "nct_id": "NCT00425737",
        "studyTitle": "A study to assess the efficacy, immunogenicity and safety of two doses of oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in healthy infants.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Rotavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3348,
        "nct_id": "NCT00729001",
        "studyTitle": "Phase II, double-blind, randomized, placebo-controlled study of 2 doses of GSK Bios\u2019 live attenuated human rotavirus vaccine at different virus concentrations (10 5.2 and 10 6.4 ffu) in healthy infants following a 0, 2 month schedule and previously uninfected with human rotavirus",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Rotavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3349,
        "nct_id": "NCT00385320",
        "studyTitle": "To assess the efficacy, immuno & safety of 2 doses of GSK HRV vaccine at different virus concentrations in healthy infants aged 2 months & previously uninfected with HRV, concurrently given with DTPw-HBV, Hib.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Rotavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3350,
        "nct_id": "NCT00346892",
        "studyTitle": "Study of safety, reactogenicity and immunogenicity of two doses of GSK Bio\u2019s oral live attenuated human rotavirus vaccine co-administered with either oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in healthy infants in South Africa",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Rotavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3353,
        "nct_id": "NCT00920803",
        "studyTitle": "A Phase 1, Double-Blind, Randomized Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects with Colorectal Cancer and Hepatic Metastases",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Neoplasms",
            "Colorectal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3384,
        "nct_id": "NCT01706263",
        "studyTitle": "U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects with Acne",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Acne Vulgaris"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3386,
        "nct_id": "NCT00108082",
        "studyTitle": "A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Modified Release Formulation (COREG MR) and Atenolol in Combination with and Compared to an Angiotensin Converting Enzyme Inhibitor (Lisinopril) on Left Ventricular Mass Regression in Hypertensive Patients with Left Ventricular Hypertrophy (LVH).",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hypertrophy",
            "Left Ventricular"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3387,
        "nct_id": "NCT00273052",
        "studyTitle": "A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Phosphate Modified Release Formulation (COREG- MR) with Metoprolol Succinate (TOPROL XL) on the Lipid Profile in Normolipidemic, or Mildly Dyslipidemic Hypertensive Patients",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hypertension"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3390,
        "nct_id": "NCT01751074",
        "studyTitle": "A Two-Part, Open-label, Sequential, Double Cohort, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Rosuvastatin when Co administered with Darapladib in Healthy Adult Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Atherosclerosis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3391,
        "nct_id": "NCT01916720",
        "studyTitle": "A multi-centre, randomised, double-blind, placebo-controlled, parallel-group study to investigate the effect of the Lp-PLA2 inhibitor SB-480848 (40, 80mg od) on carotid plaque composition in patients with carotid artery disease and planned carotid endarterectomy, stratified for statin use and gender, after 14+/-4 days treatment",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Atherosclerosis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3394,
        "nct_id": "NCT01154114",
        "studyTitle": "An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and Subjects with Moderate Hepatic Impairment",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Atherosclerosis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3401,
        "nct_id": "NCT00411073",
        "studyTitle": "A Study to Evaluate the Effect of Repeat Oral Doses of Darapladib on Cardiac Conduction as Compared to Placebo and a Single Oral Dose of Moxifloxacin",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Atherosclerosis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3402,
        "nct_id": "NCT00551317",
        "studyTitle": "A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of darapladib (SB480848) in healthy Japanese male subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Atherosclerosis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3404,
        "nct_id": "NCT00743860",
        "studyTitle": "A Study to Evaluate the Pharmacokinetics of the Enteric-Coated Micronized Free Base Formulation of Darapladib [SB-480848] and its Metabolites in Healthy Volunteers.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Atherosclerosis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3418,
        "nct_id": "NCT01499446",
        "studyTitle": "A randomised, double-blind, double dummy, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GW685698X 100mcg administered once daily either in the morning or the evening and GW685698X 250mcg administered once daily in the evening all administered by inhalation via DISKHALER for 28 days in subjects with persistent bronchial asthma.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3423,
        "nct_id": "NCT00398476",
        "studyTitle": "Study FFU108556, A Patient Preference Evaluation Study of Fluticasone Furoate Nasal Spray and FluticasonePropionate Aqueous Nasal Spray in Subjects with Allergic Rhinitis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Rhinitis",
            "Allergic",
            "Perennial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3424,
        "nct_id": "NCT01498653",
        "studyTitle": "A randomised, double-blind, double-dummy, parallel group study to evaluate the efficacy and safety of fluticasone furoate/vilanterol trifenatate (FF/VI) inhalation powder delivered once daily compared to fluticasone propionate delivered twice daily in the treatment of asthma in adolescent and adult subjects of Asian ancestry currently treated with high-strength inhaled corticosteroids or mid-strength ICS/LABA combination therapy.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3427,
        "nct_id": "NCT01376245",
        "studyTitle": "A 24-week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder Delivered Once Daily via a Dry Powder Inhaler Compared with Placebo in Subjects of Asian Ancestry with Chronic Obstructive Pulmonary Disease",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3432,
        "nct_id": "NCT00725712",
        "studyTitle": "A Phase 2 Study of GSK1363089 (XL880) Administered Orally to Subjects with Metastatic Gastric Cancer",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Neoplasms",
            "Gastrointestinal Tract"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3433,
        "nct_id": "NCT00742131",
        "studyTitle": "A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Solid Tumours"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3434,
        "nct_id": "NCT00725764",
        "studyTitle": "A Phase 2 Study of the MET RTK Inhibitor GSK1363089 (formerly XL880) in Subjects With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Neoplasms",
            "Head and Neck"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3437,
        "nct_id": "NCT01160224",
        "studyTitle": "A randomized, double-blind, placebo-controlled, parallel group study to compare GW766944 (an oral CCR3 receptor antagonist) versus placebo in patients with asthma and sputum eosinophilia.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3441,
        "nct_id": "NCT02948881",
        "studyTitle": "A one year, parallel, placebo-controlled, double-blind, randomized study to assess the effect of monthly 150mg oral ibandronate dosing versus placebo on bone quality and strength at the proximal femur in women with osteoporosis",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Osteoporosis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3442,
        "nct_id": "NCT00703846",
        "studyTitle": "A PHASE 4, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2% IN THE TREATMENT OF SEBORRHEIC DERMATITIS",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Dermatitis",
            "Seborrheic"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3450,
        "nct_id": "NCT00256854",
        "studyTitle": "A 4-Week, Randomized, Double-Blind, Cohort Study to Evaluate the Safety and Tolerability of Converting from Ropinirole Immediate Release (IR) to Ropinirole Extended Release (XR) Formulation in Patients with Restless Legs Syndrome (RLS)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Restless Legs Syndrome"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3451,
        "nct_id": "NCT00632736",
        "studyTitle": "An Open-Label Extension Study with REQUIP (ropinirole) CR for Subjects from Studies 101468/165, 101468/168 and 101468/169",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Parkinson Disease"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3460,
        "nct_id": "NCT00386100",
        "studyTitle": "A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of AVANDAMET and metformin after 80 weeks of treatment.",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3461,
        "nct_id": "NCT00067951",
        "studyTitle": "An open-label trial to evaluate the safety and efficacy of fixed dose rosiglitazone/metformin combination therapy in poorly-controlled subjects with type 2 diabetes mellitus",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3473,
        "nct_id": "NCT00989625",
        "studyTitle": "An open label, single dose, randomised, parallel group pharmacokinetic study to evaluate a combination product containing naproxen sodium and sumatriptan in adolescent subjects with migraine and healthy adult subjects administered at three doses.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Migraine Disorders"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3474,
        "nct_id": "NCT00387881",
        "studyTitle": "A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and tolerability of TREXIMA* (sumatriptan succinate/naproxen sodium) for a single moderate or severe headache in adults diagnosed with probable migraine without aura (ICHD-II 1.6.1) (*TREXIMET)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Migraine",
            "Without Aura"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3475,
        "nct_id": "NCT00596245",
        "studyTitle": "Open-Label, Placebo-Controlled, Parallel Group Study in Healthy Volunteers to Evaluate the Effects of MT 400 Tablets or Naproxen Sodium Tablets on Chromosomal Aberrations (CA) in Peripheral Blood Lymphocytes",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Migraine Disorders"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3481,
        "nct_id": "NCT00843024",
        "studyTitle": "TXA107979: A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a Combination Product Containing Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine in Adolescents",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Migraine Disorders"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3482,
        "nct_id": "NCT00488514",
        "studyTitle": "Study TXA107977, a Long-Term Safety Study of a Combination Product Containing Sumatriptan Succinate and Naproxen Sodium for the Treatment of Migraine in Adolescents",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Migraine Disorders"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3483,
        "nct_id": "NCT00875784",
        "studyTitle": "An open-label, randomized, 3-period crossover study to evaluate sumatriptan pharmacokinetics for a TREXIMA\u2122 (sumatriptan succinate / naproxen sodium) Tablet followed by IMITREX\u00ae (sumatriptan succinate) Injection 4mg administered using the IMITREX STATdose System\u00ae and a TREXIMA tablet followed by IMI",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Migraine Disorders"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3484,
        "nct_id": "NCT00383162",
        "studyTitle": "A Study of Combination Product (sumatriptan succinate and naproxen sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Migraine Disorders"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3485,
        "nct_id": "NCT00382993",
        "studyTitle": "A Study of Combination Product (sumatriptan succinate and naproxen sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Migraine Disorders"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3486,
        "nct_id": "NCT00240630",
        "studyTitle": "A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Cross-Over Study to Determine the Consistency of Response for TREXIMA\u2122 (sumatriptan 85mg/naproxen sodium 500mg)*, Administered During the Mild Pain Phase for the Acute Treatment of Multiple Migraine Attacks",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Migraine Disorders"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3487,
        "nct_id": "NCT00240617",
        "studyTitle": "A randomized, double-blind, multi-center, placebo-controlled, cross-over study to determine the consistency of response for Trexima* (sumatriptan 85mg/naproxen sodium 500mg) administered during the mild pain phase for the acute treatment of multiple migraine attacks (*Treximet)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Migraine Disorders"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3488,
        "nct_id": "NCT00385008",
        "studyTitle": "An Open Label, Single Dose, Parallel Group Study to Evaluate Absorption and Transit Characteristics of TREXIMA and RELPAX in Patients Inside and Outside of an Acute Migraine Attack.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Migraine Disorders"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3489,
        "nct_id": "NCT00329459",
        "studyTitle": "A randomized, double-blind, single migraine attack, placebo -controlled, patallel-group multicenter study to evaluate the efficacy and tolerability or Trexima (sumatriptan succinate/naproxen sodium) tablets vs placebo when administered during the mild pain phase of menstrual migraine in women with dysmenorrhea",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Migraine Disorders"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3490,
        "nct_id": "NCT00329355",
        "studyTitle": "See Detailed Description",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Migraine Disorders"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3497,
        "nct_id": "NCT01663714",
        "studyTitle": "Phase II Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for subjects with Untreated Low-Grade Non Hodgkin's Lymphoma.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Lymphoma",
            "Non-Hodgkin"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3499,
        "nct_id": "NCT00992758",
        "studyTitle": "Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody for Patients with Previously Treated Non Hodgkin\u2019s Lymphoma With More Than 25% Bone Marrow Involvement",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Lymphoma",
            "Non-Hodgkin"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3500,
        "nct_id": "NCT01224821",
        "studyTitle": "Multicenter, Phase II Dosimetry/Validation Study of 131Iodine\u2013Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas that Have Transformed to Higher Grade Histologies",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Lymphoma",
            "Non-Hodgkin"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3501,
        "nct_id": "NCT00933335",
        "studyTitle": "Fludarabine monophosphate followed by Iodine I 131 Tositumomab for untreated low-grade and follicular non-Hodgkin's lymphoma",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Lymphoma",
            "Non-Hodgkin"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3502,
        "nct_id": "NCT00938041",
        "studyTitle": "Retreatment Study of Patients with Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Lymphoma",
            "Non-Hodgkin"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3510,
        "nct_id": "NCT01371994",
        "studyTitle": "A Randomized, Double-blind, Parallel, Placebo-controlled, Phase 4, Multicenter Study to Assess Efficacy and Safety of VESIcare\u00ae (Solifenacin Succinate) to Improve Urinary Continence of Subjects After Robotic Assisted Radical Prostatectomy",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Urinary Incontinence"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3516,
        "nct_id": "NCT01648231",
        "studyTitle": "An open-label, randomized, single dose, three-way crossover study to determine the comparative bioavailability of two fixed dose combination tablet formulations of amlodipine (5mg) and losartan (100mg) in healthy adult male and female Subjects under fasting conditions",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Hypertension"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3517,
        "nct_id": "NCT01446237",
        "studyTitle": "An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects with Acne",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Acne Vulgaris"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3520,
        "nct_id": "NCT00689481",
        "studyTitle": "A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety and Efficacy of Emulsion Formulation U0267 , versus Vehicle Foam in Subjects with Plaque-type Psoriasis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Psoriasis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3523,
        "nct_id": "NCT00734032",
        "studyTitle": "A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients- A multicenter, randomized, double-blind, placebo-controlled study of SB-480848 to evaluate the Efficacy and Safety -",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Atherosclerosis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3532,
        "nct_id": "NCT00704431",
        "studyTitle": "An Open Label, Single Session Study to Collect Tolerability Information Following Repeat Dosing of Darapladib in Healthy Adult Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Atherosclerosis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3533,
        "nct_id": "NCT00622830",
        "studyTitle": "Phase I study of SB-480848 (darapladib) -A double blind, randomised, placebo-controlled, parallel-group, repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-480848 in healthy Japanese male subjects-",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Atherosclerosis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3534,
        "nct_id": "NCT00996840",
        "studyTitle": "Assessment of the Anti-Inflammatory activity, efficacy and safety of Intravenous SB-681323 in subjects at risk for development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Lung Injury",
            "Acute"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3535,
        "nct_id": "NCT00361959",
        "studyTitle": "See Detailed Description",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3537,
        "nct_id": "NCT01725672",
        "studyTitle": "An Open-Label, Randomized, Single Dose, Four-way Crossover, Multi-stage Study to determine the Comparative Bioavailability of two fixed dose combination tablet formulations, 500 mg or 1000 mg extended release metformin and 1 mg or 2 mg extended release glimepiride, in healthy adult male and female subjects in the fed state",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3542,
        "nct_id": "NCT00695448",
        "studyTitle": "A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK1059615 in Patients with Solid Tumors or Lymphoma",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Solid Tumours"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3544,
        "nct_id": "NCT00783549",
        "studyTitle": "A study in healthy volunteers of single doses of orally administered GSK1292263 to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of the compound alone and when co-administered with sitagliptin",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Dyslipidaemias"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3545,
        "nct_id": "NCT01119846",
        "studyTitle": "A study in type 2 diabetic subjects of single and multiple doses of orally administered GSK1292263 to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of the compound",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3546,
        "nct_id": "NCT01128621",
        "studyTitle": "A study in type 2 diabetic subjects on stable metformin therapy to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of co-administering single and multiple oral doses of GSK1292263",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3547,
        "nct_id": "NCT01101568",
        "studyTitle": "A study to investigate the interaction of GSK1292263 with rosuvastatin and simvastatin in healthy subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3548,
        "nct_id": "NCT00828867",
        "studyTitle": "A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Investigational Study Drug in Healthy Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Bacterial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3549,
        "nct_id": "NCT00924911",
        "studyTitle": "A Two Part Single Dose, Randomized, Balanced, Crossover Study to Assess the Relative Bioavailability of Three Formulations, Drug Interaction and Food Effect on an GSK1322322 in Healthy Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Bacterial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3550,
        "nct_id": "NCT00896558",
        "studyTitle": "A Double-Blind, Parallel, Randomized, Placebo-Controlled, Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Bacterial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3551,
        "nct_id": "NCT01610388",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled Repeat Dose Escalation, First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Bacterial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3552,
        "nct_id": "NCT01663389",
        "studyTitle": "An Open Label, Non-Randomized, Single dose, Two Period, Cross-Over, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Bacterial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3553,
        "nct_id": "NCT01209078",
        "studyTitle": "A Randomized, Double Blind, Double Dummy Multicenter Phase IIa Study to Assess Safety, Tolerability and Efficacy of GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Skin Infections",
            "Bacterial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3554,
        "nct_id": "NCT01648179",
        "studyTitle": "A Single Dose, Open Label, Randomized, Balanced, Crossover Study to Assess the Relative Bioavailability of ThreeFormulations and Food Effect on GSK1322322 in Healthy Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Bacterial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3555,
        "nct_id": "NCT01294566",
        "studyTitle": "A Randomized, Placebo Controlled Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of GSK1322888 in Healthy Caucasian and Japanese Asian Adult Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Gastroparesis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3562,
        "nct_id": "NCT01366573",
        "studyTitle": "A Randomised, Double-Blind, Single-Dose, Four-Period Cross-Over Study to Determine the Effects of Alcohol on the Pharmacokinetics and Pharmacodynamics of GSK1521498 in Healthy Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Alcoholism"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3563,
        "nct_id": "NCT00896363",
        "studyTitle": "A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of GSK163090 in Subjects with Major Depressive Disorder",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Depressive Disorder",
            "Major"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3565,
        "nct_id": "NCT01018628",
        "studyTitle": "A Phase I Randomized, Placebo-Controlled, Single-Blind, Multiple-Dose, Dose-Escalation Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3566,
        "nct_id": "NCT01262911",
        "studyTitle": "A Phase I Study to Evaluate a Single Oral Dose of SRT2379 on the Endotoxin Induced Inflammatory Response in Healthy Male Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Sepsis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3567,
        "nct_id": "NCT01416376",
        "studyTitle": "A Double blind, Placebo controlled, Phase I Dose-ranging Study to Evaluate the Activity of SRT2379 on Endotoxin induced Inflammatory Response in Healthy Male Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Sepsis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3570,
        "nct_id": "NCT01545570",
        "studyTitle": "A single-blinded, randomized, placebo-controlled, staggered-parallel, escalating dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2374697 in healthy volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3573,
        "nct_id": "NCT01009060",
        "studyTitle": "A randomised double-blind, placebo controlled, parallel group study to evaluate the cognitive enhancing effect of GSK239512 in stable patients with schizophrenia",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Schizophrenia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3575,
        "nct_id": "NCT01332552",
        "studyTitle": "A Randomized, Double Blind, Dose Escalation, Fusion, First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Hepatitis C"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3578,
        "nct_id": "NCT01147861",
        "studyTitle": "A randomized, single blind, placebo-controlled, three period crossover, dose selection study to evaluate the effect of GSK256073, an HM74A receptor agonist, on glucose and NEFA 24 hour profile in type 2 diabetic patients.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3579,
        "nct_id": "NCT01696604",
        "studyTitle": "A single-center, randomized, blinded, placebo-controlled two-part study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the Selective Androgen Receptor Modulator (SARM), GSK2849466, in single and repeat doses, with and without food, in healthy male subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Cachexia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3583,
        "nct_id": "NCT00605241",
        "studyTitle": "A randomized, double-bind, placebo controlled, two-way cross-over study to assess the effects of a single dose of GSK598809, a Selective DRD3 Antagonist, in Modulating Nicotine Reward",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Substance Dependence"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3608,
        "nct_id": "NCT01431963",
        "studyTitle": "A multi-center, uncontrolled, open-label, evaluation of Lamotrigine monotherapy in newly diagnosed epilepsy or recurrent epilepsy (currently untreated)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Epilepsy"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3613,
        "nct_id": "NCT00903409",
        "studyTitle": "An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Lovaza\u00ae and Simvastatin Therapy in Hypertriglyceridemic Subjects",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hypertriglyceridemia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3614,
        "nct_id": "NCT00402363",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Lovaza for the Prevention of Recurrent, Symptomatic Atrial Fibrillation",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Fibrillation",
            "Atrial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3615,
        "nct_id": "NCT00996268",
        "studyTitle": "An open-label single dose randomized, parallel group study followed by single-blind repeat dosing, to compare the relative bioavailability of GSK2212836",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Cardiovascular Disease"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3616,
        "nct_id": "NCT00246701",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Lovaza\u00ae and Simvastatin Therapy in Hypertriglyceridemic Subjects",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hypertriglyceridemia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3617,
        "nct_id": "NCT00246636",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 4 Study to Assess the Efficacy and Safety of Adjunctive Lovaza\u00ae Therapy in Hypertriglyceridemic Subjects Treated with Antara\u00ae",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hypertriglyceridemia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3621,
        "nct_id": "NCT01956487",
        "studyTitle": "A Phase 1, Open-Label, Crossover Study to Demonstrate the Bioequivalence of RYTHMOL SR\u00ae (propafenone hydrochloride) Manufactured at Two Different Sites",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Arrhythmia",
            "Cardiac"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3624,
        "nct_id": "NCT00733577",
        "studyTitle": "A single-blinded randomized, placebo-controlled, staggered-parallel, escalating-dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral SB756050 administered for 6 days to Subjects with Type 2 Diabetes Mellitus",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3625,
        "nct_id": "NCT00607906",
        "studyTitle": "A single-blinded, randomized, placebo-controlled, staggered-parallel, escalating single dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered SB756050 in healthy volunteers and in subjects with Type 2 Diabetes Mellitus",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3626,
        "nct_id": "NCT01536561",
        "studyTitle": "RIT-I-000/RIT-I-000A: Phase I Study of Radiolabeled Monoclonal Antibody Anti B1 for the Treatment of B Cell Lymphomas & RIT-I-000B: Extended Phase I/II study to determine the safety and efficacy of Coulter Clone\u00ae 131Iodine-B1 radioimmunotherapy of advanced non-Hodgkin\u2019s Lymphoma",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Lymphoma",
            "Non-Hodgkin"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3627,
        "nct_id": "NCT00950755",
        "studyTitle": "Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Lymphoma",
            "Non-Hodgkin"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3628,
        "nct_id": "NCT00989664",
        "studyTitle": "Multicenter, Pivotal Phase III Study of Iodine-131 Anti-B1 Antibody (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas that have Transformed to Higher Grade Histologies",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Lymphoma",
            "Non-Hodgkin"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3629,
        "nct_id": "NCT00996593",
        "studyTitle": "Phase II Study of Iodine-131 Anti-B1 Antibody for Non Hodgkin\u2019s Lymphoma Patients who have Previously Received Rituximab",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Lymphoma",
            "Non-Hodgkin"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3630,
        "nct_id": "NCT01573000",
        "studyTitle": "Phase II a randomized study of iodine-131 Anti-b1 Antibody versus anti-b1 Antibody in chemotherapy-relapsed/refractory low-grade or transformed low-grade non-Hodgkin\u2019s lymphoma (NHL)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Lymphoma",
            "Non-Hodgkin"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3631,
        "nct_id": "NCT00268203",
        "studyTitle": "Expanded Access Study of Iodine I 131 Tositumomab for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Lymphoma",
            "Non-Hodgkin"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3635,
        "nct_id": "NCT01728623",
        "studyTitle": "A Phase 2 Study of E7080 in Subjects With Advanced Thyroid Cancer",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Thyroid Cancer"
        ],
        "orgCode": "",
        "orgName": "Eisai",
        "status": "",
        "postedDate": "2015-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3637,
        "nct_id": "NCT01797926",
        "studyTitle": "An open-label, randomised, single dose, three-way crossover, parallel groups study to determine the bioequivalence of two fixed dose combination (FDC) tablet formulations of amlodipine and losartan FDC5/50 and FDC5/100 to respective reference dosages in healthy adult male and female subjects under fasting conditions",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Hypertension"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3638,
        "nct_id": "NCT02524665",
        "studyTitle": "U0289-404: An Evaluator Blinded, 8 Week, Split Face Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITYII and MURAD in Subjects with Acne",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Acne Vulgaris"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3641,
        "nct_id": "NCT00127010",
        "studyTitle": "Blinded, randomized study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals\u2019 measles-mumps-rubella-varicella candidate vaccine given to healthy children during the second year of life",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Measles; Mumps; Rubella; Varicella"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3647,
        "nct_id": "NCT00346073",
        "studyTitle": "A study to evaluate immunogenicity and safety of Boostrix compared to Adacel when administered as a booster vaccination in adults aged 19 to 64 years of age",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diphtheria; Tetanus; Acellular pertussis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3648,
        "nct_id": "NCT00385255",
        "studyTitle": "A study to evaluate immunogenicity and safety of Boostrix when co-administered with Fluarix in subjects 19 years of age and older",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diphtheria; Tetanus; Acellular pertussis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3651,
        "nct_id": "NCT01873339",
        "studyTitle": "An open-label, single-sequence study to evaluate the potential CYP 3A4 pharmacokinetic interaction of Darapladib (SB-480848) in healthy subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Atherosclerosis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3653,
        "nct_id": "NCT01802931",
        "studyTitle": "An Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole on the Pharmacokinetics of GSK239512",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Multiple Sclerosis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3656,
        "nct_id": "NCT00289796",
        "studyTitle": "Assess the feasibility of an investigational vaccination regimen, compared to a 3-dose primary vaccination with GSK Bio's Infanrix hexa\u2122 (DTPa-HBV-IPV/Hib vaccine) following hepatitis B vaccination at birth. Primary vaccination is followed in the 2nd year of life by a booster dose of Infanrix-hexa",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3659,
        "nct_id": "NCT00306982",
        "studyTitle": "An observational study to investigate the incidence of influenza, downstream complications of influenza and hospitalizations, in elderly subjects vaccinated with GSK Biologicals\u2019 influenza vaccine (Fluarix\u2122) administered intramuscularly.",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3662,
        "nct_id": "NCT01626820",
        "studyTitle": "Immunogenicity and safety study of GSK Biologicals\u2019 Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral\u00ae (2012/2013 Season) in adults aged 18 years and older",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3672,
        "nct_id": "NCT01899638",
        "studyTitle": "A Randomized, Open Label, 3 Crossover, Balanced Incomplete Block Study To Evaluate The Pharmacokinetics Of Umeclidinium Bromide and Vilanterol Trifenatate as Monotherapies and Concurrently in Healthy Chinese Subjects.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3673,
        "nct_id": "NCT00792623",
        "studyTitle": "A phase III, open-label, multi-centre study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals\u2019 live attenuated varicella vaccine (VarilrixTM), given as a primary vaccination at 4.5 months and 6.5 months post-transplantation, in autologous stem cell/ bone marrow transplant recipients aged 18 years and older.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Varicella"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3675,
        "nct_id": "NCT01827631",
        "studyTitle": "Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Crohn's Disease"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3690,
        "nct_id": "NCT00280397",
        "studyTitle": "An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Solid Tumors"
        ],
        "orgCode": "",
        "orgName": "Eisai",
        "status": "",
        "postedDate": "2015-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3691,
        "nct_id": "NCT01268293",
        "studyTitle": "A Phase 1 Study of E7080 in Subjects With Solid Tumor",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Cancer"
        ],
        "orgCode": "",
        "orgName": "Eisai",
        "status": "",
        "postedDate": "2015-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3701,
        "nct_id": "NCT00530309",
        "studyTitle": "Clinical assessment of GSK716155 for Type 2 Diabetes Mellitus\r\n\u00a0-A Phase I/II study to investigate the safety, pharmacokinetics and pharmacodynamics of GSK716155 in Japanese subjects with type 2 diabetes mellitus",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3702,
        "nct_id": "NCT01098461",
        "studyTitle": "A Dose Finding Study of GSK716155 versus Placebo in the Treatment of Type 2 Diabetes Mellitus",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3703,
        "nct_id": "NCT01527123",
        "studyTitle": "A Study to Evaluate the Pharmacokinetics of Benzoic Acid and Hippuric Acid after Topical Administration of GSK2585823 in Japanese Subjects with Acne Vulgaris",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Acne Vulgaris"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3704,
        "nct_id": "NCT01428466",
        "studyTitle": "Dermal Safety Study of GSK2585823 (Clindamycin 1%-Benzoyl peroxide 3% gel) with Healthy Japanese Male and Female Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Acne Vulgaris"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3705,
        "nct_id": "NCT01138007",
        "studyTitle": "Study AK1113351, a fixed dose study of 323U66 SR in the treatment of Major Depressive Disorder (MDD) - a multi-center, placebo-controlled, randomized, double-blind, parallel-comparison study",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Depressive Disorder"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3706,
        "nct_id": "NCT00742508",
        "studyTitle": "A study to evaluate the safety and tolerability of SK&F-105517-D in patients with chronic heart failure \u00a0- An open-label study to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of SK&F-105517-D in patients with chronic heart failure (Phase I/II study)",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Heart failure",
            "Congestive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3711,
        "nct_id": "NCT01630135",
        "studyTitle": "Study FFR116364, a double-blind, placebo-controlled study of GW685698X in paediatric subjects with perennial allergic rhinitis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Rhinitis",
            "Allergic",
            "Perennial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3712,
        "nct_id": "NCT01622231",
        "studyTitle": "Study FFR116365, an open-label study of GW685698X in paediatric subjects with perennial allergic rhinitis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Rhinitis",
            "Allergic",
            "Perennial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3713,
        "nct_id": "NCT01254032",
        "studyTitle": "A 24 Week Study to Evaluate the Predictive Ability of the COPD Assessment Test (CAT) for Acute Exacerbations (PACE) in Patients with Chronic Obstructive Pulmonary Disease",
        "overallStatus": "",
        "phase": NaN,
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3728,
        "nct_id": "NCT00721396",
        "studyTitle": "A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Meningococcal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3734,
        "nct_id": "NCT01376388",
        "studyTitle": "A 52-week, Multi-centre, Open-label Study to Evaluate the Safety and Tolerability of GSK573719 125 mcg once-daily in combination with GW642444 25 mcg once-daily via novel Dry Powder Inhaler (nDPI) in Japanese Subjects with Chronic Obstructive Pulmonary Disease.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3735,
        "nct_id": "NCT01602562",
        "studyTitle": "A multicenter, open-label study to evaluate preventive efficacy for herpes simplex virus infection and safety of 256U87 (valaciclovir hydrochloride) in adult and pediatric hematopoietic stem cell transplantation patients",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Herpes Simplex"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3776,
        "nct_id": "NCT01495013",
        "studyTitle": "Study ATG115317, a comparison of atorvastatin and glimepiride fixed dose combination and atorvastatin and glimepiride loose combination in the treatment of patients with Type 2 diabetes mellitus",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3778,
        "nct_id": "NCT01711723",
        "studyTitle": "An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and in Subjects with Severe Renal Impairment",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Atherosclerosis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3779,
        "nct_id": "NCT01231607",
        "studyTitle": "A Study of the Efficacy and Safety of Multiple Doses of Dutasteride versus Placebo and Finasteride in the Treatment of Male Subjects with Androgenetic Alopecia",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Alopecia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3782,
        "nct_id": "NCT01711463",
        "studyTitle": "A randomized, double-blind, placebo-controlled, four-way crossover study to evaluate and compare the pharmacodynamics and pharmacokinetics of fluticasone furoate /vilanterol in different dose combination (50/25mcg, 100/25mcg and 200/25mcg) after single and repeat dose administration from a novel dry powder device in healthy Chinese subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3783,
        "nct_id": "NCT01192191",
        "studyTitle": "A Long-term Study to Evaluate the Safety and Tolerability of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Japanese Subjects with Chronic Obstructive Pulmonary Disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3785,
        "nct_id": "NCT00743067",
        "studyTitle": "A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects with Solid Tumors",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Solid Tumours"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3787,
        "nct_id": "NCT01154101",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects with Moderate to Severe Plaque-Type Psoriasis",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Psoriasis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3788,
        "nct_id": "NCT01453491",
        "studyTitle": "A Phase 1b, Exploratory Study to Assess the Safety, Tolerability, Colonic Tissue Exposure, and Anti-Inflammatory Effects of Two Different Doses of SRT2104 in Subjects with Mild to Moderate Ulcerative Colitis",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Colitis",
            "Ulcerative"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3790,
        "nct_id": "NCT00723450",
        "studyTitle": "The Evaluation of Lamictal as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Bipolar Disorder"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3791,
        "nct_id": "NCT01471327",
        "studyTitle": "A single blind, placebo controlled, parallel group, single ascending intravenous dose study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of SB-240563 (mepolizumab) in healthy Japanese male subjects.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3796,
        "nct_id": "NCT00256867",
        "studyTitle": "A 16 week randomized, double-blind, parallel group study to evaluate the efficacy and safety of a new medication (GSK523338) to lower LDL-c and HbA1c in subjects with type 2 diabetes mellitus",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3798,
        "nct_id": "NCT00996996",
        "studyTitle": "Phase II Trial of Iodine-131 Anti-B1 Antibody for Previously Untreated, Advanced Stage, Low Grade Non-Hodgkin\u2019s Lymphoma",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Lymphoma",
            "Non-Hodgkin"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3799,
        "nct_id": "NCT00268983",
        "studyTitle": "A Multi-Center, Randomized, Phase 3 Study of Rituximab versus Iodine I 131 Tositumomab Therapeutic Regimen For Patients With Relapsed Follicular Non-Hodgkins Lymphoma",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Lymphoma",
            "Non-Hodgkin"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3800,
        "nct_id": "NCT01636713",
        "studyTitle": "A 24-week randomised, double-blind and placebo-controlled study to evaluate the efficacy and safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder compared with placebo Inhalation Powder delivered once-daily via a Novel Dry Powder Inhaler in subjects with Chronic Obstructive Pulmonary Disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2015-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3886,
        "nct_id": "NCT00493818",
        "studyTitle": "An Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the AKT Inhibitor GSK690693 given on Various Schedules in Subjects with Solid Tumors or Lymphoma",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Cancer"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3889,
        "nct_id": "NCT00315731",
        "studyTitle": "A Multi-Center Study to Examine the Pharmacokinetics, Whole Body and Organ Dosimetry, and Biodistribution of Fission-Derived Iodine I 131 Tositumomab for Patients With Previously Untreated or Relapsed Follicular or Transformed Follicular Non-Hodgkin's Lymphoma",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Lymphoma",
            "Follicular"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3896,
        "nct_id": "NCT00840645",
        "studyTitle": "Long-term Study of YM178: Long-term study of YM178 in subjects with overactive bladder.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Urinary Bladder",
            "Overactive"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2016-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3920,
        "nct_id": "NCT01929330",
        "studyTitle": "An Evaluation of the Bioequivalence of five 0.1 mg GI198745/dutasteride Soft Gelatin Capsules Compared to one 0.5 mg GI198745/dutasteride Gelatin Capsules in Healthy Male Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Alopecia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3923,
        "nct_id": "NCT01817777",
        "studyTitle": "A pharmacy based open study to evaluate whether pack size affects compliance for subjects diagnosed with diabetes type II who are established on metformin treatment.",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3936,
        "nct_id": "NCT00849017",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Two Dose Levels of Albiglutide Compared With Placebo in Subjects With Type 2 Diabetes Mellitus",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3940,
        "nct_id": "NCT00500058",
        "studyTitle": "A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 (SB-485232) Administered by Intravenous Infusion in Combinationwith Rituximab in Adult Patients with B Cell Non-Hodgkin's Lymphoma",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Lymphoma",
            "Non-Hodgkin"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3941,
        "nct_id": "NCT00659178",
        "studyTitle": "A phase I, dose escalation study to assess the safety & biological activity of Interleukin 18 (SB-485232) administered by IV infusion in combination with pegylated liposomal doxorubicin (Doxil) in advanced stage epithelial ovarian cancer",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Neoplasms",
            "Ovarian"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3944,
        "nct_id": "NCT01842620",
        "studyTitle": "Oral bioavailability study comparing OXEMET\u2122 1000 mg coated tablets containing metformin hydrochloride with 1000 mg of the reference product (GLAFORNIL\u2122) administered as two 500 mg tablets, through a randomized, single-dose, open label, balanced, 2-way crossover study in healthy volunteers under fasting conditions.OXEMET (TM) is a trademark of the GlaxoSmithKline group of companies. GLAFORNIL(TM) is a trademark of Merck.",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3947,
        "nct_id": "NCT01868035",
        "studyTitle": "PHASE II MULTICENTER STUDY OF IODINE-131 ANTI-B1 ANTIBODY CONSOLIDATION FOR PATIENTS WITH DIFFUSE LARGE B-CELL NON-HODGKIN'S LYMPHOMA FOLLOWING FIRST-LINE CHOP",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Lymphoma",
            "Non-Hodgkin"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3949,
        "nct_id": "NCT01702363",
        "studyTitle": "A 52-week, Multi-centre, Open-label Study to Evaluate the Safety and Tolerability of GSK573719 125 mcg once-daily via novel Dry Powder Inhaler (nDPI) in Japanese Subjects with Chronic Obstructive Pulmonary Disease.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3953,
        "nct_id": "NCT00941031",
        "studyTitle": "A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Psoriasis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3955,
        "nct_id": "NCT01071252",
        "studyTitle": "A Randomized, Double-blind, Placebo Controlled, Multicenter Dose Ranging Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Psoriasis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3956,
        "nct_id": "NCT01365455",
        "studyTitle": "A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Psoriasis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3957,
        "nct_id": "NCT01358578",
        "studyTitle": "A Randomized, Double-blind, Double-dummy, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Psoriasis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3969,
        "nct_id": "NCT01254071",
        "studyTitle": "An Open-label, Randomized, Single Dose, Two-Period Crossover study to Determine the Bioavailability of a Fixed Dose Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5mg/0.2mg) Relative to Co-administration of Dutasteride 0.5mg capsules and Tamsulosin Hydrochloride 0.2mg.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Prostatic Hyperplasia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3970,
        "nct_id": "NCT01495026",
        "studyTitle": "An Open-label, Randomized, Single Dose, Multi-stage, Cross-over study to determine the Relative bioavailability of Fixed Dose Combination Products containing a 3-oblong dutasteride soft gel capsule and tamsulosin (0.5 mg dutasteride/0.2 mg tamsulosin HCl) pellets having a range of tamsulosin release rates produced by different mixtures of enteric coated and uncoated pellets relative to Harnal-D Tablets, in Healthy Male Subjects of North East Asian ancestry.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Prostatic Hyperplasia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3971,
        "nct_id": "NCT01453023",
        "studyTitle": "A randomized, double-blind, repeat dose, two period crossover study to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of inhaled fluticasone furoate/vilanterol 100/25 micrograms in children aged 5 to 11 years with persistent asthma.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3972,
        "nct_id": "NCT01949051",
        "studyTitle": "A randomized, double-blind, placebo controlled, 3 way cross over study in subjects with allergic rhinitis to assess the effect of intranasal repeat doses of levocabastine when administered once daily or twice daily on the symptoms of rhinitis in an allergen challenge chamber.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Rhinitis",
            "Allergic",
            "Perennial and Seasonal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3975,
        "nct_id": "NCT00823940",
        "studyTitle": "A single-blind, randomized, placebo controlled, ascending single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK1362885 in healthy normal subjects.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3976,
        "nct_id": "NCT01013766",
        "studyTitle": "A Randomized, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Subjects with Type 2 Diabetes Mellitus.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3979,
        "nct_id": "NCT00639678",
        "studyTitle": "A randomized, single-blind, placebo-controlled study to evaluate the safety and tolerability of raxibacumab (human monoclonal antibody to B. anthracis protective antigen) in healthy subjects.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Therapeutic treatment of inhalation anthrax"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3982,
        "nct_id": "NCT00381667",
        "studyTitle": "A randomised, double-blind, placebo-controlled, dose ascending, five-way crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of a single administration of three inhaled doses (25, 100 and 400 \u00b5g) of GW642444M.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3991,
        "nct_id": "NCT00702910",
        "studyTitle": "A randomised, single-dose, dose-ascending, double-blind, placebo-controlled, 5-way crossover study to investigate the efficacy, pharmacokinetics and pharmacodynamics of inhaled doses of GW642444M in asthmatic patients.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3992,
        "nct_id": "NCT00866515",
        "studyTitle": "A double-blind, placebo-controlled, randomised, 2-way crossover drug interaction study to investigate the pharmacokinetic and pharmacodynamic effects following co-administration of GW642444M with ketoconazole.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3993,
        "nct_id": "NCT01453296",
        "studyTitle": "A randomized, double-blind, placebo-controlled, two-way crossover 7-day study to investigate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat dose inhaled GW642444 25\u03bcg (micrograms) in children aged 5-11 years with persistent asthma.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3997,
        "nct_id": "NCT01353729",
        "studyTitle": "A Phase I, Randomized, Placebo-Controlled, Four-Way Crossover Study to Evaluate the Effect of Intravenous (IV) Zanamivir on Cardiac Conduction as Assessed by 12-lead Electrocardiogram (ECG) with Moxifloxacin as a Positive Control in Healthy Volunteers.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Influenza",
            "Human"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 3998,
        "nct_id": "NCT01258530",
        "studyTitle": "A Randomized, Open-label, Single-Dose, Two-Period, Crossover Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Influenza",
            "Human"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4005,
        "nct_id": "NCT01822639",
        "studyTitle": "An Open-Label, Randomized, Single Dose, Two-Way Crossover Pilot Study to Evaluate the Relative Bioavailability of One Amlodipine 5 mg Tablet and One Enalapril Maleate 20mg Tablet to a Fixed Dose Combination Tablet Formulation of Amlodipine (5 mg) and Enalapril Maleate (20 mg), in Healthy Adult Male and Female Subjects under Fasting Conditions",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Hypertension"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4006,
        "nct_id": "NCT02075619",
        "studyTitle": "An open-label, randomized, single dose, three-way crossover, six sequence pilot study to evaluate the relative bioavailability of one amlodipine 10mg tablet and rosuvastatin 20mg tablet to two fixed dose combination tablet formulations of amlodipine (10mg) and rosuvastatin (20mg) in healthy adult male and female subjects under fasting conditions",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Hypertension"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4007,
        "nct_id": "NCT01516450",
        "studyTitle": "An open label, randomized, parallel, single dose study to investigate safety and pharmacokinetics following intravenous administration and subcutaneous administration of GSK1550188 in healthy Japanese males",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Systemic Lupus Erythematosus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4008,
        "nct_id": "NCT02000804",
        "studyTitle": "A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of 160 mg Enteric-coated Micronised Free Base Darapladib in Healthy Chinese Subjects.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Atherosclerosis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4009,
        "nct_id": "NCT01471678",
        "studyTitle": "An Open-label, Randomized, Single Dose, Four-Period Crossover study to compare the Bioavailability of Fixed Dose Combination Capsule Formulations of Dutasteride and Tamsulosin Hydrochloride (0.5 mg/0.2 mg) with 10% and 15% of enteric coated pellets with Harnal-D tablets and Harnal capsules co-administered with dutasteride (0.5 mg) Soft Gel Capsules in Healthy Male Subjects of North East Asian ancestry",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Prostatic Hyperplasia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4010,
        "nct_id": "NCT00996671",
        "studyTitle": "A Phase I, Randomized, Single-Blind, Placebo-Controlled Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Food Effect Following Single Oral Doses of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Healthy Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Cancer"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4015,
        "nct_id": "NCT02016963",
        "studyTitle": "An Open-Label Study to Evaluate the Immunogenicity and Safety of Raxibacumab (Human Monoclonal Antibody to B. anthracis Protective Antigen) Administered in Healthy Subjects",
        "overallStatus": "",
        "phase": "Phase 2/3",
        "studyType": "",
        "conditions": [
            "Therapeutic treatment of inhalation anthrax"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4016,
        "nct_id": "NCT01812382",
        "studyTitle": "A Study to Evaluate the Feasibility of Microdialysis to Determine Skin Concentrations of Retapamulin in Healthy Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Skin Infections",
            "Bacterial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4017,
        "nct_id": "NCT00549120",
        "studyTitle": "A study to optimise the propranolol block model for assessment of the pharmacological activity of bronchodilators in healthy volunteers.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4040,
        "nct_id": "NCT01297517",
        "studyTitle": "Three Month Efficacy and Safety Study of a Fixed Combination of Brinzolamide 1 %/Brimonidine 0.2 % Compared to Brinzolamide 1 % and Brimonidine 0.2 % All Dosed Three Times Daily in Patients With Open-Angle Glaucoma and/or Ocular Hypertension",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Open-Angle Glaucoma; Ocular Hypertension"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4041,
        "nct_id": "NCT01297920",
        "studyTitle": "A Three-Month, Randomized, Double-Masked, Parallel-Group Study with a Planned Three-Month Safety Extension of the Efficacy and Safety of a Fixed Combination of Brinzolamide 1 %/Brimonidine 0.2 % Compared to Brinzolamide 1 % and Brimonidine 0.2 % All Dosed Three Times Daily in Patients with Open-Angle Glaucoma and/or Ocular Hypertension",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Open-Angle Glaucoma; Ocular Hypertension"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4042,
        "nct_id": "NCT01310777",
        "studyTitle": "Safety and IOP-Lowering Efficacy of Brinzolamide 10 mg/mL/Brimonidine 2 mg/mL Fixed Combination Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension and Brimonidine 2 mg/mL Eye Drops, Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Open-Angle Glaucoma; Ocular Hypertension"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4044,
        "nct_id": "NCT00879333",
        "studyTitle": "A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Cancer",
            "Advanced Gastric"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4045,
        "nct_id": "NCT00620022",
        "studyTitle": "A Phase III Randomized, Double-blind, Placebo-controlled, 2-period Crossover, Multicenter Study to Assess the Effect of Indacaterol (300 \u03bcg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic Obstructive Pulmonary Disease (COPD)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4046,
        "nct_id": "NCT01294787",
        "studyTitle": "A Randomized, Blinded, Double Dummy, Multi-center, Placebo Controlled, 3 Period, Crossover Study to Assess the Effect of QVA149 (110/50 \u00b5g o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic Obstructive Pulmonary Disease (COPD)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4047,
        "nct_id": "NCT00760877",
        "studyTitle": "An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients With Evidence of Persistent Leukemia by RQ-PCR.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic Myelogenous Leukemia"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2019-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4048,
        "nct_id": "NCT01154127",
        "studyTitle": "A Multi-center, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over Study to Assess the Effect of 50\u00b5g Inhaled NVA237 on Exercise Endurance in Patients With Moderate to Severe COPD",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic Obstructive Pulmonary Disease (COPD)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4050,
        "nct_id": "NCT01287117",
        "studyTitle": "A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Xolair\u00ae (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic Idiopathic Urticaria (CIU)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4051,
        "nct_id": "NCT01292473",
        "studyTitle": "A Phase III, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Antihistamine Treatment (H1)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic Idiopathic Urticaria (CIU)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4053,
        "nct_id": "NCT00050947",
        "studyTitle": "A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Monotherapy in Pediatric Patients With Inadequately-controlled Partial Seizures",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Epilepsy"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4054,
        "nct_id": "NCT00050934",
        "studyTitle": "A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Adjunctive Therapy in Pediatric Patients With Inadequately-controlled Partial Seizures",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Epilepsy"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4061,
        "nct_id": "NCT01922089",
        "studyTitle": "A multicenter, randomized, double-blind, parallel group study to assess the safety and tolerability of initiating LCZ696 in heart failure patients comparing two titration regimens",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Heart Failure"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4062,
        "nct_id": "NCT01035255",
        "studyTitle": "A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Heart Failure",
            "Chronic (CHF)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4068,
        "nct_id": "NCT01406938",
        "studyTitle": "A randomized, double-blind, multicenter study of subcutaneous secukinumab, assessing Psoriasis Area and Severity Index (PASI) response and maintenance of response in subjects with moderate to severe chronic plaque-type psoriasis on either a fixed dose regimen or on a retreatment at start of relapse regimen Study Comparing secukinumab Use in Long-term Psoriasis maintenance therapy: fixed regimens vs reTreatment Upon start of RElapse (SCULPTURE",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Psoriasis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4069,
        "nct_id": "NCT01412944",
        "studyTitle": "A randomized, double-blind, double dummy, multicenter study to assess the safety, tolerability and long-term efficacy of intravenous (10 mg/kg) and subcutaneous (300 mg) secukinumab in patients with moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab Secukinumab Trial Analyzing the potential of intravenous administration To Upgrade the REsponse in psoriasis (STATURE)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Psoriasis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4070,
        "nct_id": "NCT01555125",
        "studyTitle": "A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, tolerability, usability and long-term efficacy in subjects with chronic plaque-type psoriasis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Psoriasis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4071,
        "nct_id": "NCT01636687",
        "studyTitle": "A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab in autoinjectors to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, tolerability, usability and long-term efficacy in subjects with chronic plaque-type psoriasis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Psoriasis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4074,
        "nct_id": "NCT01453855",
        "studyTitle": "A Multicenter, Double-Masked Study of the Safety and Efficacy of Travoprost Ophthalmic Solution, 0.003 % Compared to Travatan in Patients with Open-Angle Glaucoma or Ocular Hypertension",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Open-Angle Glaucoma; Ocular Hypertension"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4083,
        "nct_id": "NCT00170950",
        "studyTitle": "A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hypertension"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2017-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4084,
        "nct_id": "NCT00289978",
        "studyTitle": "A 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of Fingolimod 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Multiple Sclerosis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4085,
        "nct_id": "NCT00340834",
        "studyTitle": "A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon \u00df-1a (Avonex) Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Multiple Sclerosis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4086,
        "nct_id": "NCT00423085",
        "studyTitle": "A 24-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Evaluation of the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease (MMSE 10-20)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Alzheimer's Disease"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4087,
        "nct_id": "NCT00097786",
        "studyTitle": "A Multinational, Randomized, Double-blind, Placebo-controlled, Forced-titration, 2 x 2 Factorial Design Study of the Efficacy and Safety of Long-term Administration of Nateglinide and Valsartan in the Prevention of Diabetes and Cardiovascular Outcomes in Subjects With Impaired Glucose Tolerance (IGT)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4089,
        "nct_id": "NCT00355134",
        "studyTitle": "24-month Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Multiple Sclerosis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4095,
        "nct_id": "NCT01023308",
        "studyTitle": "A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Multiple myeloma (MM); Myelodysplastic syndrome (MDS)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4107,
        "nct_id": "NCT02446496",
        "studyTitle": "Comparative Randomized, Single Dose, Two-way Crossover, Open-label Study to Determine the Bioequivalence of Cefadroxil from Duricef 1 gm Film Coated Tablets (Smithkline Beecham Egypt, LLC Affiliated Co. to GlaxoSmithKline ) and Biodroxil 1 gm Film Coated tablets (Kahira Pharm &Chem .Ind. Co. for Novartis Pharma ) After a Single Oral Dose Administration of Each to Healthy Adults Under Fasting Conditions",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Healthy Subjects"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4108,
        "nct_id": "NCT01808339",
        "studyTitle": "A randomised, repeat-dose, placebo-controlled, three-way crossover, double dummy study to evaluate and compare the efficacy of Fluticasone Furoate inhalation powder delivered via the single strip dry powder inhaler when administered either in the morning or in the evening, in male and female asthmatic subjects",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4111,
        "nct_id": "NCT01890863",
        "studyTitle": "An Open-Label, Randomised, Two Treatment, Four-Way Cross-Over (Replicate Design), Two Sequence, Repeat Dose, Single Centre Study in Healthy Volunteers to Compare the Pharmacokinetics of Fluticasone Propionate/Salmeterol (100/50 mcg) Delivered Via the Low Airflow Resistance ROTAHALER Inhaler Relative to Fluticasone Propionate/Salmeterol (100/50 mcg) Delivered Via the DISKUS Inhaler",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4114,
        "nct_id": "NCT00274703",
        "studyTitle": "A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Provide a Preliminary evaluation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Intravenous anti-human interleukin-5 (mepolizumab, 750mg and 1500mg) in the treatment of Eosinophilic Oesophagitis in Adults",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Oesophagitis",
            "Eosinophilic"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4118,
        "nct_id": "NCT01309204",
        "studyTitle": "Efficacy and Safety of Brinzolamide 10 mg/mL/Brimonidine 2 mg/mL Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension Plus Brimonidine 2 mg/mL Eye Drops, Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Open-Angle Glaucoma; Ocular Hypertension"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4120,
        "nct_id": "NCT01283516",
        "studyTitle": "A Phase I, Multi-center, Open Label Dose Escalation Study of LDK378, Administered Orally in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)",
        "overallStatus": "",
        "phase": "Phase 1/2",
        "studyType": "",
        "conditions": [
            "Tumors Characterized by Genetic Abnormalities of ALK"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4121,
        "nct_id": "NCT01685060",
        "studyTitle": "A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Adult Patients With ALK-activated Non-small Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Non-small cell lung carcinoma (NSCLC)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2017-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4123,
        "nct_id": "NCT01153763",
        "studyTitle": "A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Melanoma"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4124,
        "nct_id": "NCT01266967",
        "studyTitle": "BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Na\u00efve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Melanoma"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2017-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4131,
        "nct_id": "NCT00678587",
        "studyTitle": "Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasive Procedures",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Liver Diseases"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4137,
        "nct_id": "NCT00251004",
        "studyTitle": "Efficacy and Safety Study Comparing Concentration-controlled Everolimus in Two Doses (1.5 and 3.0 mg/Day Starting Doses) With Reduced Cyclosporine Versus 1.44 g Mycophenolic Acid (as Sodium Salt) With Standard Dose Cyclosporine in de Novo Renal Transplant Recipients",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Kidney Transplantation"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4138,
        "nct_id": "NCT01927588",
        "studyTitle": "An Exploratory Evaluation of Early Use of Everolimus (EVE) on Tacrolimus (TAC)-Based Immunosuppressive Regiment vs. Mycophenolate Sodium (MPS) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Kidney Transplantation"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4139,
        "nct_id": "NCT01927588",
        "studyTitle": "An Exploratory Evaluation of Early Use of Everolimus (EVE) on Tacrolimus (TAC)-Based Immunosuppressive Regiment vs. Mycophenolate Sodium (MPS) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Kidney Transplantation"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4141,
        "nct_id": "NCT00622869",
        "studyTitle": "A 24 Month, Multicenter, Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Liver Transplantation"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4151,
        "nct_id": "NCT00062686",
        "studyTitle": "An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects with Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving HERCEPTIN-Containing Regimens",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Neoplasms",
            "Breast"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4154,
        "nct_id": "NCT00320385",
        "studyTitle": "A Randomized, Multicenter, Open-Label, Phase III Study of Lapatinib in Combination with Trastuzumab versus Lapatinib Monotherapy in Subjects with HER2-positive Metastatic Breast Cancer whose disease has progressed on Trastuzumab-Containing Regimens",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Neoplasms",
            "Breast"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4155,
        "nct_id": "NCT00075270",
        "studyTitle": "A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Phase III Study of Oral GW572016 in Combination with Paclitaxel in Subjects Previously Untreated or Advanced or Metastatic Breast Cancer",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Neoplasms",
            "Breast"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2014-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4163,
        "nct_id": "NCT00753688",
        "studyTitle": "A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Sarcoma",
            "Soft tissue"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2013-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4164,
        "nct_id": "NCT00334282",
        "studyTitle": "A Randomised, Double-blind, Placebo controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or Metastatic Renal Cell Carcinoma",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Carcinoma",
            "Renal Cell"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4165,
        "nct_id": "NCT00244764",
        "studyTitle": "A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects with Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Carcinoma",
            "Renal Cell"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4178,
        "nct_id": "NCT00297258",
        "studyTitle": "Phase II Study of GW786034 in Patients With Relapsed or Refractory Soft Tissue Sarcoma",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Sarcoma",
            "Soft tissue"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2017-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4183,
        "nct_id": "NCT01392326",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Psoriatic Arthritis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Psoriatic Arthritis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2017-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4184,
        "nct_id": "NCT01752634",
        "studyTitle": "Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis (FUTURE 2)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Psoriatic Arthritis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4187,
        "nct_id": "NCT01037127",
        "studyTitle": "An Open-Label, Multi-Center Study to Investigate the Objective Response Rate, Safety, and Pharmacokinetics of GSK1120212, a MEK Inhibitor, in BRAF Mutation-positive Melanoma Subjects Previously Treated with or without a BRAF Inhibitor",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Cancer"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2013-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4189,
        "nct_id": "NCT00046254",
        "studyTitle": "Multinational, multicenter, double-blind, randomized, placebo-controlled, parallel group study assessing the efficacy of intravenous zoledronic acid in preventing subsequent osteoporotic fractures after a hip fracture",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Osteoporosis; Hip Fracture"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4190,
        "nct_id": "NCT00049829",
        "studyTitle": "A multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of zoledronic acid in the treatment of osteoporosis in postmenopausal women taking cal-cium and vitamin D",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Osteoporosis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4191,
        "nct_id": "NCT00145327",
        "studyTitle": "A 3-year, Double-blind Extension to CZOL446H2301 to Evaluate the Long-term Safety and Efficacy of Zoledronic Acid in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Osteoporosis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4192,
        "nct_id": "NCT00718861",
        "studyTitle": "A 3-year, Multicenter, Double-blind, Randomized, Placebo-controlled Extension to CZOL446H2301E1 to Evaluate the Efficacy and Long Term Safety of 6 and 9 Years Zoledronic Acid Treatment of Postmenopausal Women With Osteoporosis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Osteoporosis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4193,
        "nct_id": "NCT00439244",
        "studyTitle": "A One-year Partial Double-blinded, Randomized, Multi-center, Multi-national Study to Assess the Effects of Combination Therapy of Annual Zoledronic Acid (5 mg) and Daily Subcutaneous Teriparatide (2mcrg) on Postmenopausal Women With Severe Osteoporosis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Osteoporosis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4194,
        "nct_id": "NCT00097825",
        "studyTitle": "Randomized, multicenter, double-blind, double-dummy, parallel group study to determine the efficacy and safety of intravenous zoledronic acid 5 mg annually compared to oral alendronate 70 mg weekly for the treatment of osteoporosis in men",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Osteoporosis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4195,
        "nct_id": "NCT00439647",
        "studyTitle": "A Two Year Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Fracture Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Annually for the Treatment of Osteoporosis in Men",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Osteoporosis",
            "Male"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4196,
        "nct_id": "NCT00100620",
        "studyTitle": "Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Osteoporosis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4204,
        "nct_id": "NCT00424255",
        "studyTitle": "A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or Placebo Monotherapy in High-Risk Subjects With Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Neoplasms",
            "Head and Neck"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2017-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4217,
        "nct_id": "NCT01733758",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects with Type 2 Diabetes Mellitus",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4221,
        "nct_id": "NCT01957189",
        "studyTitle": "An Open Label, Single Sequence, Three Period, Drug-Drug Interaction Study To Examine The Pharmacokinetics Of Dutasteride And Tamsulosin And Their Interactions In Chinese Male Healthy Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Prostatic Hyperplasia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4222,
        "nct_id": "NCT02064504",
        "studyTitle": "An open label, randomised, six-way crossover, single dose study to determine the pharmacokinetics of GSK961081 and fluticasone furoate when administered alone or in combination",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4223,
        "nct_id": "NCT01962467",
        "studyTitle": "A Relative Bioavailability Study to Compare the Pharmacokinetics of a Fixed Dose Combination of Fluticasone Furoate and Levocabastine with Levocabastine and Fluticasone Furoate Alone",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Rhinitis",
            "Allergic",
            "Perennial and Seasonal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4224,
        "nct_id": "NCT01916226",
        "studyTitle": "Study 200165, A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Compare the Efficacy of a 2-Week Treatment with Fluticasone Propionate Nasal Spray versus Cetirizine in Adult Subjects with Seasonal Allergic Rhinitis (SAR)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Rhinitis",
            "Allergic",
            "Perennial and Seasonal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4226,
        "nct_id": "NCT01974895",
        "studyTitle": "Immunogenicity and safety study of GSK Biologicals\u2019 quadrivalent influenza vaccine (GSK2282512A) in children 6 to 35 months of age",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4228,
        "nct_id": "NCT00697749",
        "studyTitle": "Phase III study to compare immunogenicity, safety and reactogenicity of GSK Bios\u2019 novel adjuvanted hepatitis B vaccine admind intramuscularly, according to a 0, 6 month schedule, to Engerix\u2122-B 20 mcg admind according to a 0,1,6 month schedule in healthy volunteers positive for the HLA-DQ2 genotype",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4229,
        "nct_id": "NCT00697554",
        "studyTitle": "Study to compare the immunogenicity and safety of GSK Biologicals\u2019 novel adjuvanted HBV vaccine (0, 21-day schedule) to a double dose of Engerix\u2122 -B (0, 7, 21-day schedule), in pre-liver transplant patients \u2265 18 y, boosted at month 6-12",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4230,
        "nct_id": "NCT00697866",
        "studyTitle": "Evaluating the consistency of 3 consecutive lots of GSK Biologicals' novel adjuvanted HBV vaccine with single-blind safety evaluation using Engerix\u2122-B as a control, administered according to a 0, 1, 2-month schedule in healthy volunteers (15-50y).",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4238,
        "nct_id": "NCT00866294",
        "studyTitle": "A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Controlled Release Paroxetine in the Treatment of Major Depressive Disorder",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Depressive Disorder"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4240,
        "nct_id": "NCT01177826",
        "studyTitle": "Case-control Study to Evaluate the Vaccine Effectiveness of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Human Rotavirus (HRV) Vaccine (Rotarix\u2122) Against Community-acquired Rotavirus Severe Gastroenteritis (RV SGE) Among Hospitalised Children Born After 1 October 2006, in Belgium",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Infections",
            "Rotavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4289,
        "nct_id": "NCT00169481",
        "studyTitle": "A randomized, controlled, phase II study to evaluate the safety and immunogenicity of different formulations of GlaxoSmithKline Biologicals\u2019 11-valent pneumococcal conjugate vaccine, when administered intramuscularly as a 3-dose primary immunization (2-3-4 month schedule) before 6 months of age",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "acellular pertussis; Diphtheria; Haemophilus influenzae type b; Hepatitis B; Poliomyelitis; Tetanus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4290,
        "nct_id": "NCT02169583",
        "studyTitle": "A Two Part, Phase I, Randomized, Placebo Controlled, Double Blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects Protocol 201022",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Respiratory Tract"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4292,
        "nct_id": "NCT01209104",
        "studyTitle": "A single-dose, open, randomized, crossover investigation of age, gender, food-effect and proton-pump interaction on the pharmacokinetics of GSK1325756 in healthy adult subjects and a single-dose, double blind, parallel-group, placebo- controlled investigation of the pharmacokinetics of GSK1325756",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Nutritional Status"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4295,
        "nct_id": "NCT02578953",
        "studyTitle": "Bioequivalence Study of Dutasteride Capsules-An evaluation of the bioequivalence of dutasteride capsule manufactured at GSK compared to dutasteride capsule manufactured at Catalent in healthy Japanese male subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Prostatic Hyperplasia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4296,
        "nct_id": "NCT01498679",
        "studyTitle": "A randomised, double-blind, placebo-controlled, parallel group, multicentre study to evaluate the efficacy and safety of fluticasone furoate/vilanterol trifenatate (FF/VI) inhalation powder delivered once daily for 12 weeks in the treatment of asthma in adolescent and adult subjects of Asian ancestry currently treated with low to mid-strength inhaled corticosteroid or low-strength combination therapy.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4297,
        "nct_id": "NCT01751113",
        "studyTitle": "A randomised, double-blind, double dummy, 3 way cross-over study evaluating the effects of ADOAIR 50/250mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual treatments (tiotropium bromide 18mcg alone and ADOAIR 50/250mcg alone) in the treatment of Japanese subjects with COPD",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4299,
        "nct_id": "NCT01934205",
        "studyTitle": "An Open-label Study To Evaluate Plasma and Pulmonary Pharmacokinetics Following Intravenous Administration of GSK2140944 in Healthy Adult Subjects (BTZ116666)",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Bacterial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4300,
        "nct_id": "NCT01615796",
        "studyTitle": "A Two-Part Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses of GSK2140944 in Healthy Adult Subjects.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Respiratory Tract"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4301,
        "nct_id": "NCT01706315",
        "studyTitle": "A Randomized, Single Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Repeat Escalating Oral Doses of GSK2140944 in Healthy Adult Subjects (BTZ116778)",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Respiratory Tract"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4302,
        "nct_id": "NCT01376232",
        "studyTitle": "Open Label Study to Assess the Pharmacokinetics of GSK1278863A Coadministered with a High Fat Meal or an Inhibitor of CYP2C8 (gemfibrozil)",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Anaemia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4303,
        "nct_id": "NCT02135848",
        "studyTitle": "A multi-center, placebo-controlled study to evaluate the safety and efficacy of GSK1278863 vs. placebo in subjects with peripheral artery disease (PAD).",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Vascular Disease",
            "Peripheral"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4304,
        "nct_id": "NCT01319006",
        "studyTitle": "A randomized, open-label, 3-period crossover study in healthy subjects to determine the effect of particle size on the pharmacokinetics of single oral 100mg doses of GSK1278863A",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Anaemia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4305,
        "nct_id": "NCT02348372",
        "studyTitle": "A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation (Part 1), fixed Sequence and Open-Label (Part 2), Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Anaemia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4306,
        "nct_id": "NCT01673555",
        "studyTitle": "A randomized, placebo-controlled, study to evaluate the effects of GSK1278863A on pulmonary artery pressure in healthy volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Anaemia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4310,
        "nct_id": "NCT01607372",
        "studyTitle": "A randomised, double blind, placebo-controlled study to investigate the safety, pharmacodynamics and efficacy against allergic reactivity of repeat intranasal administration of the TLR7 agonist GSK2245035 in subjects with respiratory allergies",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Asthma and Rhinitis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4312,
        "nct_id": "NCT01031186",
        "studyTitle": "A First Time in Human study to assess the safety, tolerability and pharmacokinetics of GSK356278 (PDE4 inhibitor) in healthy volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Depressive Disorder and Anxiety Disorders"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4315,
        "nct_id": "NCT01879423",
        "studyTitle": "A Single-Dose, Open-Label, Randomized, Two-Period Crossover Study to Demonstrate the Bioequivalence of Lamotrigine Dispersible/Chewable Tablets (5mg\u00d75) and Lamotrigine Compressed Tablet (25mg) in Healthy Chinese Male Subjects.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Epilepsy"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4316,
        "nct_id": "NCT02064465",
        "studyTitle": "A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Demonstrate the Bioequivalence of Lamotrigine Dispersible/Chewable Tablet (100mg) and Lamotrigine Compressed Tablet (100mg) in Healthy Chinese Male Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Epilepsy"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4322,
        "nct_id": "NCT00938184",
        "studyTitle": "An open label, randomized, three-period crossover study to compare the pharmacokinetic profile of paroxetine after single doses of the controlled-release paroxetine tablets at the dose levels of 12.5, 25 and 50mg in healthy Japanese male subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Depressive Disorder"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4323,
        "nct_id": "NCT01000857",
        "studyTitle": "A steady-state, two-period crossover study to compare the pharmacokinetic profile of paroxetine after repeated daily dosing of the controlled-release paroxetine tablet (25 mg) with that of the standard immediate-release paroxetine tablet (20 mg) in healthy Japanese male subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Depressive Disorder"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4325,
        "nct_id": "NCT01867996",
        "studyTitle": "To evaluate the pharmacokinetics, safety and tolerability of Retosiban (GSK221149) co-administered with EFAVIRENZ",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Obstetric Labour",
            "Premature"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4326,
        "nct_id": "NCT01702376",
        "studyTitle": "A Randomized, Placebo-Controlled, Double-Blind, Four-way Crossover Study to Assess the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, with Moxifloxacin as a Positive Control in Healthy Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Obstetric Labour",
            "Premature"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4327,
        "nct_id": "NCT01627587",
        "studyTitle": "A two cohort, open-label study to evaluate the pharmacokinetics of GSK2847065, the metabolite of Retosiban (GSK221149) after single and repeat oral doses, the pharmacokinetics of GSK221149 coadministered with a high fat meal, and the pharmacokinetics of GSK221149 coadministered with an inhibitor of CYP3A4 (Ketoconazole)",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Obstetric Labour",
            "Premature"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4330,
        "nct_id": "NCT00964249",
        "studyTitle": "Phase I study of GW642444M- A randomized, double blind, placebo controlled, parallel-group, 7 day repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled dose of GW642444M from a novel dry powder device in healthy Japanese male subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4331,
        "nct_id": "NCT01428479",
        "studyTitle": "Phase1 study of GR121167- A double blind, placebo controlled, randomized, dose ascending, single and multiple dose study to investigate the safety and pharmacokinetics following intravenous administration of GR121167 in healthy Japanese males",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Influenza",
            "Human"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4332,
        "nct_id": "NCT01527110",
        "studyTitle": "An open-label, multi-center, single arm study to evaluate the safety and efficacy of intravenous zanamivir in the treatment of hospitalized patients with confirmed influenza infection (NAI115215)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza",
            "Human"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4372,
        "nct_id": "NCT00966004",
        "studyTitle": "Phase III Study of YM178: A double-blind group comparison study in patients with overactive bladder",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Urinary Bladder",
            "Overactive"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4373,
        "nct_id": "NCT01604928",
        "studyTitle": "A randomized, double-blind, parallel group, proof of concept study of YM178 in comparison with placebo and tolterodine in patients with symptomatic overactive bladder",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Urinary Bladder",
            "Overactive"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2016-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4400,
        "nct_id": "NCT01039805",
        "studyTitle": "A double-blind, randomized, placebo controlled Phase II study to evaluate the pharmacodynamics, safety, tolerability, and pharmacokinetics of Single Doses of the Oral Motilin Receptor Agonist GSK962040, in critically ill male and female patients with enteral feed intolerance",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Gastroparesis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4407,
        "nct_id": "NCT01669083",
        "studyTitle": "A Phase I Non-Randomized Multi Cohort, Open Label, Bridging Study to Evaluate the Pharmacokinetics, Safety and Tolerability of GSK557296 in Healthy Women Volunteers after Single and Repeat Dosing",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Embryo Transfer"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4409,
        "nct_id": "NCT01725685",
        "studyTitle": "A randomized, double blind, single-dose, three-period, crossover study to investigate pharmacokinetic, safety and tolerability of Fluticasone Furoate with Umeclidinium when administered in combination and as monotherapies in adult healthy volunteer subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4410,
        "nct_id": "NCT01894386",
        "studyTitle": "An Open Label, Randomised, Four-Period Crossover, Single Dose Study in Healthy Volunteers to Evaluate the Pharmacokinetics of FF/UMEC/VI Combination Administered at Dose Levels 100/62.5/25 mcg and 100/125/25 mcg and in Comparison with FF/VI (100/25 mcg) and UMEC/VI (62.5/25 mcg).",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Pulmonary disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4411,
        "nct_id": "NCT01691547",
        "studyTitle": "A randomized, double-blind, single dose, four way cross-over study to assess the systemic exposure, systemic pharmacodynamics and safety and tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol following single inhaled doses of Umeclidinium/Vilanterol blend + Fluticasone Furoate, Umeclidinium + Vilanterol, Fluticasone Furoate + Vilanterol and Fluticasone Furoate + Umeclidinium in healthy subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4413,
        "nct_id": "NCT01929863",
        "studyTitle": "A Randomized, Double-blind (Sponsor Unblinded), Placebo Controlled, Repeat Dose Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4414,
        "nct_id": "NCT01416324",
        "studyTitle": "A first time in human, single blind, randomized, placebo-controlled, dose escalating crossover study to evaluate the safety,tolerability, pharmacokinetic and pharmacodynamic parameters of single doses of GSK2330672 in healthy volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4417,
        "nct_id": "NCT02033668",
        "studyTitle": "A Randomized, Open Label, Parallel-Group Study to Estimate Bioavailability and to Assess the Pharmacokinetic Profile, Safety and Tolerability of GSK933776 Administered by Subcutaneous or Intramuscular Injection Relative to Intravenous Administration to Healthy Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Atrophy",
            "Geographic"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4420,
        "nct_id": "NCT01756495",
        "studyTitle": "A Single Center Phase 1 Double Blind Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Acute Coronary Syndrome"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4427,
        "nct_id": "NCT01648192",
        "studyTitle": "A Phase I, Randomized, Single-Blind, Three-Period Cross-Over, Placebo-Controlled, Single Oral Dose, Dose-Escalation (Part 1), Fixed Sequence, and Repeat Dose (Part 2) Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of losmapimod in Healthy Japanese Subjects.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Acute Coronary Syndrome"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4431,
        "nct_id": "NCT02322671",
        "studyTitle": "An Open-label, Randomised, Single Dose, Three-Way Crossover, Six Sequence, Pilot Study to Determine the Relative Bioavailability of Montelukast Sodium 5mg from Two Candidate Chewable Tablet Formulations of GW483100 Relative to One 5mg Chewable Tablet of Reference Montelukast Sodium in Healthy Adult Subjects Under Fasting Conditions",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Respiratory Disorders"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4436,
        "nct_id": "NCT00524303",
        "studyTitle": "Phase II Randomized Trial of Neoadjuvant Trastuzumab and/or Lapatinib plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women with ErbB2- (HER2/neu-) Overexpressing Invasive Breast Cancer",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Cancer",
            "Breast"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4437,
        "nct_id": "NCT01479374",
        "studyTitle": "A Multi-Center, Randomized, Double-Masked, Vehicle and Active Controlled, Parallel-Group Efficacy and Safety Study of AL-4943A Ophthalmic Solution, 0.77% in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Allergic conjunctivitis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4438,
        "nct_id": "NCT01698814",
        "studyTitle": "A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AL-4943A Ophthalmic Solution Administered Once Daily",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Allergic conjunctivitis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4439,
        "nct_id": "NCT01743027",
        "studyTitle": "Phase 3, Efficacy and Safety Study of AL-4943A Ophthalmic Solution, 0.77% in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Allergic conjunctivitis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2016-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4478,
        "nct_id": "NCT01043666",
        "studyTitle": "A Phase 3, Randomized, Double-Blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron (YM178) in Asian Patients with Symptoms of Overactive Bladder",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Urinary Bladder",
            "Overactive"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2016-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4479,
        "nct_id": "NCT00527033",
        "studyTitle": "YM178 Phase II study - A Randomized, Double-blind, Parallel-group, Placebo-controlled Study in Patients With Symptomatic Overactive Bladder",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Urinary Bladder",
            "Overactive"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2016-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4494,
        "nct_id": "NCT02006589",
        "studyTitle": "An open-label, randomised, single dose, two-way crossover pilot study to determine the relative bioavailability of one 8mg tablet formulation of candesartan cilexetil (GW615775) relative to one 8mg reference tablet of candesartan cilexetil (Atacand) in healthy adult human subjects under fasting conditions",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Hypertension"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4495,
        "nct_id": "NCT02094924",
        "studyTitle": "An Open-Label, Randomised, Single Dose, Two-Way Crossover Pilot Study to Determine the Relative Bioavailability of a Fixed Dose Combination Tablet Formulation of GSK587323 (16mg Candesartan Cilexetil/12.5mg Hydrochlorothiazide) Relative to Respective Reference Dosage Atacand D in Healthy Adult Human Subjects Under Fasting Conditions",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Hypertension"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4496,
        "nct_id": "NCT01837316",
        "studyTitle": "A randomized, double-blind, placebo-controlled cross-over study to determine the bronchodilator effect of a single dose of fluticasone furoate (FF)/ vilanterol (VI) 100/25 mcg combination administered in the morning in adult patients with asthma",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4504,
        "nct_id": "NCT02006537",
        "studyTitle": "A Study to Evaluate the Effect of Age, Food and Gender on Tolerability and Pharmacokinetics of GSK2256294 Following a Single Oral Administration in Healthy Fed and Fasted Elderly Subjects. This Study will also Evaluate the Biliary Metabolites in Healthy Young Males Following a Single Dose of GSK2256294",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4505,
        "nct_id": "NCT02262689",
        "studyTitle": "A Randomised Placebo-controlled Study to Evaluate the Effects of GSK2256294 Following Repeat Dosing on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4507,
        "nct_id": "NCT02202161",
        "studyTitle": "A Randomized, Placebo Controlled, Repeat Dose, Double Blind (sponsor unblind) Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered with Metformin to Type 2 Diabetes Patients",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4508,
        "nct_id": "NCT01934127",
        "studyTitle": "An observer-blind study to evaluate the safety and immunogenicity of GSK Biologicals\u2019 influenza vaccine(s) GSK2789869A and GSK2789868A administered in adults 21 to 64 years of age",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4510,
        "nct_id": "NCT01627340",
        "studyTitle": "An open-label study to assess the immunogenicity and safety of GSK Biologicals\u2019 hepatitis B vaccine Engerix\u2122-B (103860) in adults with or without type 2 diabetes mellitus",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4517,
        "nct_id": "NCT01648101",
        "studyTitle": "A randomised, double-blind, placebo-controlled, parallel-group, multicentre study to determine the efficacy and safety of 2 doses of retigabine immediate release (900 mg/day and 600 mg/day) used as adjunctive therapy in adult Asian subjects with drug-resistant partial-onset seizures.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Epilepsy"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4520,
        "nct_id": "NCT01928914",
        "studyTitle": "A Randomized, Placebo-Controlled Study to Evaluate the Effect of Tafenoquine (SB252263) on the Electrocardiogram (ECG) with Focus on Cardiac Repolarization (QTc duration) in Healthy Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Malaria",
            "Vivax"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2016-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4553,
        "nct_id": "NCT00669617",
        "studyTitle": "A Phase III, Randomized, Double-blind, Triple-dummy, Placebo Controlled, Multicenter, 5-period, Single-dose Complete Block Crossover Study to Determine the Onset of Action of Indacaterol (150 and 300 \u03bcg) in Patients With Moderate to Severe COPD Using Salbutamol (200 \u03bcg) and Salmeterol/Fluticasone (50/500 \u03bcg) as Active Controls",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic Obstructive Pulmonary Disease (COPD)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2017-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4556,
        "nct_id": "NCT00623103",
        "studyTitle": "A 76-week Prospective, Open-label, Multicenter Study to Evaluate the Long-term Effect of Rivastigmine Capsule and Transdermal Patch on Worsening of the Underlying Motor Symptoms of PD in Patients With Mild to Moderately Severe Dementia Associated With Parkinson's Disease (PDD)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Parkinson's Disease Dementia"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2017-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4572,
        "nct_id": "NCT02124798",
        "studyTitle": "An Open-Label Single-Arm Study to Evaluate the Reliability of an Autoinjector that Administers Belimumab Subcutaneously in Subjects with Systemic Lupus Erythematosus (SLE)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Systemic Lupus Erythematosus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4573,
        "nct_id": "NCT02094937",
        "studyTitle": "201135 : A Randomised, Double-blind, Multicenter, Parallel-group Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily with Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Subjects Stepped Down from a Maintenance Therapy with RELVAR\u00ae inhaler (FF/VI) 100/25 mcg Once-daily in Japanese Subjects",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4574,
        "nct_id": "NCT02397915",
        "studyTitle": "A Patient Preference Evaluation Study of Fluticasone Furoate Nasal Spray and Mometasone Furoate Nasal Spray in Subjects with Allergic Rhinitis",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Rhinitis",
            "Allergic",
            "Perennial and Seasonal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4576,
        "nct_id": "NCT02184624",
        "studyTitle": "An open-label study of inhaler device attributes investigating critical and overall errors, ease of use, and preference between a number of inhaler devices (ELLIPTA, TURBUHALER, HANDIHALER, BREEZHALER, MDI, and DISKUS/ACCUHALER) in adult subjects with Chronic Obstructive Pulmonary Disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4577,
        "nct_id": "NCT01978119",
        "studyTitle": "A Randomised, Multi-Centre, Double-Blind, Double-Dummy, Two Way Cross-Over, Twelve Weeks Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol 250/50 mcg Twice Daily Delivered through a Capsule-Based Inhaler and a Multi-Dose Inhaler in Adults and Adolescents with Asthma",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4580,
        "nct_id": "NCT01607385",
        "studyTitle": "A single blind, randomized, placebo-controlled, dose escalating study to evaluate the safety, tolerability,pharmacokinetic and pharmacodynamic parameters of repeat doses of GSK2330672 in healthy volunteers, given alone and with a single day of dosing with GSK1614235",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4583,
        "nct_id": "NCT02369341",
        "studyTitle": "A Phase III study for the evaluation of the immunogenicity and reactogenicity of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 season Southern Hemisphere) in adults 18 years of age and above",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4587,
        "nct_id": "NCT01857869",
        "studyTitle": "Efficacy, safety and immunogenicity study of GSK Biologicals\u2019 candidate malaria vaccine 257049 in the sporozoite challenge model in healthy malaria-na\u00efve adults",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Malaria"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4589,
        "nct_id": "NCT01376167",
        "studyTitle": "A multi-centre, double-blind, randomised, parallel-group, active controlled study to evaluate the efficacy, safety and tolerability of tafenoquine (SB-252263, WR238605) in subjects with Plasmodium vivax malaria.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Malaria",
            "Vivax"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4590,
        "nct_id": "NCT00226499",
        "studyTitle": "Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Varicella"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4591,
        "nct_id": "NCT00226499",
        "studyTitle": "Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Varicella"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4592,
        "nct_id": "NCT00226499",
        "studyTitle": "Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Varicella"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4594,
        "nct_id": "NCT00731692",
        "studyTitle": "A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Multiple Sclerosis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2017-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4595,
        "nct_id": "NCT01782326",
        "studyTitle": "A 52-week Treatment, Multi-center, Randomized, Double-blind, Double Dummy, Parallel-group, Active Controlled Study to Compare the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) With Salmeterol/Fluticasone on the Rate of Exacerbations in Subjects With Moderate to Very Severe COPD. (FLAME).",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic Obstructive Pulmonary Disease (COPD)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2017-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4596,
        "nct_id": "NCT01853072",
        "studyTitle": "Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Cataract"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2017-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4597,
        "nct_id": "NCT01872611",
        "studyTitle": "Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Cataract"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2017-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4608,
        "nct_id": "NCT01316094",
        "studyTitle": "Long-term Study of ASP1941 \u2014 Long-term Study in Patients with Type 2 Diabetes Mellitus with Decreased Renal Function (Japanese) \u2014",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2017-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4609,
        "nct_id": "NCT01057628",
        "studyTitle": "Phase III Study of ASP1941 \u2013A Phase III, Randomized, Double-Blind, Placebo-controlled, Monotherapy Study to Assess the Efficacy, Safety, and Tolerability of ASP1941 in Japanese Patients with Type 2 Diabetes Mellitus\u2013",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2017-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4610,
        "nct_id": "NCT01135433",
        "studyTitle": "A Phase 3 Study to Assess the Efficacy and Safety of ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2017-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4611,
        "nct_id": "NCT01225081",
        "studyTitle": "A Phase III Study to Assess the Efficacy, Safety and Tolerability of ASP1941 in Combination with Pioglitazone in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitazone Alone",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2017-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4612,
        "nct_id": "NCT01242202",
        "studyTitle": "Phase III Study of ASP1941 - Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Combination with an \u03b1-Glucosidase Inhibitor in Japanese Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control with an \u03b1-Glucosidase Inhibitor Alone",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2017-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4613,
        "nct_id": "NCT01242215",
        "studyTitle": "A Phase III Study to Assess the Efficacy, Safety and Tolerability of ASP1941 in Combination with Sulfonylurea in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Alone",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2017-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4614,
        "nct_id": "NCT01242228",
        "studyTitle": "Phase III Study of ASP1941 - Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Combination with a Dipeptidyl Peptidase-4 Inhibitor in Japanese Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control with a Dipeptidyl Peptidase-4 Inhibitor Alone -",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2017-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4615,
        "nct_id": "NCT01316107",
        "studyTitle": "Phase III Study of ASP1941 - Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Combination with Nateglinide in Japanese Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control with Nateglinide Alone -",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2017-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4616,
        "nct_id": "NCT01054092",
        "studyTitle": "Long-term Study of ASP1941 - A Phase III, Open-Label, Uncontrolled, Monotherapy Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Japanese Patients with Type 2 Diabetes Mellitus -",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2017-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4630,
        "nct_id": "NCT01353742",
        "studyTitle": "A Randomized, Open-label, Single-dose, Two-period, Crossover Study to Demonstrate the Bioequivalence of the Fixed Dose Combination (FDC) of lamivudine and adefovir dipivoxil (100mg/10mg) to Heptodin\u00ae (100mg ) and Hepsera\u00ae (10mg)",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Hepatitis B",
            "Chronic"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4631,
        "nct_id": "NCT01777282",
        "studyTitle": "A 52-Week, Open-Label, Multicenter Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination with Monotherapy of Oral Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4642,
        "nct_id": "NCT00307021",
        "studyTitle": "Bridging Safety & Immunogenicity study of GSK Biologicals' Candidate Malaria Vaccine RTS,S/AS01E (0.5 mL Dose) to RTS,S/AS02D (0.5 mL Dose) Administered IM According to a 0, 1, 2-Month Schedule in Gabonese Children Aged 18 Months to 4 Years",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Malaria"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4644,
        "nct_id": "NCT00360230",
        "studyTitle": "A partially-blind (observer-blind) study to evaluate the safety and immunogenicity of 3 different vaccination schedules with 2 GSK Biologicals candidate Plasmodium falciparum vaccines in children aged 5 to 17 months living in Ghana",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Malaria"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4645,
        "nct_id": "NCT00380393",
        "studyTitle": "A study of the efficacy against episodes of clinical malaria due to P. falciparum infection of GSK Biologicals candidate vaccine RTS,S/AS01, administered according to a 0,1,2-months schedule in children aged 5 to 17 months living in Tanzania & Kenya",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Malaria"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4648,
        "nct_id": "NCT01323972",
        "studyTitle": "Consistency of immunogenicity and non inferiority of three production lots of GSK Biologicals candidate malaria vaccine in children",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Malaria"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4649,
        "nct_id": "NCT01366534",
        "studyTitle": "Safety, immunogenicity and efficacy against malaria in the sporozoite challenge model of one dose of Ad35.CS.01 malaria vaccine followed by two doses of malaria 257049 vaccine in healthy malaria-na\u00efve adults",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Malaria"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4650,
        "nct_id": "NCT01148459",
        "studyTitle": "Safety and immunogenicity study of GSK Biologicals Plasmodium falciparum malaria vaccine 257049 administered to HIV infected infants and children",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Malaria"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4654,
        "nct_id": "NCT00411567",
        "studyTitle": "An Open Label Study to Assess the Utility of Measuring Markers of Inflammation, to Detect Transition From Optimal to Sub-Optimal Inhaled Corticosteroid Therapy in Moderate-Severe Bronchial Asthma",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2017-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4660,
        "nct_id": "NCT02371603",
        "studyTitle": "An Open Label, Randomized, Two Part Study to Evaluate the CYP2C8- and OATP1B1-Mediated Drug-Drug Interaction Potential of GSK1278863 with Pioglitazone and Rosuvastatin as Victims and Trimethoprim as Perpetrator in Healthy Adult Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Anaemia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4662,
        "nct_id": "NCT01999842",
        "studyTitle": "An observer-blind study to evaluate the safety and immunogenicity of GSK Biologicals\u2019 influenza vaccine(s) GSK3206641A and GSK3206640A administered in adults 18 to 64 years of age",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4671,
        "nct_id": "NCT01984086",
        "studyTitle": "An open-label, randomised, cross-over, two cohort, single dose study in healthy volunteers to evaluate the Unit Dose Dry Powder Inhaler (UD-DPI) for the delivery of salbutamol and to compare the pharmacokinetic profile with the MDI and Diskus presentations.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4687,
        "nct_id": "NCT00387764",
        "studyTitle": "An Open-label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects With Renal Cell Carcinoma Previously Enrolled on Protocol VEG105192",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Carcinoma",
            "Renal Cell"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2017-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4688,
        "nct_id": "NCT00099242",
        "studyTitle": "Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Alzheimer's Disease"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2017-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4689,
        "nct_id": "NCT00506415",
        "studyTitle": "A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Com-parative Efficacy, Safety, and Tolerability of Exelon\u00ae 10 and 15 cm2 Patch in Patients with Alzheimer\u2019s Disease Showing Cognitive Decline during an Initial Open-Label Treatment Phase",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Alzheimer's Disease"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2017-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4731,
        "nct_id": "NCT02141217",
        "studyTitle": "Efficacy, safety and tolerability of amoxicillin + clavulanic acid (875mg/125mg) two times a day compared to clindamycin (150mg) four times a day for 5-7 days in treatment of acute odontogenic infection with or without abscess",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Focal Infection",
            "Dental"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4732,
        "nct_id": "NCT01934231",
        "studyTitle": "A Multicenter, Open-Label Study To Assess The Efficacy And Safety Of Potassium Clavulanate/Amoxicillin (CVA/AMPC 1:14 combination) In The Treatment Of Children With Acute Bacterial Rhinosinusitis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Sinusitis",
            "Acute"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4734,
        "nct_id": "NCT01577693",
        "studyTitle": "An open-label, single dose, randomized, two-period crossover study to investigate the bioavailability of a novel dosage form of dutasteride in healthy male subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Prostatic Hyperplasia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4749,
        "nct_id": "NCT00948766",
        "studyTitle": "A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm^2 vs. Rivastigmine Patch 5 cm^2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION) and a 24-week Open-label Extension to Study ENA713DUS44",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Alzheimer's Disease"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2017-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4753,
        "nct_id": "NCT00132808",
        "studyTitle": "A 2-year Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Administered Either Annually at Randomization and 12 Months, or Administered at Randomization Only in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Osteopenia"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2017-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4774,
        "nct_id": "NCT01847404",
        "studyTitle": "An open label, balanced, randomized, three-treatment, three-period, six-sequence, cross-over, single dose, comparative bioavailability pilot study of two test formulations of fixed dose combination capsules of acetylsalicylic acid (ASA) and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK comparing with Aspirin\u00ae Protect 100 mg tablets by Bayer vital GmbH, and Protium\u00ae 20 mg gastro-resistant tablets by Nycomed GmbH, in healthy, adult, human subjects, under fasting conditions",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Ulcers",
            "Duodenal and Gastric"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4775,
        "nct_id": "NCT01847417",
        "studyTitle": "An open label, balanced, randomized, three-treatment, three-period, six-sequence, cross-over, single dose, comparative bioavailability pilot study of two test formulations of fixed dose combination capsules of acetylsalicylic acid (ASA) and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK comparing with Aspirin\u00ae Protect 100 mg tablets by Bayer vital GmbH, and Protium\u00ae 20 mg gastro-resistant tablets by Nycomed GmbH, in healthy, adult, human subjects, under fed conditions",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Ulcers",
            "Duodenal and Gastric"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4777,
        "nct_id": "NCT01039974",
        "studyTitle": "An open-label, randomized, single sequence, two period study to assess the effect of repeat oral dosing of ketoconazole on the pharmacokinetics of a single oral dose of GSK962040 in healthy volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Gastroparesis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4779,
        "nct_id": "NCT02019719",
        "studyTitle": "A 4-Week, Phase II, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects with Anemia Associated with Chronic Kidney Disease",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Anaemia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4781,
        "nct_id": "NCT01852565",
        "studyTitle": "An Open-Label, Three Period, Single Sequence Study To Determine The Effect Of Repeat Oral Dosing Of Diltiazem On The Pharmacokinetics Of Repeat Oral Dosing Of Darapladib (SB-480848).",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Atherosclerosis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4782,
        "nct_id": "NCT01978145",
        "studyTitle": "A Randomised Multi-Centre, Double-Blind, Double-Dummy, Two Way Cross-Over, Twelve Weeks Non-inferiority Study to Evaluate The Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol 250/50 mcg Twice Daily Delivered Through a Capsule-Based Inhaler and a Multi-Dose Inhaler for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4783,
        "nct_id": "NCT01494610",
        "studyTitle": "A comparative bioavailability study to compare the pharmacokinetic (PK) and pharmacodynamic (PD) effects of Fluticasone propionate and Salmeterol delivered by Fluticasone propionate/ Salmeterol combination in a capsule-based inhaler and a multi-dose dry powder inhaler, in moderate asthma patients and moderate to severe Chronic obstructive pulmonary disease (COPD) patients.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4784,
        "nct_id": "NCT00920192",
        "studyTitle": "A Phase 1/2, Open-Label, Multicenter Study of GSK1363089G in Adult Subjects with Hepatocellular Carcinoma",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Carcinoma",
            "Hepatocellular"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4786,
        "nct_id": "NCT02257398",
        "studyTitle": "A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, 4-Period Crossover Study to Evaluate the Effect of GSK2140944 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Respiratory Tract"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4787,
        "nct_id": "NCT02045849",
        "studyTitle": "A Single-Center, Three-Part, Open Label Study to Evaluate the Relative Bioavailability of Two Formulations, Food Effect, and Interaction with Itraconazole Following Single Dose of GSK2140944 in Healthy Subjects and Effect of Food on Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of GSK2140944 in Healthy Elderly Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Bacterial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4788,
        "nct_id": "NCT01818011",
        "studyTitle": "A Three-Part Phase I, Open-Label, Single Ascending Dose, and A Single-Blind, Placebo-Controlled, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Relative Bioavailability of Intravenous and Oral GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Bacterial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4792,
        "nct_id": "NCT02242643",
        "studyTitle": "Immunogenicity and safety study of GSK Biologicals\u2019 quadrivalent influenza vaccine (GSK2282512A) compared to Fluzone\u00ae Quadrivalent in children 6 to 35 months of age",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4793,
        "nct_id": "NCT02637206",
        "studyTitle": "Skin Irritation Study of GSK2894512 Cream-An Evaluator-Blinded Study to Evaluate the Skin Irritation of GSK2894512 Cream and Placebo following Single Application by Simple-Patch Test and Photo-Patch Test, and Repeat Application under non-occlusive condition in Healthy Japanese Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Dermatitis",
            "Atopic"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4799,
        "nct_id": "NCT02184637",
        "studyTitle": "A Five-cohort, Randomized, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine (SB252263) 300mg when Co-administered with the Artemisinin-based Combination Therapies (ACT) Artemether + Lumefantrine (AL) and Dihydroartemisinin + Piperaquine tetraphosphate (DHA+PQP)",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Malaria",
            "Vivax"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4829,
        "nct_id": "NCT01451203",
        "studyTitle": "A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of CDP870 in Patients With Early-stage Rheumatoid Arthritis Who Are Na\u00efve to Methotrexate and Have Poor Prognostic Factors",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Rheumatoid Arthritis"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2017-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4831,
        "nct_id": "NCT02175784",
        "studyTitle": "Postmarketing Clinical Study of Ipragliflozin - Double-blind, Parallel-group Study in Combination with Insulin in Patients with Type 2 Diabetes Mellitus -",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2017-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4832,
        "nct_id": "NCT01618669",
        "studyTitle": "A Phase 3b, Open-label, Parallel Group, Randomized, Multicenter Study to Assess Regadenoson Administration following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone For Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Myocardial Perfusion Imaging"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2017-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4876,
        "nct_id": "NCT01831791",
        "studyTitle": "Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects with Androgenetic Alopecia",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Alopecia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4879,
        "nct_id": "NCT00964106",
        "studyTitle": "Validation Study of Simultaneous Administration of Multiple Cytochrome P450/Transporter Probes for Drug Interaction Evaluation in Healthy Adult Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Healthy Subjects"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4899,
        "nct_id": "NCT00537082",
        "studyTitle": "A 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Multiple Sclerosis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2017-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4900,
        "nct_id": "NCT00670449",
        "studyTitle": "An Extension of the 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Multiple Sclerosis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2017-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4907,
        "nct_id": "NCT02138747",
        "studyTitle": "A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq\u00ae and Detrol\u00ae LA in Subjects with Overactive Bladder (OAB)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Urinary Bladder",
            "Overactive"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2017-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4914,
        "nct_id": "NCT02045797",
        "studyTitle": "A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Bacterial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4916,
        "nct_id": "NCT01702467",
        "studyTitle": "A Single-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Alzheimer's Disease"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4920,
        "nct_id": "NCT02446483",
        "studyTitle": "Comparative Randomized, Single dose, Two-way Crossover Open-label Study to Determine the Bioequivalence of Rabeprazole from Idiazole 20mg DR tabs (GSK, Egypt) and PARIET 20 mg DR tabs (JANSSEN, EGYPT) after a Single Oral Dose Administration of each to Healthy Adults under Fasting Conditions",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Gastrointestinal Diseases"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4921,
        "nct_id": "NCT02605395",
        "studyTitle": "Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Rabeprazole from Raperazole 20mg DR tabs (GSK, Egypt) and PARIET 20 mg DR tabs (JANSSEN, EGYPT) after a single oral dose administration of each to healthy adults under fed conditions",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Gastrointestinal Diseases"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4923,
        "nct_id": "NCT01929317",
        "studyTitle": "A Study ROP116991, Clinical Evaluation of 18 to 24mg/day Ropinirole CR for Parkinson\u2019s disease.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Parkinson Disease"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4952,
        "nct_id": "NCT02184585",
        "studyTitle": "An Open-label, Randomized, Single Dose, three-way Crossover study to determine the Bioavailability of Two Fixed Dose Combination Capsule Formulations of Dutasteride and Tamsulosin Hydrochloride (0.5mg/0.2mg) Relative to Co-administration of Dutasteride 0.5mg capsules and Tamsulosin Hydrochloride 0.2mg tablets in Healthy Male Subjects in the fed and fasted states",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Prostatic Hyperplasia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4953,
        "nct_id": "NCT02509104",
        "studyTitle": "An Open-label, Randomized, Single Dose, Two-way Crossover study to Determine the Bioavailability of one Fixed Dose Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5 mg/0.2 mg) Relative to Coadministration of one Dutasteride 0.5 mg capsule and one Tamsulosin Hydrochloride 0.2 mg tablet in Healthy Male Subjects in the Fed and Fasted States",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Prostatic Hyperplasia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4954,
        "nct_id": "NCT01857895",
        "studyTitle": "An Open-Label Exploratory Study to Investigate the Feasibility of Administering Exenatide by Continuous Subcutaneous Infusion to Healthy Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Obesity"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4957,
        "nct_id": "NCT00315744",
        "studyTitle": "Steroid-sparing management of the salmeterol/fluticasone 50/100\u00b5g b.i.d. combination compared to fluticasone 200\u00b5g b.i.d. in children and adolescents with moderate asthma",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4963,
        "nct_id": "NCT01340911",
        "studyTitle": "A Randomized, Placebo-Controlled, Single-Blind, Dose-Escalation, First-Time-in-Human Study to Assess the Safety and Pharmacokinetics of Single and Repeat Doses of SRT3025 in Normal Healthy Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4964,
        "nct_id": "NCT01725126",
        "studyTitle": "A double-blind [sponsor unblinded], randomized, placebo-controlled, staggered-parallel study to investigate the safety, tolerability, and pharmacodynamics of GSK2890457 in healthy volunteers and subjects with type 2 diabetes",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Obesity"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4966,
        "nct_id": "NCT01258608",
        "studyTitle": "A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Carcinoma",
            "Hepatocellular"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4967,
        "nct_id": "NCT00451321",
        "studyTitle": "TRX4 Therapeutic Evaluation of Different Multi-Dose Regimens in Type 1 Diabetes Mellitus (TTEDD)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 1"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4970,
        "nct_id": "NCT00290355",
        "studyTitle": "A Phase IIB Study to Assess the Efficacy of GSK 249553 as Adjuvant Therapy Given to MAGE-3-Positive Patients With Non-Small-Cell Lung Cancer in Stage IB (T2/N0) or II (T1/N1 or T2/N1 or T3/N0), Who Have Had Complete Surgical Resection",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Lung Cancer",
            "Non-Small Cell"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4993,
        "nct_id": "NCT02006602",
        "studyTitle": "An open-label, randomised, single dose, two-way crossover pilot study to determine the relative bioavailability of one 16mg tablet formulation of candesartan cilexetil (GW615775) relative to one 16mg reference tablet of candesartan cilexetil (Atacand) in healthy adult human subjects under fasting conditions",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Hypertension"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4994,
        "nct_id": "NCT02254447",
        "studyTitle": "An Open-label, Randomized, Single Dose, Three-way Crossover, Six Sequence Pilot Study to Determine the Relative Bioavailability of Candesartan Cilexetil 16mg From Two Candidate Tablet Formulations of GW615775 Relative to One 16mg Tablet of Reference Candesartan Cilexetil in Healthy Adult Human Subjects Under Fasting Conditions",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Respiratory Disorders"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4996,
        "nct_id": "NCT01788813",
        "studyTitle": "A randomized, double blind, placebo-controlled study to investigate the safety, pharmacodynamics and effect on allergic reactivity of repeat intranasal administration of the TLR7 agonist GSK2245035 in subjects with respiratory allergies",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Mild Asthma and Allergic Rhinitis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4997,
        "nct_id": "NCT02446613",
        "studyTitle": "A single-centre, follow-up study to investigate the effect of GSK2245035 on nasal allergic reactivity in subjects who completed treatment in study TL7116958 in 2014",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Asthma and Rhinitis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 4998,
        "nct_id": "NCT01808365",
        "studyTitle": "Neisseria meningitidis carriage study",
        "overallStatus": "",
        "phase": NaN,
        "studyType": "",
        "conditions": [
            "Infections",
            "Meningococcal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 5006,
        "nct_id": "NCT01358175",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the 16 Week Efficacy and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Ankylosing Spondylitis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2017-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 5021,
        "nct_id": "NCT02496221",
        "studyTitle": "A randomized, double-blind, single-dose, placebo controlled, 2-way cross-over study evaluating effect of albiglutide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 5031,
        "nct_id": "NCT01086449",
        "studyTitle": "Safety and Immunogenicity of GSK Biologicals\u2019 Herpes Zoster vaccine 1437173A in healthy ethnic Japanese adults",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Herpes Zoster"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 5032,
        "nct_id": "NCT02581410",
        "studyTitle": "Immunogenicity and safety study of GSK Biologicals\u2019 Herpes Zoster vaccine GSK1437173A in adults \u2265 65 years of age with and without Zostavax\u00ae vaccination at least 5 years earlier",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Herpes Zoster"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 5033,
        "nct_id": "NCT01360398",
        "studyTitle": "Contribution of infectious pathogens to acute respiratory illness in adults and elderly",
        "overallStatus": "",
        "phase": NaN,
        "studyType": "",
        "conditions": [
            "Respiratory Disorders"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 5047,
        "nct_id": "NCT01334918",
        "studyTitle": "A Phase 2, Open-Label, Randomized, Cross-Over Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging by Multidetector Computed Tomography (MDCT) and Single Photon Emission Computed Tomography (SPECT)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Coronary Artery Disease"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2017-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 5050,
        "nct_id": "NCT01458249",
        "studyTitle": "An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Soft Tissue Sarcoma"
        ],
        "orgCode": "",
        "orgName": "Eisai",
        "status": "",
        "postedDate": "2017-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 5091,
        "nct_id": "NCT02453022",
        "studyTitle": "A Single Centre, Open-label, 5-Period, Cross over, Randomized Study in Healthy Elderly Subjects to Evaluate the Relative Bioavailability of Hydrobromide Salt and Free Base Immediate Release Tablet Formulations of Danirixin in the Fed State, and to Evaluate the Effect of Food and Gastric Acid Secretion Suppression on Danirixin Pharmacokinetics Following Administration of Hydrobromide Salt Tablets",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 5092,
        "nct_id": "NCT00375765",
        "studyTitle": "A randomized, open-label, parallel-group study, to assess the pharmocodynamic effect on dihydrotestosterone regulated gene expression, longitudinally and in a dose dependent manner, of 0.5mg and 3.5mg dutasteride administered orally once daily, for one year in men with symptomatic benign prostatic hyperplasia and during a two month period between baseline and radical prostatectomy in men with biopsy-proven, clinically localized prostate cancer",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Prostatic Hyperplasia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 5093,
        "nct_id": "NCT00441116",
        "studyTitle": "An randomised, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of dutasteride 0.5mg once daily for 6 months in the treatment of male subjects with androgenetic alopecia (Norwood-Hamilton classification type IIIv, IV and V)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Alopecia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 5094,
        "nct_id": "NCT02014584",
        "studyTitle": "A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Alopecia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 5095,
        "nct_id": "NCT00527605",
        "studyTitle": "A randomized, double-blind, placebo-controlled, six-month parallel-group study to assess efficacy and safety of dutasteride 0.5mg once daily in Chinese patients with Benign Prostatic Hyperplasia (BPH), followed by a 12-month open-label treatment phase",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Prostatic Hyperplasia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 5097,
        "nct_id": "NCT00398580",
        "studyTitle": "A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered with 0.25mg Dutasteride Compared with 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Hypogonadism",
            "Male"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 5098,
        "nct_id": "NCT02058368",
        "studyTitle": "A randomized, double-blind, parallel group study to compare the efficacy and safety of combination treatment with dutasteride (0.5mg) and tamsulosin (0.2mg) with tamsulosin (0.2mg) monotherapy, administered once daily for 2 years, on the improvement of symptoms and health outcomes in men with moderate to severe benign prostatic hyperplasia",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Prostatic Hyperplasia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 5099,
        "nct_id": "NCT01673490",
        "studyTitle": "A pivotal, open-label trial assessing the safety and efficacy of the 0.5 mg dutasteride and 0.4 mg tamsulosin combination once daily for six months in patients with benign prostatic hyperplasia",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Prostatic Hyperplasia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 5103,
        "nct_id": "NCT02218723",
        "studyTitle": "An open-label, randomised, cross-over, single dose study in healthy volunteers to evaluate the Unit Dose Dry Powder Inhaler (UD-DPI) with four different formulations for the delivery of fluticasone fuorate and to compare the pharmacokinetic profile with the fluticasone fuorate ELLIPTA presentation",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 5109,
        "nct_id": "NCT01659086",
        "studyTitle": "An observer-blind study to evaluate the safety and immunogenicity of GSK Biologicals\u2019 influenza vaccines GSK2654911A and GSK2654909A administered to adults 18 to 64 years of age",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 5110,
        "nct_id": "NCT02045940",
        "studyTitle": "A Randomized Double Blinded (Sponsor Unblind), Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Selective Androgen Receptor Modulator (SARM) in Single and Repeat Doses in Healthy Male Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Cachexia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 5112,
        "nct_id": "NCT00799825",
        "studyTitle": "Safety study of GSK Biologicals\u2019 human papillomavirus vaccine (GSK580299) in female American and Canadian subjects who had received control vaccine in study 580299/008",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 5114,
        "nct_id": "NCT01418937",
        "studyTitle": "Safety study of GSK Biologicals\u2019 human papillomavirus vaccine (GSK-580299) in healthy female control subjects from the GSK HPV-023 study",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 5118,
        "nct_id": "NCT01878825",
        "studyTitle": "Immunogenicity and safety study of GSK Biologicals\u2019 Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral\u2122 (2013-2014 Season) in adults aged 18 years and older",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 5123,
        "nct_id": "NCT01190202",
        "studyTitle": "Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa",
        "overallStatus": "",
        "phase": NaN,
        "studyType": "",
        "conditions": [
            "Malaria"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 14488,
        "nct_id": "NCT01484496",
        "studyTitle": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Systemic Lupus Erythematosus (SLE)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Systemic Lupus Erythematosus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2017-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 14493,
        "nct_id": "NCT02213029",
        "studyTitle": "Study IVF116828:A Multi-Cohort Phase I Study to Investigate the Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban (GSK557296) in Healthy Female Volunteers During Control and Challenge States With and Without Oxytocin",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Embryo Transfer"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 14496,
        "nct_id": "NCT01205178",
        "studyTitle": "A Phase I Study to Investigate the Hemolytic Potential of Tafenoquine in Healthy Subjects with Glucose-6-phosphate Dehydrogenase Deficiency and the Safety and Tolerability of Tafenoquine in Acute Plasmodium vivax Malaria Patients with Glucose-6-phosphate Dehydrogenase Deficiency",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Malaria"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 14530,
        "nct_id": "NCT02293148",
        "studyTitle": "A Two-part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a High, Single Oral Dose of GSK1278863 (Part A), and a Randomized, Single-blind, Placebo- and Positive-controlled, Four-way Crossover Study to Assess the Effect of Single, Oral Dose of GSK1278863 on Cardiac Repolarization (Part B) in Healthy Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Anaemia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 14531,
        "nct_id": "NCT02377414",
        "studyTitle": "A Phase I, Subject and Investigator Blind Randomized, Study to Investigate the Pharmacokinetics, Safety and Tolerability of Retosiban in Healthy Japanese Women",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Obstetric Labour",
            "Premature"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 14532,
        "nct_id": "NCT01597492",
        "studyTitle": "A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTA\u2122 (belimumab; HGS1006) on Vaccine Responses in Subjects with Systemic Lupus Erythematosus (SLE)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Systemic Lupus Erythematosus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 14533,
        "nct_id": "NCT01879462",
        "studyTitle": "A Randomized, Single-Blind, Dose Escalation, First Time in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of GSK2878175 in Healthy Adults",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Hepatitis C",
            "Chronic"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 14534,
        "nct_id": "NCT02014571",
        "studyTitle": "A Randomized, Single Blind, Dose Escalation, Placebo-Controlled Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects with Chronic Hepatitis C.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Hepatitis C",
            "Chronic"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 14540,
        "nct_id": "NCT02275052",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effect of the Combination of Umeclidinium and Vilanterol on Exercise Endurance Time in Subjects with COPD",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 14542,
        "nct_id": "NCT03028467",
        "studyTitle": "A Phase 1/2, Double-Blind, Placebo-Controlled Study of the Pharmacokinetics, Safety and Tolerability of GSK3196165 in Combination with Methotrexate Therapy, in Japanese Subjects with Active Moderate-Severe Rheumatoid Arthritis Despite Treatment with Methotrexate",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Arthritis",
            "Rheumatoid"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 14543,
        "nct_id": "NCT02786927",
        "studyTitle": "An open-label study to evaluate the preference attributes of the ELLIPTA\u2122 dry powder inhaler (DPI) compared to the HandiHaler\u2122 DPI in subjects with Chronic Obstructive Pulmonary Disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 14544,
        "nct_id": "NCT02563899",
        "studyTitle": "A Phase 2a Study to Evaluate the Pharmacokinetic, Safety, Tolerability and Clinical Effect of Topically Applied Umeclidinium/GSK573719 in Subjects with Primary Axillary Hyperhidrosis",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Hyperhidrosis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 14545,
        "nct_id": "NCT01687283",
        "studyTitle": "A multicenter, randomized, single blind, active controlled, parallel group study to determine efficacy and safety of nebulized fluticasone propionate 1mg BID compared with nebulized budesonide 2mg BID administered for 12 weeks in Chinese adult and adolescent patients with severe persistent asthma",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 14546,
        "nct_id": "NCT02698553",
        "studyTitle": "An open-label, fixed sequence study to evaluate pharmacokinetics, safety and tolerability of single and repeated dose of extended-release bupropion hydrochloride (bupropion XL) tablets 150 mg and 300 mg once daily in Chinese healthy volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Depressive Disorder",
            "Major"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 14549,
        "nct_id": "NCT02345174",
        "studyTitle": "An Open Label Positron Emission Tomography (PET) Imaging Study Using 89Zirconium to Investigate the Biodistribution of Anti-HER3 monoclonal Antibody (mAb) GSK2849330 and Characterize its Dose-receptor Occupancy Relationship in Subjects with Advanced HER3-Positive Solid Tumors",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Cancer"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 14551,
        "nct_id": "NCT02257359",
        "studyTitle": "A Phase 1, Open Label, Ascending Cohort, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban and its Metabolite in Healthy Female Volunteers Following Administration of Epelsiban",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Embryo Transfer"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 14552,
        "nct_id": "NCT02703181",
        "studyTitle": "A Randomized, Placebo-controlled, Double-Blind (Sponsor Unblind), Repeat Dose, Ascending Cohort, Dose Escalation Phase I Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban and its Major Metabolite in Healthy Women Volunteers Following Administration of Repeat Dosing of Epelsiban",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Embryo Transfer"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 14567,
        "nct_id": "NCT00248170",
        "studyTitle": "Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Breast Cancer"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 14569,
        "nct_id": "NCT01626222",
        "studyTitle": "A Phase IIIB, Multi-Center, Open Label Study For Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination With Exemestane: 4EVER - Efficacy, Safety, Health Economics, Translational Research",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Metastatic Breast Cancer"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 14570,
        "nct_id": "NCT02069093",
        "studyTitle": "A Phase II, Single Arm Study of the Use of Steroid-based Mouthwash to Prevent Stomatitis in Postmenopausal Women With Advanced or Metastatic Hormone Receptor Positive Breast Cancer Being Treated With Everolimus Plus Exemestane",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Advanced Breast Cancer"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 14583,
        "nct_id": "NCT01199731",
        "studyTitle": "A Phase 2b study to select a once daily oral dose of GSK2248761 in HIV-1 infected antiretroviral therapy experienced adults with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2018-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 14584,
        "nct_id": "NCT01231555",
        "studyTitle": "Phase 2b study to select a once daily oral dose of GSK2248761 administered with tenofovir/emtricitabine or abacavir/lamivudine in HIV-1 infected antiretroviral therapy naive adult subjects",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2018-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16029,
        "nct_id": "NCT01476202",
        "studyTitle": "A Pilot Study to Evaluate Relief of Provoked Acute Craving by Nicotine Mouth Strip, Nicorette \u00ae Nicotine Lozenge and Gum",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Smoking Cessation"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16040,
        "nct_id": "NCT01738477",
        "studyTitle": "Evaluation of immunogenicity and safety of GSK Biologicals' Tdap booster vaccine (Boostrix\u2122) in young adults, administered 10 years after previous Tdap boosting",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diphtheria; Tetanus; Acellular pertussis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16047,
        "nct_id": "NCT02705807",
        "studyTitle": "An Open Label, Single-arm Study Evaluating a New Thermostable Formulation of FLOLAN\u2122 in Japanese Subjects with Pulmonary Arterial Hypertension (PAH)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Cardiovascular Disease"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16058,
        "nct_id": "NCT01499199",
        "studyTitle": "A Single-arm Study of the Safety, Efficacy and Central Nervous System and Plasma PK of GSK1349572 (Dolutegravir, DTG) 50 mg Once Daily in Combination with the Abacavir/Lamivudine Fixed Dose Combination Tablet over 96 Weeks in HIV-1 Infected Antiretroviral Naive Adult Subjects",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2018-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16059,
        "nct_id": "NCT01568892",
        "studyTitle": "A Phase III Randomized, Double-blind Trial Investigating the Activity of Dolutegravir 50 mg BID vs Placebo over 7 Days in HIV-1-infected Subjects with RAL/ELV resistance, Followed by an Open-label Phase with an Optimized Background Regimen",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2018-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16061,
        "nct_id": "NCT00489970",
        "studyTitle": "Persistence study of GSK Biologicals\u2019 Tdap vaccine (776423), 1, 3, 5 and 9 years following administration as a single dose in NCT00346073 study and to evaluate the immunogenicity and safety of Boostrix as a second dose of Tdap, when administered at Year 9",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diphtheria; Tetanus; Acellular pertussis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16062,
        "nct_id": "NCT00489970",
        "studyTitle": "Persistence study of GSK Biologicals\u2019 Tdap vaccine (776423), 1, 3, 5 and 9 years following administration as a single dose in NCT00346073 study and to evaluate the immunogenicity and safety of Boostrix as a second dose of Tdap, when administered at Year 9",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diphtheria; Tetanus; Acellular pertussis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16063,
        "nct_id": "NCT00489970",
        "studyTitle": "Persistence study of GSK Biologicals\u2019 Tdap vaccine (776423), 1, 3, 5 and 9 years following administration as a single dose in NCT00346073 study and to evaluate the immunogenicity and safety of Boostrix as a second dose of Tdap, when administered at Year 9",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diphtheria; Tetanus; Acellular pertussis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16064,
        "nct_id": "NCT00489970",
        "studyTitle": "Persistence study of GSK Biologicals\u2019 Tdap vaccine (776423), 1, 3, 5 and 9 years following administration as a single dose in NCT00346073 study and to evaluate the immunogenicity and safety of Boostrix as a second dose of Tdap, when administered at Year 9",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diphtheria; Tetanus; Acellular pertussis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16065,
        "nct_id": "NCT02676895",
        "studyTitle": "A Phase 2a, Observer Blind, Randomized, Controlled, Single Center Study To Evaluate The Safety, Reactogenicity And Immunogenicity Of 2 Doses Of The GVGH 1790GAHB Vaccine Against Shigella Sonnei, Administered Intramuscularly In Adult Subjects From A Country Endemic For Shigellosis",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Shigella sonnei infection"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16071,
        "nct_id": "NCT02377401",
        "studyTitle": "A Randomized, Double Blinded, Parallel Study to Evaluate the Pharmacokinetics of Zanamivir after Single and Repeated Dose (300 mg and 600 mg) Infusion Administration in Healthy Chinese Adults",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Influenza",
            "Human"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16108,
        "nct_id": "NCT01262976",
        "studyTitle": "Safety and immunogenicity of GSK Biologicals\u2019 candidate tuberculosis vaccine (692342) when administered to HIV-positive adults living in a Tuberculosis endemic region",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Tuberculosis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16109,
        "nct_id": "NCT00057330",
        "studyTitle": "A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of gD-Alum/MPL Vaccine in the Prevention of Genital Herpes Disease in Young Women Who are HSV-1 and -2 Seronegative",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Herpes Simplex"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16112,
        "nct_id": "NCT00621322",
        "studyTitle": "Dose range study evaluating safety and immunogenicity study of GSK Biologicals' candidate tuberculosis vaccines (692342) when administered to healthy adults aged 18 to 45 years.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Tuberculosis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16113,
        "nct_id": "NCT00950612",
        "studyTitle": "Safety and immunogenicity study of GSK Biologicals\u2019 candidate tuberculosis vaccine (692342) when administered to healthy HIV-negative adolescents living in a TB endemic region",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Tuberculosis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16114,
        "nct_id": "NCT00707967",
        "studyTitle": "Safety and immunogenicity of a candidate tuberculosis (TB) vaccine (692342) in HIV-positive adults.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Tuberculosis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16117,
        "nct_id": "NCT02466152",
        "studyTitle": "A Pharmacokinetic Study for Systemic Exposure of Twice Daily Topically applied GSK2894512 Cream in Subjects with Atopic Dermatitis",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Dermatitis",
            "Atopic"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16119,
        "nct_id": "NCT02751294",
        "studyTitle": "A randomized, open-label, single-period, parallel-group study in healthy subjects to determine the effects of dissolution profile on the pharmacokinetics (via both venous and peripheral micro-samples) of single oral 300 mg doses of Tafenoquine (SB-252263) tablets + 30 mg Tafenoquine stable isotope labelled (SIL) solution",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Malaria",
            "Vivax"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16120,
        "nct_id": "NCT02548052",
        "studyTitle": "A Phase I Trial to Evaluate Safety and Efficacy of Topically Applied GSK2981278 Ointment in a Psoriasis Plaque Test",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Psoriasis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16128,
        "nct_id": "NCT00073528",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing GW572016 and Letrozole Versus Letrozole in Subjects With Estrogen/Progesterone Receptor-Positive Advanced or Metastatic Breast Cancer",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Breast Cancer"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16129,
        "nct_id": "NCT01202188",
        "studyTitle": "A 26-week Treatment Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled (Open Label) Study to Assess the Efficacy, Safety and Tolerability of QVA149 (110/50 \u03bcg q.d.) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic obstructive pulmonary disease (COPD)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16130,
        "nct_id": "NCT01610037",
        "studyTitle": "A Placebo and Active Controlled Study to Assess the Long-term Safety of Once Daily QVA149 for 52 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate to Severe Airflow Limitation",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic obstructive pulmonary disease (COPD)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16131,
        "nct_id": "NCT01727141",
        "studyTitle": "A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic obstructive pulmonary disease (COPD)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16132,
        "nct_id": "NCT01712516",
        "studyTitle": "A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic obstructive pulmonary disease (COPD)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16133,
        "nct_id": "NCT01120691",
        "studyTitle": "A 64-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Effect of QVA149 (110/50 \u03bcg o.d.) vs NVA237 (50 \u03bcg o.d.) and Open-label Tiotropium (18 \u03bcg o.d.) on COPD Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic obstructive pulmonary disease (COPD)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16134,
        "nct_id": "NCT01285492",
        "studyTitle": "A 52-week Treatment, Multi-center, Randomized, Open Label, Parallel Group Study to Assess the Long Term Safety and Tolerability of QVA149 (110 Mcg Indacaterol / 50 Mcg Glycopyrrolate o.d.) Using Tiotropium (18 Mcg o.d.) as an Active Control in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic obstructive pulmonary disease (COPD)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16135,
        "nct_id": "NCT01120717",
        "studyTitle": "A Multicener, Randomised, Double-blind, Placebo-controlled Study, to Assess the Long Term Safety of 52 Weeks Treatment With QVA149 (110 ug Indacaterol/50ug Glycopyrrolate) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic obstructive pulmonary disease (COPD)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16137,
        "nct_id": "NCT01682863",
        "studyTitle": "A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic obstructive pulmonary disease (COPD)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16139,
        "nct_id": "NCT00608335",
        "studyTitle": "A Phase 1, Open-Label Study Of The Safety And Pharmacokinetics Of Repeated-Dose Micafungin (FK463) In Children (2-5 Years AND 6-11 Years) And Adolescents (12-16 Years) With Esophageal Candidiasis Or Other Invasive Candidiasis",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Invasive Candidiasis"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2018-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16153,
        "nct_id": "NCT00375752",
        "studyTitle": "Neoadjuvant Therapy for Postmenopausal Women With ER and/or PgR Positive Breast Cancer. A Randomized Open Phase II Trial Evaluating the Efficacy of a 6 Months Preoperative Treatment With Letrozole (2.5 mg/Day) With or Without Zoledronic Acid (4 mg Every 4 Weeks)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Breast Neoplasms"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16154,
        "nct_id": "NCT01870778",
        "studyTitle": "A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Heart Failure"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16155,
        "nct_id": "NCT02064868",
        "studyTitle": "A multicenter, prospective, randomized, open-label study to assess the effect of serelaxin versus Standard of Care in Acute Heart Failure (AHF) patients",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Heart Failure"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16156,
        "nct_id": "NCT00520806",
        "studyTitle": "A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure",
        "overallStatus": "",
        "phase": "Phase 2/3",
        "studyType": "",
        "conditions": [
            "Heart Failure"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16158,
        "nct_id": "NCT01064310",
        "studyTitle": "A randomised double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment na\u00efve locally advanced or metastatic renal cell carcinoma",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Renal cell carcinoma"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16159,
        "nct_id": "NCT00863655",
        "studyTitle": "A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Breast Cancer"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 16160,
        "nct_id": "NCT01064310",
        "studyTitle": "A Randomised Double-blind Cross-over Patient Preference Study of Pazopanib Versus Sunitinib in Treatment na\u00efve Locally Advanced or Metastatic Renal Cell Carcinoma",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Renal cell carcinoma"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19523,
        "nct_id": "NCT01520909",
        "studyTitle": "A Two Part, Double-blind, Randomized, Placebo-controlled and Open-label Study to Investigate the Efficacy, Safety and Tolerability of Eltrombopag, a Thrombopoietin Receptor Agonist, in Pediatric Patients With Previously Treated Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). PETIT2: Eltrombopag in PEdiatric Patients With Thrombocytopenia From ITP",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Idiopathic Thrombocytopenic Purpura"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19531,
        "nct_id": "NCT01750931",
        "studyTitle": "AN OPEN LABEL, BALANCED, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, SINGLE ORAL DOSE, BIOEQUIVALENCE STUDY OF MELOXICAM GSK 15 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND MOBIC\u00ae 15 MG TABLETS OF BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG BINGER STR.173, 5521 INGELHEIM AM RHEIN, GERMANY, IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FED CONDITION.",
        "overallStatus": "",
        "phase": NaN,
        "studyType": "",
        "conditions": [
            "Arthritis",
            "Rheumatoid"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19533,
        "nct_id": "NCT01934192",
        "studyTitle": "NUTRItional Adequacy Therapeutic Enhancement in the critically ill: A randomized double blind, placebo-controlled trial of the motilin receptor agonist GSK962040. The NUTRIATE Study",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Gastroparesis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19536,
        "nct_id": "NCT02982187",
        "studyTitle": "A randomized, open-label, cross-over, placebo-device study investigating critical and over all errors, training/teaching time, and preference attributes of the ELLIPTA dry powder Inhaler (DPI) as compared to HANDIHALER DPI used in combination with either DISKUS DPI or TURBUHALER DPI, in adult patients with Chronic Obstructive Pulmonary Disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19539,
        "nct_id": "NCT02513654",
        "studyTitle": "An open-label study to evaluate the pharmacokinetics, safety and tolerability of repeat dosing lamotrigine in healthy Chinese subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Bipolar Disorder"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19547,
        "nct_id": "NCT00849381",
        "studyTitle": "Safety study of GSK Biologicals\u2019 human papillomavirus vaccine (GSK580299) in female Brazilian, Taiwanese and Thai subjects who had received control vaccine in study 580299/008",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19580,
        "nct_id": "NCT00103727",
        "studyTitle": "A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects with Schizophrenia",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Schizophrenia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19583,
        "nct_id": "NCT01762800",
        "studyTitle": "Evaluating the control of COPD symptoms in patients treated with tiotropium bromide 18mcg once daily alone, ADOAIR 50/250mcg twice daily alone or ADOAIR 50/250mcg plus tiotropium bromide 18mcg",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19585,
        "nct_id": "NCT02411162",
        "studyTitle": "Skin Residency Study of Topically Applied GSK2894512 Cream in Healthy Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Dermatitis",
            "Atopic"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19586,
        "nct_id": "NCT02691325",
        "studyTitle": "A single centre, three part, randomised, study to evaluate the safety, tolerability and pharmacokinetics of GSK2269557 administered via the ELLIPTA\u2122 dry powder inhaler to Healthy Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19588,
        "nct_id": "NCT02660736",
        "studyTitle": "A Randomized, Double-blind, Single-dose, Crossover Study to Compare Two Albiglutide Drug Products for Bioequivalence in Healthy Adult Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19589,
        "nct_id": "NCT02564055",
        "studyTitle": "Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Dermatitis",
            "Atopic"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19591,
        "nct_id": "NCT02801981",
        "studyTitle": "A double-blind, randomized, placebo controlled, dose escalating crossover study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic parameters of single doses of GSK2330672 in Japanese healthy male volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Cholestasis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19592,
        "nct_id": "NCT00871156",
        "studyTitle": "Safety, Tolerability, and Pharmacokinetic Study of Concomitant Chloroquine and Tafenoquine in Healthy Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Malaria"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19593,
        "nct_id": "NCT02202187",
        "studyTitle": "A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of GSK2140944 in Healthy Adult Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Respiratory Tract"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19595,
        "nct_id": "NCT02712047",
        "studyTitle": "A randomised, placebo-controlled, double-blind, two period crossover study to characterise the exhaled nitric oxide time profile as a biomarker of airway inflammation in adult asthma patients following repeat administration of inhaled Fluticasone Furoate (FF)/ Vilanterol (VI) 100/25 mcg.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19598,
        "nct_id": "NCT02925546",
        "studyTitle": "An Open Label, Randomized, Single Dose, Crossover study to determine the Pharmacokinetics of Three Tablet Formulations of GSK2798745 in Healthy Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Heart failure",
            "Congestive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19601,
        "nct_id": "NCT00058526",
        "studyTitle": "A multicenter Phase I open-label dose-escalation vaccine trial of dHER2 protein with AS15 adjuvant in HER2-overexpressing patients with high-risk breast cancer",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Neoplasms",
            "Breast"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19602,
        "nct_id": "NCT00058526",
        "studyTitle": "A multicenter Phase I open-label dose-escalation vaccine trial of dHER2 prot. with AS15 adj. in HER2-overexpressing patients with high-risk breast cancer.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Neoplasms",
            "Breast"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19604,
        "nct_id": "NCT00196937",
        "studyTitle": "A long-term open, age-stratified follow-up of the immunogenicity and safety of an HPV-16/18 VLP vaccine in healthy female subjects vaccinated in study HPV-014",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19605,
        "nct_id": "NCT00196937",
        "studyTitle": "A long-term open, age-stratified follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals'HPV-16/18 L1 AS04 vaccine in healthy female subjects vaccinated in study HPV-014",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19607,
        "nct_id": "NCT01657526",
        "studyTitle": "An observer-blind study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals\u2019 Non-typeable Haemophilus influenzae (NTHi) investigational vaccine (GSK2838497A) in healthy adults",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Respiratory Disorders"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19613,
        "nct_id": "NCT02634073",
        "studyTitle": "An Open-label Single-Center, 4-Period William\u2019s Cross-Over Design Drug Interaction Trial to Determine the Effects of Sorbitol-Containing Solutions on Lamivudine Exposure Following Administration of Lamivudine Oral Solution in Healthy Adult Subjects",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2018-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19614,
        "nct_id": "NCT00876395",
        "studyTitle": "A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination With Trastuzumab and Paclitaxel, as First Line Therapy in Women With HER2 Positive Locally Advanced or Metastatic Breast Cancer",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Breast Cancer"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19615,
        "nct_id": "NCT01007942",
        "studyTitle": "A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "HER2/Neu Over-expressing Locally Advanced Breast Cancer or Metastatic Breast Cancer"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19622,
        "nct_id": "NCT01949090",
        "studyTitle": "An observer-blind study to evaluate the safety and immunogenicity of GSK Biologicals\u2019 influenza vaccine(s) GSK2789869A administered in adults 65 years of age and older",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19623,
        "nct_id": "NCT01905215",
        "studyTitle": "An observer-blind study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals\u2019 Respiratory Syncytial Virus (RSV) investigational vaccine (GSK3003891A) in healthy men",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Respiratory Syncytial Virus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19624,
        "nct_id": "NCT00337818",
        "studyTitle": "Immunogenicity: 3 consecutive lots of GSK Biologicals\u2019 HPV-16/18 vaccine administered intramuscularly at 0,1,6 month schedule in healthy females aged 10\u201325 years and demonstrate non-inferiority of candidate HPV vaccine manufactured by modified production process",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19625,
        "nct_id": "NCT03001440",
        "studyTitle": "Subject Understanding of the Risks Associated with ZYBAN\u00ae, WELLBUTRIN\u00ae, WELLBUTRIN SR\u00ae, and WELLBUTRIN XL\u00ae",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Depressive Disorder",
            "Major"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19653,
        "nct_id": "NCT00946153",
        "studyTitle": "Phase I/II Study of E7080 in Patients With Advanced Hepatocellular Carcinoma (HCC)",
        "overallStatus": "",
        "phase": "Phase 1 / Phase 2",
        "studyType": "",
        "conditions": [
            "Hepatocellular Carcinoma (HCC)"
        ],
        "orgCode": "",
        "orgName": "Eisai",
        "status": "",
        "postedDate": "2018-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19654,
        "nct_id": "NCT01618695",
        "studyTitle": "A Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Partial-onset Seizures"
        ],
        "orgCode": "",
        "orgName": "Eisai",
        "status": "",
        "postedDate": "2018-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19671,
        "nct_id": "NCT01480284",
        "studyTitle": "A multi-center, randomized, active controlled, double-blind, parallel group comparison study and subsequent open-label study of GSK548470 in patients with compensated chronic hepatitis B untreated with nucleic acid analogue",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatitis B",
            "Chronic"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19674,
        "nct_id": "NCT02289482",
        "studyTitle": "A Double-Blind, Randomized, Placebo-Controlled, Continuation Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 with and without Ritonavir, and to Evaluate Different Formulations of GSK2838232, in Healthy Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19675,
        "nct_id": "NCT02289495",
        "studyTitle": "A Double Blind, Placebo Controlled, Single and Repeat Dose Escalation Study of GSK2838232 with and without Ritonavir for 8-11 days in Healthy Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19676,
        "nct_id": "NCT02795754",
        "studyTitle": "A Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled, Continuation Single and Repeated Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 with Ritonavir, in Healthy Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19677,
        "nct_id": "NCT01802918",
        "studyTitle": "A Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 and to Evaluate the Effect of Food and Ritonavir on GSK2838232 in Healthy Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19678,
        "nct_id": "NCT02727283",
        "studyTitle": "A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Ascending Dose Escalating, 4 Period Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effect of Single Doses of GSK3179106, a REarranged during Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Normal Healthy Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Irritable Bowel Syndrome"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19679,
        "nct_id": "NCT02798991",
        "studyTitle": "A Phase I, 14 Day, Randomized, Double-Blind (sponsor unblinded), Placebo-Controlled, Repeat Dose, Ascending Cohort Study to Evaluate the Safety, Tolerability Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic biomarkers of GSK3179106, a REarranged during Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Normal Healthy Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Irritable Bowel Syndrome"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19680,
        "nct_id": "NCT00549497",
        "studyTitle": "A randomized, double-blind, placebo-controlled, dose ascending, 3-cohort parallel group study to measure the systemic cortisol profile and evaluate the safety, tolerability and pharmacokinetics of GW870086X, administered as single doses (12mg and 15mg), and repeat doses over 3 days (6mg, 12mg and 15mg) in healthy male subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19681,
        "nct_id": "NCT02972905",
        "studyTitle": "A single center, double-blind, randomized, placebo-controlled, parallel, single and repeat, dose-ascending study to evaluate the safety, tolerability and pharmacokinetics of GSK2269557 administered via the ELLIPTA\u2122 dry powder inhaler to healthy Japanese subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19682,
        "nct_id": "NCT02564042",
        "studyTitle": "Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Psoriasis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19683,
        "nct_id": "NCT02837380",
        "studyTitle": "An Open Label Study to Evaluate the Pharmacokinetics of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 mcg) after Single and Repeat Dose Administration from a Dry Powder Inhaler in Healthy Chinese Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2018-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19685,
        "nct_id": "NCT00975715",
        "studyTitle": "A Multicentre, Randomized, Double-blind, Placebo Controlled, Parallel-group Study in Children With Inadequately Controlled Partial Onset Seizures to Investigate Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) as Adjunctive Therapy",
        "overallStatus": "",
        "phase": "Phase 2/3",
        "studyType": "",
        "conditions": [
            "Partial Onset Seizures"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19686,
        "nct_id": "NCT01025817",
        "studyTitle": "A 12 Month, Multi-center, Randomized, Open-label Non-inferiority Study Comparing Safety and Efficacy of Concentration-controlled Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in de Novo Renal Transplant Recipients",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Kidney Transplantation"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19687,
        "nct_id": "NCT01114529",
        "studyTitle": "A 24-month, multi-center, open-label, randomized, controlled trial to investigate efficacy, safety and evolution of cardiovascular parameters in de novo renal transplant recipients after early calcineurin inhibitor to everolimus conversion.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Kidney Transplantation"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19688,
        "nct_id": "NCT02294227",
        "studyTitle": "A phase III, randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab (150 mg) in pre-filled syringe, with or without loading regimen, to demonstrate efficacy, safety and tolerability up to 2 years in patients with active psoriatic arthritis (FUTURE 4)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Psoriatic arthritis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19695,
        "nct_id": "NCT01098526",
        "studyTitle": "A Phase 1, Open Label, Single Sequence, Three Period Study to Evaluate the Single Dose Pharmacokinetics of GSK1349572 100mg versus 50mg and the Effect of Efavirenz 600mg Once Daily on the Pharmacokinetics, Safety and Tolerability of GSK1349572 50mg Once Daily in Healthy Adult Subjects (ING114005)",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Human Immunodeficiency Virus and Herpesviridae"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2018-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19696,
        "nct_id": "NCT02741557",
        "studyTitle": "An Open-label, Randomized, Two-way Crossover, Single dose, Pivotal Bioequivalence Study of a Fixed-dose Combination of Dolutegravir and Rilpivirine in Healthy Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2018-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19758,
        "nct_id": "NCT03150082",
        "studyTitle": "An open-label, randomised, single-dose, two-period cross-over study to evaluate bioequivalence of GR37547 ciprofloxacin 500 mg tablet versus ciprofloxacin 500 mg tablet reference product in healthy adult participants under fasting conditions",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Bacterial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19759,
        "nct_id": "NCT00933530",
        "studyTitle": "A Phase I Randomized, Placebo-Controlled, Single-Blind, Multiple-Dose, Dose-Escalation Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19760,
        "nct_id": "NCT00937872",
        "studyTitle": "A Phase I Study to Evaluate the Intravenous Pharmacokinetics and the Absolute Bioavailability of SRT2104 given as a 250mg Oral Suspension in Healthy Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19761,
        "nct_id": "NCT02567773",
        "studyTitle": "A randomized double-blind (sponsor unblind) placebo controlled study in healthy subjects to evaluate: safety, tolerability, pharmacokinetics, and pharmacodynamics of the repeat doses of GSK2881078, the Selective Androgen Receptor Modulator with an open label dosing arm to evaluate the effect of CYP3A4 inhibition on pharmacokinetics of GSK2881078",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Cachexia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19762,
        "nct_id": "NCT02113436",
        "studyTitle": "Clinical assessment of fluticasone propionate/ salmeterol xinafoate HFA MDI in 6-month to 4-year-old Japanese patients with bronchial asthma",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19763,
        "nct_id": "NCT02586493",
        "studyTitle": "An open-label study of the correct use and ease of use of placebo ELLIPTA dry powder inhaler in subjects with chronic obstructive pulmonary disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19764,
        "nct_id": "NCT02586506",
        "studyTitle": "An open-label study of the ease of use and correct use of placebo ELLIPTA dry powder inhaler in subjects with asthma",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19766,
        "nct_id": "NCT01345253",
        "studyTitle": "GSK1550188 A 52 week study of belimumab versus placebo in the treatment of subjects with systemic lupus erythematosus (SLE) located in Northeast Asia",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Systemic Lupus Erythematosus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19767,
        "nct_id": "NCT00724867",
        "studyTitle": "A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B\u2122), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 Protocol HGS1006-C1056 in the United States",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Systemic Lupus Erythematosus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19768,
        "nct_id": "NCT00237991",
        "studyTitle": "A multicentric, post-marketing surveillance to monitor the safety and reactogenicity of GlaxoSmithKline Biologicals Hepatitis A vaccine administered in Korean population.",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis A"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19790,
        "nct_id": "NCT00374322",
        "studyTitle": "A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib (GW572016) in Women With Early-Stage ErbB2 Overexpressing Breast Cancer",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Neoplasms",
            "Breast"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2019-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19797,
        "nct_id": "NCT02625207",
        "studyTitle": "AN OPEN-LABEL, MULTICENTER, MULTIPLE-DOSE PHARMACOKINETIC, SAFETY AND EFFICACY TRIAL OF MARAVIROC IN COMBINATION WITH OPTIMIZED BACKGROUND THERAPY FOR THE TREATMENT OF ANTIRETROVIRAL-EXPERIENCED CCR5-TROPIC HIV-1 INFECTED CHILDREN 2-<18 YEARS OF AGE",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2019-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19801,
        "nct_id": "NCT01954264",
        "studyTitle": "Epidemiology study of malariometric determinants in selected Post-Approval Programme study sites in sub-Saharan Western Africa",
        "overallStatus": "",
        "phase": NaN,
        "studyType": "",
        "conditions": [
            "Malaria"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19804,
        "nct_id": "NCT01767402",
        "studyTitle": "A study to evaluate the safety, reactogenicity and immunogenicity of the pneumococcal protein PhtD vaccine without or with adjuvant, administered at 2 different concentrations according to a 0-2 month schedule, in healthy adults",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Streptococcal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19805,
        "nct_id": "NCT00307528",
        "studyTitle": "A Study to Evaluate the Safety, Reactogenicity & Immunogenicity of the GSK Biologicals Candidate Pneumococcal Vaccine Without or With Adjuvant, Administered at 2 Different Concentrations, in Healthy Elderly Subjects",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Streptococcal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19806,
        "nct_id": "NCT00307528",
        "studyTitle": "A phase I-II, randomized, controlled, single-blind study to evaluate the safety, reactogenicity and immunogenicity of the pneumococcal protein PhtD vaccine without or with adjuvant (AlPO4 or AS02V), administered at 2 differrent concentrations according to a 0-2 month schedule, in healthy elderly subjects",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Streptococcal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19807,
        "nct_id": "NCT00307528",
        "studyTitle": "A phase I-II, randomized, controlled, single-blind study to evaluate the safety, reactogenicity and immunogenicity of the pneumococcal protein PhtD vaccine without or with adjuvant (AlPO4 or AS02V), administered at 2 different concentrations according to a 0-2 month schedule, in healthy elderly subjects",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Streptococcal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19808,
        "nct_id": "NCT00197067",
        "studyTitle": "A bridging study to evaluate the safety and immunogenicity of GSK Biologicals\u2019 candidate vaccines RTS,S/AS02D (0.5 mL dose) and RTS,S/AS02A (0.25 mL dose) administered according to a 0, 1, 2 month vaccination schedule in children aged 3 to 5 years living in a malaria-endemic region of Mozambique.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Malaria"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19809,
        "nct_id": "NCT00197054",
        "studyTitle": "A Phase IIb randomized, double-blind, controlled study of the safety, immunogenicity and proof-of-concept of RTS,S/AS02A, and RTS,S/AS01B, two candidate malaria vaccines in malaria-experienced adults living in Western Kenya.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Malaria"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19810,
        "nct_id": "NCT01342926",
        "studyTitle": "A phase 2, multi-centre, randomised, double-masked, placebo-controlled, parallel-group study to investigate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GSK933776 in adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Atrophy",
            "Geographic"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19812,
        "nct_id": "NCT02497937",
        "studyTitle": "A Randomized, Double-blind, Sponsor un-blinded, Placebo-controlled, Phase 2a Crossover Study to Evaluate the Effect of the TRPV4 Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients with Congestive Heart Failure",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Heart Failure"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19828,
        "nct_id": "NCT02293161",
        "studyTitle": "A Randomised, Double-Blind (Sponsor Unblind), Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Single Ascending Doses of a Fully Humanized Anti-IL-7 Receptor \u03b1 Monoclonal Antibody (GSK2618960) in Healthy Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Autoimmune Diseases"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19829,
        "nct_id": "NCT02751424",
        "studyTitle": "A Phase I, Randomized, Double-Blind (Sponsor Unblinded), Single-Center, Placebo-Controlled, Two-Part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Ascending Single and Repeat Intravenous Doses of GSK3342830 in Healthy Adult Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Bacterial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19831,
        "nct_id": "NCT01406340",
        "studyTitle": "A repeat-dose, open-label, parallel-group study to assess the pharmacokinetics of GSK1278863 and metabolites in normal subjects and subjects with impaired renal function",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Anaemia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19832,
        "nct_id": "NCT01984801",
        "studyTitle": "A Single-Blind Study to Evaluate the Irritation Potential of Repeat Topical Applications of GSK1940029 Gel on the Intact Skin of Healthy Human Subjects and Acne Patients",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Acne Vulgaris"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19833,
        "nct_id": "NCT01938482",
        "studyTitle": "A Randomized, Single-Blind, Dose-Rising Study to Evaluate the Safety, Tolerability and Preliminary Pharmacokinetics of Single and 14 Day Repeat Topical Applications of GSK1940029 Gel on the Intact Skin of Healthy Human Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Acne Vulgaris"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19834,
        "nct_id": "NCT01831804",
        "studyTitle": "Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Topical GSK1278863 in Healthy Volunteers and Diabetic Patients, and Repeat Doses of GSK1278863 in Diabetic Patients for the Treatment of Diabetic Foot Ulcer",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Wound Healing"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19835,
        "nct_id": "NCT02216123",
        "studyTitle": "A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) versus Primaquine in the Treatment of Subjects with Plasmodium vivax Malaria",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Malaria",
            "Vivax"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19837,
        "nct_id": "NCT03089879",
        "studyTitle": "A Phase 1, open label, non-randomized, single center study to evaluate the safety and immunogenicity of 1 booster vaccination with (GVGH Shigella sonnei 1790GAHB) vaccine administered intramuscularly in healthy adults previously primed with three doses of the same vaccine in study H03_01TP compared to 1 vaccination with (1790GAHB) administered intramuscularly either to subjects who received placebo in the H03_01TP study or na\u00efve subjects who were not part of H03_01TP study",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Dysentery",
            "Bacillary"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19845,
        "nct_id": "NCT01190189",
        "studyTitle": "Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the Primary NCT00294047 Study",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Papillomavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19846,
        "nct_id": "NCT02231190",
        "studyTitle": "A Randomized, Placebo-Controlled, Double-Blind (Sponsor Unblinded) Study to Investigate Protective Effects of GSK1278863 on Eccentric Exercise Induced Muscle Damage in Healthy Male Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Tendon Injuries"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19847,
        "nct_id": "NCT01950819",
        "studyTitle": "A 24 Month, Multicenter, Randomized, Open-label Safety and Efficacy Study of Concentration-controlled Everolimus With Reduced Calcineurin Inhibitor vs Mycophenolate With Standard Calcineurin Inhibitor in de Novo Renal Transplantation",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Kidney Transplantation"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2019-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19878,
        "nct_id": "NCT02794480",
        "studyTitle": "204980: An open-label study to evaluate the correct use of placebo ELLIPTA\u2122 dry powder inhaler (DPI) compared to placebo metered dose inhalers (MDI) in subjects with moderate persistent asthma",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19879,
        "nct_id": "NCT00583362",
        "studyTitle": "A Multi-Center, Open-Label, Continuation Trial LymphoStat-B\u2122 Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Systemic Lupus Erythematosus (SLE) who Completed the Phase 2 Protocol LBSL02",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Systemic Lupus Erythematosus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19880,
        "nct_id": "NCT02647281",
        "studyTitle": "A Double-Blind, Placebo-Controlled, Dose-Escalation, First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19884,
        "nct_id": "NCT01218204",
        "studyTitle": "A study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of administering multiple oral doses of GSK1292263 alone and with atorvastatin",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Dyslipidaemias"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19888,
        "nct_id": "NCT00802841",
        "studyTitle": "A Randomized Phase Lll Study of Imatinib Dose Optimization Compared With Nilotinib in Patients With Chronic Myelogenous Leukemia and Suboptimal Response to Standard-dose Imatinib",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic Myelogenous Leukemia"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2019-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19890,
        "nct_id": "NCT02742766",
        "studyTitle": "A Phase I, Randomized, Placebo-Controlled, Double-Blind (sponsor unblind), Three Part Study to Evaluate the Safety, Tolerability, Preliminary PK and PD of Single and Repeat Oral Doses of GSK3008356 in Healthy Subjects and Obese Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Healthy Volunteers"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19893,
        "nct_id": "NCT02469298",
        "studyTitle": "A randomized, double-blind, placebo controlled study to evaluate the safety, tolerability and clinical effect of oral danirixin (GSK1325756) in the treatment of healthy adults with acute, uncomplicated influenza (201682)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Virus Diseases"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19895,
        "nct_id": "NCT02683746",
        "studyTitle": "A Repeat-dose Study in Subjects with Type 2 Diabetes Mellitus to Assess the Efficacy, Safety, Tolerability and Pharmacodynamics, of Albiglutide Liquid Drug Product",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19898,
        "nct_id": "NCT02014519",
        "studyTitle": "Seroprevalence of Bordetella pertussis in adults in Hungary",
        "overallStatus": "",
        "phase": NaN,
        "studyType": "",
        "conditions": [
            "Pertussis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19907,
        "nct_id": "NCT00902174",
        "studyTitle": "A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Pulmonary Arterial Hypertension"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2019-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19908,
        "nct_id": "NCT00332709",
        "studyTitle": "An open phase III trial with Letrozole (Femara\u00ae) alone or in combination with Zoledronic acid (Zometa\u00ae) as extended adjuvant treatment of postmenopausal patients with primary breast cancer",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Breast cancer"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2019-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19909,
        "nct_id": "NCT00003884",
        "studyTitle": "Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zoledronate (4 and 8 mg) Administered Intravenously as an Adjuvant to Anticancer Therapy to Patients With Any Cancer With Bone Metastases Other Than Breast Cancer, Multiple Myeloma or Prostate Cancer",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Solid Tumor cancer with Bone metastases"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2019-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19917,
        "nct_id": "NCT01788228",
        "studyTitle": "Safety and tolerability of GSK 1557484A vaccine in adults at occupational risk for influenza A (H5N1) exposure",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19926,
        "nct_id": "NCT01466361",
        "studyTitle": "Evaluation of the nicotine lozenge in relief of provoked acute craving",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Tobacco Use Disorder"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19927,
        "nct_id": "NCT01506908",
        "studyTitle": "Evaluation of the Nicotine Mini Lozenge in Relief of Provoked Acute Craving",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Tobacco Use Disorder"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19935,
        "nct_id": "NCT01702480",
        "studyTitle": "Effects of Medium-Chain Triglycerides on Cognitive Function in Older Subjects with Age-Related Cognitive Decline",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Alzheimer's Disease"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19936,
        "nct_id": "NCT02829307",
        "studyTitle": "An open label positron emission tomography (PET) imaging study using 89Zirconium labeled GSK3128349 to investigate the biodistribution and clearance of an albumin binding domain antibody (AlbudAb) GSK3128349 following single dose intravenous administration in healthy male subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Drug-Related Side Effects and Adverse Reactions"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19937,
        "nct_id": "NCT03136380",
        "studyTitle": "A Single Centre, Double Blind (Sponsor Open), Placebo Controlled, 3-Period Crossover, Ascending Dose Study in Japanese Healthy Elderly Male Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of Danirixin in the Fed State (Part1) and an open label, 2-way crossover to evaluate food effect on the pharmacokinetics of Danirixin (Part2)",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19938,
        "nct_id": "NCT02658435",
        "studyTitle": "A Phase 1, Multi-center, Single-masked, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Ophthalmologic Safety and Pharmacodynamics of 300mg Single Doses of Tafenoquine (SB 252263) in Adult Healthy Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Malaria",
            "Vivax"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19940,
        "nct_id": "NCT02178592",
        "studyTitle": "ING117175: a Phase IIIb, randomized, open-label study of the safety and efficacy of dolutegravir or efavirenz each administered with two NRTIs in HIV-1-infected antiretroviral therapy-na\u00efve adults starting treatment for rifampicin-sensitive tuberculosis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2019-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19941,
        "nct_id": "NCT01231542",
        "studyTitle": "Phase 1, open label, two arm, fixed sequence study to evaluate the effect of rifampin and rifabutin on GSK1349572 pharmacokinetics in healthy male and female volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2019-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19975,
        "nct_id": "NCT00165659",
        "studyTitle": "A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Alzheimer's Disease"
        ],
        "orgCode": "",
        "orgName": "Eisai",
        "status": "",
        "postedDate": "2019-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19976,
        "nct_id": "NCT00096473",
        "studyTitle": "A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients With Severe Alzheimer's Disease Followed by a 12 Week Open-Label Extension Period",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Alzheimer's Disease"
        ],
        "orgCode": "",
        "orgName": "Eisai",
        "status": "",
        "postedDate": "2019-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19980,
        "nct_id": "NCT01404169",
        "studyTitle": "A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Alzheimer's Disease"
        ],
        "orgCode": "",
        "orgName": "Eisai",
        "status": "",
        "postedDate": "2019-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19986,
        "nct_id": "NCT02059291",
        "studyTitle": "A Randomized, Double-blind, Placebo Controlled Study of Canakinumab in Patients With Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), With Subsequent Randomized Withdrawal/Dosing Frequency Reduction and Open-label Long-term Treatment Epochs",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hereditary Periodic Fevers"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2019-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 19987,
        "nct_id": "NCT01697696",
        "studyTitle": "A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic Obstructive Pulmonary Disease (COPD)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2019-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20036,
        "nct_id": "NCT01520922",
        "studyTitle": "A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients with Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Chronic Lymphocytic Leukemia (CLL)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2019-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20037,
        "nct_id": "NCT00378014",
        "studyTitle": "Presentation of Renal Function in Liver Transplant Recipients With Certican Therapy: PROTECT Study A Twelve-month, Multicenter, Randomized, Open-label Study of Safety, Tolerability and Efficacy of Certican-based Regimen Versus Calcineurin Inhibitor-based Regimen in de Novo Liver Transplant Recipients",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Liver Transplantation"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2019-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20045,
        "nct_id": "NCT02207816",
        "studyTitle": "Extension to study MALARIA-055 PRI (NCT00866619) for evaluation of long-term efficacy, safety and immunogenicity of GSK Biologicals\u2019 candidate malaria vaccine (SB257049) in infants and children in Africa",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Malaria"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20061,
        "nct_id": "NCT00903617",
        "studyTitle": "A two part, multicenter Phase IIa, placebo controlled study, to examine the safety, tolerability, and effects of GSK256073 on lipids in subjects with dyslipidemia",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Dyslipidaemias"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20062,
        "nct_id": "NCT02829320",
        "studyTitle": "A 24-week, Phase III, open-label, non-comparative, multi-center study to evaluate efficacy and safety of GSK1278863 in Japanese hemodialysis subjects with anemia associated with chronic kidney disease who are not taking erythropoiesis stimulating agents",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Anaemia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20064,
        "nct_id": "NCT00992992",
        "studyTitle": "Phase II Study Of Iodine-131 Anti-B1 Antibody Plus CHOP For Patients With Previously Untreated Mantle Cell Lymphoma",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Lymphoma",
            "Mantle-Cell"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20099,
        "nct_id": "NCT00817063",
        "studyTitle": "Efficacy and safety of alitretinoin in the treatment of severe chronic hand eczema refractory to topical therapy",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Eczema"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20100,
        "nct_id": "NCT03055195",
        "studyTitle": "Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects with Moderate to Severe Atopic Dermatitis",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Dermatitis",
            "Atopic"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20102,
        "nct_id": "NCT02191397",
        "studyTitle": "A Multi-centre, Randomised, Double-blind, Parallel Active-controlled Study Evaluating the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release (bupropion XL 300mg once daily), Escitalopram oxalate (escitalopram, 10mg-20mg once daily) in Subjects with Major Depressive Disorder",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Depressive Disorder",
            "Major"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20104,
        "nct_id": "NCT01755598",
        "studyTitle": "Efficacy of GSK Biologicals\u2019 candidate tuberculosis (TB) vaccine GSK 692342 against TB disease, in adults living in a TB endemic region",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Tuberculosis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20171,
        "nct_id": "NCT00782067",
        "studyTitle": "A Single Arm, Phase II, Open-Label Study to Determine the Efficacy of 100mg Twice Daily Oral Dosing of Midostaurin Administered to Patients with Aggressive Systemic Mastocytosis or Mast Cell Leukemia with or without an Associated Hematological Clonal Non-Mast Cell Lineage Disease",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Mastocytosis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2019-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20173,
        "nct_id": "NCT03408392",
        "studyTitle": "An open-label, randomised, single-dose, two-period cross-over study to evaluate bioequivalence of SKF101804 Cefixime 200 mg/5 mL suspension versus Cefixime 200 mg/5 mL suspension reference product in healthy adult participants under fasting conditions",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Bacterial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2019-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20187,
        "nct_id": "NCT01685138",
        "studyTitle": "A phase II, multicenter, single-arm study of oral LDK378 in crizotinib naive adult patients with ALK-activated non-small cell lung cancer",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Non-small cell lung carcinoma (NSCLC)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2019-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20188,
        "nct_id": "NCT00045942",
        "studyTitle": "An open-label, phase II (Proof of Concept) trial of PKC412 monotherapy in patients with acute myeloid leukemia (AML) and patients with high risk myelodysplastic syndrome (MDS).",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Myelodysplastic syndrome (MDS)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2019-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20264,
        "nct_id": "NCT02074982",
        "studyTitle": "A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekinumab and to assess long-term safety, tolerability and efficacy in subjects with moderate to severe plaque psoriasis (CLEAR)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Psoriasis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20265,
        "nct_id": "NCT02826603",
        "studyTitle": "A 52-week, randomized, double-blind study of secukinumab (300 mg) compared to ustekinumab in subjects with moderate to severe plaque psoriasis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Psoriasis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20266,
        "nct_id": "NCT01806597",
        "studyTitle": "A randomized, double-blind, placebo-controlled, multicenter study to demonstrate the efficacy at 16 weeks of secukinumab 150 and 300 mg s.c. and to assess safety, tolerability and long-term efficacy up to 132 weeks in subjects with moderate to severe palmoplantar psoriasis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Psoriasis",
            "Palmoplantar"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20267,
        "nct_id": "NCT01807520",
        "studyTitle": "A randomized, double-blind, placebo-controlled, multicenter, study to demonstrate the efficacy at 16 weeks of secukinumab 150 and 300 mg s.c. and to assess safety, tolerability and long-term efficacy up to 132 weeks in subjects with moderate to severe nail psoriasis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Psoriasis",
            "nail"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20269,
        "nct_id": "NCT00378690",
        "studyTitle": "A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in patients with relapsing or locally advanced prostate cancer who are responsive to such therapy",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Prostate Cancer"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2020-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20272,
        "nct_id": "NCT02216214",
        "studyTitle": "A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center, Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects with Overactive Bladder (OAB)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Urinary Bladder",
            "Overactive"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2020-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20273,
        "nct_id": "NCT02478632",
        "studyTitle": "An evaluation of bone mineral density in HIV-1-infected adult subjects switching from a tenofovir-containing antiretroviral therapy regimen to a dolutegravir plus rilpivirine regimen",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2020-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20280,
        "nct_id": "NCT01777139",
        "studyTitle": "A Multicentre, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults with Partial Onset Seizures (Extension of Study RTG114855)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Epilepsy"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20281,
        "nct_id": "NCT03045861",
        "studyTitle": "A Phase 2a, Multicenter, Randomized, Adaptive, Open-label, Dose ranging study to evaluate the antiviral effect, safety, tolerability and pharmacokinetics of Cobicistat-boosted GSK2838232 monotherapy over 10 days in HIV-1 infected treatment-naive adults",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20287,
        "nct_id": "NCT02014558",
        "studyTitle": "Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Acute myeloid leukemia"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2020-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20291,
        "nct_id": "NCT02302079",
        "studyTitle": "A Phase 2, Double-Masked, Randomized, Active Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Diabetic macular edema"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2020-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20295,
        "nct_id": "NCT02296424",
        "studyTitle": "\u03b2-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab An Open-label Canakinumab (ACZ885) Dose Reduction or Dose Interval Prolongation Efficacy and Safety Study in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Systemic Juvenile Idiopathic Arthritis (SJIA)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20296,
        "nct_id": "NCT00879658",
        "studyTitle": "A Phase II, Double-blind, Randomized, Multi-center, Adaptive Dose-ranging, Placebo-controlled, Parallel-group Study Evaluating Safety, Tolerability and Efficacy on MRI Lesion Parameters and Determining the Dose Response Curve of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Relapsing-remitting Multiple Sclerosis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20304,
        "nct_id": "NCT02880852",
        "studyTitle": "A single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK1550188 in Chinese subjects with Systemic Lupus Erythematosus (SLE)",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Systemic Lupus Erythematosus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20305,
        "nct_id": "NCT03258762",
        "studyTitle": "A single centre, open-label, parallel-group, single oral dose study to evaluate the pharmacokinetics, safety and tolerability of Pyrimethamine in healthy Japanese and Caucasian male subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Toxoplasmosis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20306,
        "nct_id": "NCT03329573",
        "studyTitle": "Randomized, open label, 2-way crossover, single dose bioequivalence study of Paroxetine IR tablets manufactured in GSKT and Mississauga sites in healthy Chinese participants under fasting and fed conditions",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Anxiety Disorders"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20307,
        "nct_id": "NCT01597622",
        "studyTitle": "BEL114333, a Multicenter, Continuation Study of Belimumab in subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase III study BEL113750 in Northeast Asia or completed the open-label extension of HGS1006-C1115 in Japan",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Systemic Lupus Erythematosus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20308,
        "nct_id": "NCT01650194",
        "studyTitle": "A Phase 2 Study Determining Safety and Tolerability of Enzalutamide (formerly MDV3100) in Combination with Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Prostate cancer"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2020-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20311,
        "nct_id": "NCT02113813",
        "studyTitle": "An open-label, phase 1 dose escalation study of oral ASP8273 in subjects with non-small-cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) mutations",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Non-small cell lung cancer"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2020-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20313,
        "nct_id": "NCT02425722",
        "studyTitle": "Phase II Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study in Patients With Chronic Constipation (Not Including Constipation Due to Organic Diseases)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Chronic constipation"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2020-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20314,
        "nct_id": "NCT02809105",
        "studyTitle": "Phase 3 Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study and an Open-label, Uncontrolled, Long-term Dosing Study in Patients with Chronic Constipation (Not Including Constipation Due to Organic Diseases) -",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic constipation"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2020-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20316,
        "nct_id": "NCT00240942",
        "studyTitle": "Letrozole in the Treatment of Severe and Recurrent Endometriosis",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Endometriosis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20317,
        "nct_id": "NCT01185821",
        "studyTitle": "An Extension Study to the CBAF312A2201 study to evaluate long-term safety, tolerability and efficacy of BAF312 given orally once daily in patients with relapsing- remitting multiple sclerosis",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Relapsing Remitting Multiple Sclerosis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20318,
        "nct_id": "NCT02014636",
        "studyTitle": "A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK 3475 in Patients With Advanced Renal Cell Carcinoma",
        "overallStatus": "",
        "phase": "Phase 1/2",
        "studyType": "",
        "conditions": [
            "Renal cell carcinoma"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20319,
        "nct_id": "NCT00719264",
        "studyTitle": "A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-line Treatment of Patients With Metastatic Clear Cell Carcinoma of the Kidney",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Renal cell carcinoma"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20324,
        "nct_id": "NCT02794792",
        "studyTitle": "A Phase 3, Double-blind, Randomized Study to Assess the Efficacy and Safety of Ipragliflozin in Combination with Metformin Compared to Metformin Plus Placebo in Subjects in Russia with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2020-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20326,
        "nct_id": "NCT01096862",
        "studyTitle": "A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects with Moderate to Severe Plaque Psoriasis",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Psoriasis"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2020-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20329,
        "nct_id": "NCT02483975",
        "studyTitle": "A randomized, double-blind, placebo-controlled, parallel group study of once-daily inhaled Fluticasone Furoate Inhalation Powder for six weeks on the hypothalamic-pituitary-adrenocortical axis of children aged 5-11 years with asthma",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20330,
        "nct_id": "NCT03398421",
        "studyTitle": "A single centre, open label, one sequence, cross-over study to evaluate the effect of itraconazole on the pharmacokinetics of single inhaled doses of nemiralisib in healthy subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20331,
        "nct_id": "NCT03368053",
        "studyTitle": "Long-term immunogenicity of the HIV gp120-NefTat/AS01B vaccine (GSK SB732461)",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20343,
        "nct_id": "NCT03261167",
        "studyTitle": "A phase III study (a placebo controlled, randomized, double-blind comparative study and an open-label, uncontrolled study) to evaluate the efficacy and safety of GSK1358820 in patients with post-stroke upper limb spasticity",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Spasticity",
            "Post-Stroke"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20344,
        "nct_id": "NCT03555890",
        "studyTitle": "A single centre, single dose, open-label, randomized, 2-part, 2-way crossover study to determine the bioequivalence of levocetirizine oral disintegrating tablet given with water and without water compared to levocetirizine immediate release tablet in healthy Japanese male subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Rhinitis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20346,
        "nct_id": "NCT01772160",
        "studyTitle": "Population based surveillance to estimate the burden of herpes zoster and post-herpetic neuralgia in Italy",
        "overallStatus": "",
        "phase": NaN,
        "studyType": "",
        "conditions": [
            "Herpes Zoster"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20347,
        "nct_id": "NCT01873365",
        "studyTitle": "Physician-practice based cohort study to estimate the burden of herpes zoster and postherpetic neuralgia in Japan",
        "overallStatus": "",
        "phase": NaN,
        "studyType": "",
        "conditions": [
            "Herpes Zoster"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20349,
        "nct_id": "NCT02485301",
        "studyTitle": "Safety and immunogenicity study of GSK Biologicals\u2019 investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (GSK3390107A) in adults in Africa",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Virus Diseases"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20355,
        "nct_id": "NCT02892344",
        "studyTitle": "A Multi-center, Randomized, 12-week Treatment, Doubleblind Study to Assess the Efficacy and Safety of QMF149 (150/80 Microgram) Compared With MF Twisthaler\u00ae (200 Microgram) in Adult and Adolescent Patients With Asthma",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20356,
        "nct_id": "NCT02554786",
        "studyTitle": "A multi-center, randomized, 52 week treatment, double-blind, triple-dummy, parallel-group study to assess the efficacy and safety of QMF149 compared with mometasone furoate in patients with asthma.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20357,
        "nct_id": "NCT01845025",
        "studyTitle": "A 26 week, randomized, active-controlled safety study of double-blind formoterol fumarate in free combination with an inhaled corticosteroid versus an inhaled corticosteroid in adolescent and adult patients with persistent asthma.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20359,
        "nct_id": "NCT02656173",
        "studyTitle": "A Phase 4, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Mirabegron in Japanese and Korean Male Patients with Overactive Bladder under Treatment with the \u03b1-Blocker Tamsulosin for Benign Prostatic Hyperplasia",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Urinary Bladder",
            "Overactive"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2020-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20361,
        "nct_id": "NCT02354950",
        "studyTitle": "A Phase I Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 in Subjects with Hepatic Impairment and Healthy Matched Control Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2020-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20362,
        "nct_id": "NCT02354937",
        "studyTitle": "A Phase I, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 in Subjects with Severe Renal Impairment and Healthy Matched Control Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2020-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20365,
        "nct_id": "NCT03296072",
        "studyTitle": "A randomized, examiner blind, crossover, in situ erosion study to investigate the efficacy of an experimental dentifrice in remineralization of previously softened enamel compared to a placebo dentifrice",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Tooth Erosion"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20367,
        "nct_id": "NCT02184611",
        "studyTitle": "A 24 Week Randomised, Double blind and Placebo controlled Study to Evaluate the Efficacy and Safety of 62.5 mcg Umeclidinium Inhalation Powder Delivered Once daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20368,
        "nct_id": "NCT03568942",
        "studyTitle": "A Phase IIa Single-Center, Open-Label Study Evaluating the Pharmacokinetics of Repeat Oral Doses of Gepotidacin (GSK2140944) in Adult Female Participants With Uncomplicated Urinary Tract Infection (Acute Cystitis)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Bacterial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20369,
        "nct_id": "NCT03493386",
        "studyTitle": "A single centre, single dose, open-label, randomised, 2-way crossover study in healthy Japanese male subjects to evaluate the bioequivalence of daprodustat tablets (2 mg tablet vs. 4 mg tablet) (Part 1) and the food effect on the pharmacokinetics of daprodustat (Part 2)",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Anaemia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20372,
        "nct_id": "NCT03227445",
        "studyTitle": "A randomized, open-label, cross-over, placebo inhaler study to evaluate the correct use of ELLIPTA\u2122 dry powder inhaler (DPI) compared to DISKUS\u2122 DPI used in combination with HandiHaler DPI in participants with Chronic Obstructive Pulmonary Disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20374,
        "nct_id": "NCT02776033",
        "studyTitle": "A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled, repeat dose study to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with active plaque-type psoriasis",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Psoriasis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20375,
        "nct_id": "NCT00310375",
        "studyTitle": "A multicenter, open-label, long-term, safety, tolerability and efficacy study of retigabine in adult epilepsy patients with partial-onset seizures (Extension of study VRX-RET-E22-301)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Epilepsy"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20377,
        "nct_id": "NCT01745094",
        "studyTitle": "Safety and Efficacy of Mirabegron as Add-on Therapy in Patients with Overactive Bladder Treated with Solifenacin: A Postmarketing Open-label Study in Japan",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Urinary Bladder",
            "Overactive"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2020-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20378,
        "nct_id": "NCT02294396",
        "studyTitle": "Postmarketing Study of Mirabegron in Japan: Long-term Add-on Therapy with Antimuscarinics in Patients with Overactive Bladder Treated with Mirabegron",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Urinary Bladder",
            "Overactive"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2020-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20380,
        "nct_id": "NCT03094195",
        "studyTitle": "A double-blind, placebo-controlled, randomized dose ranging trial to determine the safety and efficacy of three dose levels of EMA401 in reducing 24-hour average pain intensity score in patients with post-herpetic neuralgia",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Postherpetic neuralgia (PHN)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20381,
        "nct_id": "NCT03297294",
        "studyTitle": "A double-blind, placebo-controlled, randomized trial to determine the safety and efficacy of EMA401 in reducing 24-hour average pain intensity score in patients with painful diabetic neuropathy (EMPADINE)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Diabetic Neuropathic Pain"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20383,
        "nct_id": "NCT02573870",
        "studyTitle": "201546, A repeat-dose study of batefenterol/FF (GSK961081/GW685698) compared with placebo in the treatment of COPD",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20384,
        "nct_id": "NCT02339155",
        "studyTitle": "A Randomized, Open-label Study to Evaluate the Immunogenicity of Anthrax Vaccine Adsorbed Alone or Concomitantly with Raxibacumab (GSK3068483)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Infections",
            "Bacterial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20385,
        "nct_id": "NCT02729038",
        "studyTitle": "A Phase I, Open-Label, Single-Dose, Multi-Part Study to Assess the Pharmacokinetics of Gepotidacin (GSK2140944) in Male and Female Adult Subjects with Varying Degrees of Renal Impairment and in Matched Control Subjects with Normal Renal Function",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Bacterial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20388,
        "nct_id": "NCT03170232",
        "studyTitle": "A randomized, double-blind, Sponsor open, placebo-controlled, 52 week study evaluating the effect of danirixin (GSK1325756) on lung function and health related quality of life in participants with mild to moderate Chronic Obstructive Pulmonary Disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20565,
        "nct_id": "NCT02847091",
        "studyTitle": "Post-marketing Clinical Study of Ipragliflozin; Multicenter, Open-label Study to Assess the Efficacy of Ipragliflozin Add-on in Reducing Insulin Dose in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2020-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20566,
        "nct_id": "NCT02291874",
        "studyTitle": "Postmarketing Clinical Study of Ipragliflozin - Long-term Study in Combination With GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2020-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20567,
        "nct_id": "NCT02897219",
        "studyTitle": "Phase III Study of ASP1941 Double-blind, Parallel-group Study in Combination With Insulin in Patients With Type 1 Diabetes Mellitus",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 1"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2020-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20568,
        "nct_id": "NCT01649999",
        "studyTitle": "Phase 2b Study of ASP015K \u2013 A Double-Blind, Placebo-Controlled, Dose-Finding Study in Moderate to Severe Rheumatoid Arthritis Patients \u2013",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Rheumatoid Arthritis"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2020-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20569,
        "nct_id": "NCT02308163",
        "studyTitle": "Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to DMARDs -",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Rheumatoid Arthritis"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2020-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20570,
        "nct_id": "NCT02305849",
        "studyTitle": "Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to MTX -",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Rheumatoid Arthritis"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2020-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20572,
        "nct_id": "NCT02884635",
        "studyTitle": "A randomized, placebo-controlled, double-blind, parallel group phase 2a study of ASP1707 in postmenopausal female patients with rheumatoid arthritis (RA) taking methotrexate (MTX)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Rheumatoid Arthritis"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2020-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20573,
        "nct_id": "NCT01584648",
        "studyTitle": "A Phase III, Randomized, Double-blinded Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to Dabrafenib and Placebo as First-line Therapy in Subjects With Unresectable (Stage IIIC) or Metastatic (Stage IV) BRAF V600E/K Mutation-positive Cutaneous Melanoma",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Melanoma"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20574,
        "nct_id": "NCT01597908",
        "studyTitle": "A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects With Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Melanoma"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20575,
        "nct_id": "NCT02291029",
        "studyTitle": "A multi-center, randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CFZ533 in patients with primary Sjoegren's syndrome",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Sjoegren's syndrome"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20589,
        "nct_id": "NCT03234036",
        "studyTitle": "A Two Part Study to Assess i) the Relative Bioavailability and Food Effect of a Novel Tablet Formulation of Boosted-GSK2838232 Compared to Capsule and ii) the Safety and Pharmacokinetics of Repeated Once-Daily Doses of Non-boosted GSK2838232",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20591,
        "nct_id": "NCT03114969",
        "studyTitle": "An open-label, low interventional clinical study investigating error rates (critical and overall) prior to any retraining in correct use of the ELLIPTA dry powder inhaler (DPI) compared to other DPIs including; DISKUS, Turbuhaler, HandiHaler and Breezhaler as a monotherapy or in combination, in adult patients with Chronic Obstructive Pulmonary Disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20596,
        "nct_id": "NCT02979639",
        "studyTitle": "Study to evaluate the impact of reactogenicity on Quality of Life (QoL), after administration of GSK Biologicals\u2019 candidate Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A) in adults \u2265 50 years of age",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Herpes Zoster"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20601,
        "nct_id": "NCT00940602",
        "studyTitle": "A multi-center, randomized, double-blind, placebo-controlled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Myelodysplastic syndrome (MDS)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20602,
        "nct_id": "NCT03176238",
        "studyTitle": "A phase IIIb, multi-center, open-label study of RAD001 in combination with EXemestane in post-menopausal women with EStrogen receptor positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Breast cancer"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20603,
        "nct_id": "NCT00263588",
        "studyTitle": "A Phase II Study of Lapatinib for Brain Metastases in Subjects with ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Breast cancer"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20604,
        "nct_id": "NCT00171340",
        "studyTitle": "A Phase IIIB open-label, randomized, multicenter study to evaluate the use of zoledronic acid in the prevention of cancer treatment-related bone loss in post-menopausal women with ER+ and/or PgR+ breast cancer receiving letrozole as adjuvant therapy.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Breast cancer"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20605,
        "nct_id": "NCT00171314",
        "studyTitle": "An open-label, randomized, multicenter study to evaluate the use of zoledronic acid in the prevention of cancer treatment related bone loss in post-menopausal women with ER+ and/or PgR+ breast cancer receiving Letrozole as adjuvant therapy",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Breast cancer"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20606,
        "nct_id": "NCT00934544",
        "studyTitle": "A randomized study of the JAK inhibitor INC424 tablets compared to best available therapy in subjects with primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Myelofibrosis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20607,
        "nct_id": "NCT01254188",
        "studyTitle": "Extending molecular responses with Nilotinib in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic myeloid leukemia (CML)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20608,
        "nct_id": "NCT01275196",
        "studyTitle": "ENESTChina: A phase III multi-center, open-label, randomized study of nilotinib versus imatinib in Chinese adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic myeloid leukemia (CML)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20609,
        "nct_id": "NCT00471497",
        "studyTitle": "A phase III multi-center, open-label, randomized study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph positive) chronic myelogenous leukemia in chronic phase (CML-CP).",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic myeloid leukemia (CML)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20610,
        "nct_id": "NCT00109707",
        "studyTitle": "phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec\u00ae (imatinib)-resistant/intolerant CML in chronic or accelerated phase or blast crisis, relapsed/refractory Ph+ ALL, and other hematologic malignancies.",
        "overallStatus": "",
        "phase": "Phase 1/2",
        "studyType": "",
        "conditions": [
            "Chronic myeloid leukemia (CML)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20611,
        "nct_id": "NCT00006053",
        "studyTitle": "An expanded access protocol of imatinib mesylate in patients with chronic myeloid leukemia who are hematologically or cytogenetically resistant or refractory to, or intolerant of interferon-alpha",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Chronic myeloid leukemia (CML)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20620,
        "nct_id": "NCT01923168",
        "studyTitle": "A phase II randomized, double-blind placebo controlled, study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive HER2-negative breast cancer",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Breast cancer"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20621,
        "nct_id": "NCT03215758",
        "studyTitle": "A 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to standard-of-care asthma therapy in patients with uncontrolled asthma",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Uncontrolled asthma"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20622,
        "nct_id": "NCT01377012",
        "studyTitle": "A randomized, double-blind, placebo-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 2 years in patients with active rheumatoid arthritis who have an inadequate response to anti-TNF\u00bf agents (CAIN457F2302) and a three year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active rheumatoid arthritis (CAIN457F2302E1)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Rheumatoid arthritis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20719,
        "nct_id": "NCT03162614",
        "studyTitle": "Efficacy, immunogenicity and safety study of GSK Biologicals\u2019 candidate malaria vaccine (SB257049) evaluating various dose schedules in a sporozoite challenge model in healthy malaria-na\u00efve adults",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Malaria"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20724,
        "nct_id": "NCT02706535",
        "studyTitle": "A single center, two part, randomized, open label cross-over study to evaluate the effect of itraconazole and rifampicin on the pharmacokinetics of GSK525762 in healthy female subjects of non child bearing potential",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Neoplasms"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20728,
        "nct_id": "NCT02192697",
        "studyTitle": "An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Non-small cell lung cancer"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2020-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20729,
        "nct_id": "NCT02038673",
        "studyTitle": "An Open-label Phase 1 Study of Oral ASP5878 at Single and Multiple Doses in Patients with Solid Tumors",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Solid tumors"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2020-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20730,
        "nct_id": "NCT02452632",
        "studyTitle": "A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-group, Placebo-Controlled Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2020-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20731,
        "nct_id": "NCT01325571",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Control, Multicenter Clinical Trial evaluating the Efficacy and Safety of Tacrolimus Capsules in the Treatment of Myasthenia Gravis Patients with Inadequate Response to Glucocorticoid Therapy",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Myasthenia gravis"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2020-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20737,
        "nct_id": "NCT02969655",
        "studyTitle": "A 52-week, Phase III, double-blind, active-controlled, parallel-group, multi-center study to evaluate efficacy and safety of daprodustat compared to darbepoetin alfa in Japanese hemodialysis-dependent subjects with anemia associated with chronic kidney disease who are currently ESA users",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Anaemia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20738,
        "nct_id": "NCT02820844",
        "studyTitle": "A phase III study to evaluate the efficacy and safety of GSK1358820 (botulinum toxin type A) in patients with overactive bladder",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Urinary Bladder",
            "Overactive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20739,
        "nct_id": "NCT03310268",
        "studyTitle": "A Randomized, 8 Week Clinical Study to Evaluate the Efficacy of an Experimental Stannous Fluoride Dentifrice in the Relief of Dentinal Hypersensitivity",
        "overallStatus": "",
        "phase": NaN,
        "studyType": "",
        "conditions": [
            "Dentin Sensitivity"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20740,
        "nct_id": "NCT03640832",
        "studyTitle": "A Clinical Study to Assess the Local Cutaneous and Ocular Tolerance of a Developmental Cosmetic Facial Serum Formulation in Healthy Females with Sensitive Skin",
        "overallStatus": "",
        "phase": NaN,
        "studyType": "",
        "conditions": [
            "Skin Care"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20741,
        "nct_id": "NCT02807857",
        "studyTitle": "A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Heart Failure"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20742,
        "nct_id": "NCT02757963",
        "studyTitle": "Implementation of a screening tool for subjects with benign prostatic enlargement/obstruction to identify men >=50 years presenting in General Practice with other co-morbidities who should be assessed for BPH",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Prostatic Hyperplasia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20743,
        "nct_id": "NCT02424539",
        "studyTitle": "A Randomized, Doubled-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of Fluticasone Furoate Nasal Spray 55 mcg and 110 mcg for 4 Weeks in Chinese Pediatric Subjects Ages 2 to 12 Years with Allergic Rhinitis",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Rhinitis",
            "Allergic",
            "Perennial and Seasonal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20744,
        "nct_id": "NCT02504671",
        "studyTitle": "A Phase IIb, Double-Blind, Placebo-Controlled, Dose-Adaptive, Study of the Efficacy and Safety of GSK3196165 in Combination with Methotrexate Therapy, in Subjects with Active Moderate-Severe Rheumatoid Arthritis Despite Treatment with Methotrexate",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Arthritis",
            "Rheumatoid"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20745,
        "nct_id": "NCT02799472",
        "studyTitle": "A Phase IIa, Double-Blind, Mechanistic Study of GSK3196165 in Combination with Methotrexate Therapy in Subjects with Active Rheumatoid Arthritis Despite Treatment with DMARDs",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Arthritis",
            "Rheumatoid"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20746,
        "nct_id": "NCT02683785",
        "studyTitle": "A multi-centre Phase IIa double-blind, placebo-controlled study to investigate the efficacy and safety of GSK3196165 in subjects with inflammatory hand osteoarthritis",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Osteoarthritis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20750,
        "nct_id": "NCT03207750",
        "studyTitle": "Immunogenicity, reactogenicity and safety study of Pediarix\u00ae, Hiberix\u00ae and Prevenar 13\u00ae co-administered with two different formulations of GSK Biologicals\u2019 HRV vaccine (444563) in healthy infants 6-12 weeks of age",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Rotavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20751,
        "nct_id": "NCT02046148",
        "studyTitle": "A Phase II, Multicenter, Randomized, Observer-Blind, Controlled Study to Evaluate Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Streptococcus agalactiae"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2020-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20752,
        "nct_id": "NCT01555151",
        "studyTitle": "A randomized, double-blind, double-dummy, 4-week treatment, parallel-group study to evaluate the efficacy and safety of two doses of mometasone furoate delivered via Concept1 or Twisthaler\u00ae in adult and adolescent patients with persistent asthma",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20755,
        "nct_id": "NCT03257852",
        "studyTitle": "Phase 2a Study of ASP5094 - A Phase 2a, Randomized, Placebo-controlled, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate -",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Rheumatoid Arthritis"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2021-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20756,
        "nct_id": "NCT02161237",
        "studyTitle": "A multi-center, randomized, open-label, pilot and exploratory study investigating safety and efficacy in OPTIMIZEd dosing of Advagraf\u00ae kidney transplantation in Asia.",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Prevention of rejection after organ transplant"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2021-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20757,
        "nct_id": "NCT02180789",
        "studyTitle": "An open-label, prospective interventional study of the tolerability and efficacy of oral Harnalidge\u00ae OCAS\u00ae (Tamsulosin) 0.4 mg in patients who are unsatisfied with the treatment of Tamsulosin 0.2 mg",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Lower Urinary Tract Symptoms / Benign Prostatic Hyperplasia"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2021-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20758,
        "nct_id": "NCT03306277",
        "studyTitle": "Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "SMA - Spinal Muscular Atrophy"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20760,
        "nct_id": "NCT01007149",
        "studyTitle": "A 16-week Treatment, Multicenter, Randomized, Double Blind, Placebo-controlled, Parallel-group Study to Assess the Effect of Omalizumab on the Expression of Fc\u03b5RI Receptors of Blood Basophils and Dendritic Cells in Patients With Severe Persistent Non-atopic Asthma, Uncontrolled Despite Optimal Therapy",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20761,
        "nct_id": "NCT01202903",
        "studyTitle": "A 24-week, Phase III randomized, double-blind, placebo-controlled, parallelgroup, multicenter study of Xolair\u00ae (omalizumab) in patients with moderate to severe persistent allergic asthma who remain not adequately controlled despite GINA (2009) Step 4 therapy",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Persistent Asthma"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20765,
        "nct_id": "NCT03478657",
        "studyTitle": "An open-label study to evaluate correct use and ease of use of the ELLIPTA Dry Powder Inhaler (DPI) in pediatric patients currently receiving inhaled therapy for treatment of their asthma",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20771,
        "nct_id": "NCT02712359",
        "studyTitle": "Long term hepatitis A virus (HAV) antibody persistence in children vaccinated with 1 dose and those vaccinated with 2 doses of Havrix in Panama",
        "overallStatus": "",
        "phase": NaN,
        "studyType": "",
        "conditions": [
            "Hepatitis A"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20776,
        "nct_id": "NCT00633100",
        "studyTitle": "Phase II Clinical Study of E7389 for Locally Advanced or Metastatic Breast Cancer",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Breast Cancer"
        ],
        "orgCode": "",
        "orgName": "Eisai",
        "status": "",
        "postedDate": "2021-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20777,
        "nct_id": "NCT00965523",
        "studyTitle": "Phase II Extension Study of E7389 for Locally Advanced or Metastatic Breast Cancer",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Breast Cancer"
        ],
        "orgCode": "",
        "orgName": "Eisai",
        "status": "",
        "postedDate": "2021-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20780,
        "nct_id": "NCT02225470",
        "studyTitle": "An Open-label Randomized Parallel Two-arm Multicenter Study of Eribulin Versus Vinorelbine in Female Subjects With Locally Recurrent or Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Breast Cancer"
        ],
        "orgCode": "",
        "orgName": "Eisai",
        "status": "",
        "postedDate": "2021-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20781,
        "nct_id": "NCT02481050",
        "studyTitle": "A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "HER2-Negative Metastatic Breast Cancer"
        ],
        "orgCode": "",
        "orgName": "Eisai",
        "status": "",
        "postedDate": "2021-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20782,
        "nct_id": "NCT00165815",
        "studyTitle": "The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Dementia With Parkinson\u2019s Disease"
        ],
        "orgCode": "",
        "orgName": "Eisai",
        "status": "",
        "postedDate": "2021-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20783,
        "nct_id": "NCT00543855",
        "studyTitle": "Double-blind Study of E2020 in Patients With Dementia With Lewy Bodies - Phase II",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Dementia with Lewy bodies"
        ],
        "orgCode": "",
        "orgName": "Eisai",
        "status": "",
        "postedDate": "2021-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20784,
        "nct_id": "NCT01278407",
        "studyTitle": "A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Dementia with Lewy bodies"
        ],
        "orgCode": "",
        "orgName": "Eisai",
        "status": "",
        "postedDate": "2021-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20788,
        "nct_id": "NCT02513472",
        "studyTitle": "An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC) (ENHANCE-1)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Metastatic Triple-Negative Breast Cancer"
        ],
        "orgCode": "",
        "orgName": "Eisai",
        "status": "",
        "postedDate": "2021-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20791,
        "nct_id": "NCT03562117",
        "studyTitle": "A Phase I, Open-Label, Single-Dose, Two-Part Study to Assess the Pharmacokinetics of Gepotidacin (GSK2140944) in Male and Female Adult Participants with Varying Degrees of Hepatic Impairment and in Matched Control Participants with Normal Hepatic Function",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Bacterial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20805,
        "nct_id": "NCT02791763",
        "studyTitle": "A 52-week, Phase III, open-label, multi-center study to evaluate efficacy and safety of GSK1278863 in Japanese non-dialysis and peritoneal dialysis subjects with anemia associated with chronic kidney disease",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Anaemia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20806,
        "nct_id": "NCT03031496",
        "studyTitle": "An open-label, randomized, single-dose, two-period cross-over study to evaluate bioequivalence of GSK3542503 hydrochlorothiazide + amiloride hydrochloride 50 mg: 5 mg fixed dose combination tablets versus reference product in healthy adult participants under fasting conditions",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Hypertension"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20808,
        "nct_id": "NCT03457727",
        "studyTitle": "A Two Part, Randomized, Open-label, Cross over Study in Healthy Elderly Participants to Evaluate the Relative Bioavailability of Hydrobromide Salt Tablet Formulations of Danirixin in the Fed and Fasted States, and to Evaluate the Effect of Food and Gastric Acid Secretion Suppression on Danirixin Pharmacokinetics Following Administration of Hydrobromide Salt Tablets",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20811,
        "nct_id": "NCT00171223",
        "studyTitle": "A phase II study to determine the efficacy and safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha (Extension 1: 2002-2004 and Extension 2: 2004-2013).",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Philadelphia chromosome positive acute lymphoblastic leukemia (PH+ ALL)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20813,
        "nct_id": "NCT00171249",
        "studyTitle": "A phase II study to determine the safety and anti-leukemic effects of STI571 in adult patients with Philadelphia chromosome positive leukemia including acute lymphoblastic leukemia, acute myeloid leukemia, lymphoid blast crisis chronic myeloid leukemia and accelerated phase chronic myeloid leukemia extended for a total of 11 years (Extension 1: 2002-2004 and Extension 2: 2004-2013)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Chronic myeloid leukemia (CML)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20814,
        "nct_id": "NCT00171249",
        "studyTitle": "A phase II study to determine the safety and anti-leukemic effects of STI571 in adult patients with Philadelphia chromosome positive leukemia including acute lymphoblastic leukemia, acute myeloid leukemia, lymphoid blast crisis chronic myeloid leukemia and accelerated phase chronic myeloid leukemia extended for a total of 11 years (Extension 1: 2002-2004 and Extension 2: 2004-2013)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Chronic myeloid leukemia (CML)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20815,
        "nct_id": "NCT00171158",
        "studyTitle": "A phase II open-label study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome-positive chronic myeloid leukemia in myeloid blast crisis extended for in total of 11 years (Extension 1: 2002-2004 and Extension 2: 2004- 2013)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Chronic myeloid leukemia (CML)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20816,
        "nct_id": "NCT00171158",
        "studyTitle": "A phase II open-label study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome-positive chronic myeloid leukemia in myeloid blast crisis extended for in total of 11 years (Extension 1: 2002-2004 and Extension 2: 2004- 2013)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Chronic myeloid leukemia (CML)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20817,
        "nct_id": "NCT00333840",
        "studyTitle": "A phase III study of imatinib versus interferon-\u00bf (IFN-\u00bf) combined with cytarabine (Ara-C) in patients with newly diagnosed previously untreated Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP).",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic myeloid leukemia (CML)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20818,
        "nct_id": "NCT01035229",
        "studyTitle": "A randomized Phase III, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of everolimus (RAD001) in adult patients with advanced hepatocellular carcinoma after failure of sorafenib treatment\u00bf the EVOLVE-1 Study",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hepatocellular carcinoma (HCC)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20822,
        "nct_id": "NCT03461289",
        "studyTitle": "Phase 3, Open Label, Single Arm, Single Dose Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy Type 1 with One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "SMA - Spinal Muscular Atrophy"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20828,
        "nct_id": "NCT03804710",
        "studyTitle": "A Clinical Study to Investigate the Effects of Two Developmental Cosmetic Moisturizing Cream Formulations on the Barrier Function of Human Skin on the Face and Legs",
        "overallStatus": "",
        "phase": NaN,
        "studyType": "",
        "conditions": [
            "Skin Care"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20829,
        "nct_id": "NCT00903175",
        "studyTitle": "An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as first-line followed by second-line RAD001 in the treatment of patients with metastatic renal cell carcinoma.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Renal cell carcinoma (RCC)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20830,
        "nct_id": "NCT01304693",
        "studyTitle": "Safety and Efficacy Study of ESBA1008 Versus LUCENTIS for the Treatment of Exudative Age-Related Macular Degeneration",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Wet age related macular degeneration (AMD)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20831,
        "nct_id": "NCT01796964",
        "studyTitle": "Efficacy and Safety Study of ESBA1008 Versus EYLEA",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Wet age related macular degeneration (AMD)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20832,
        "nct_id": "NCT01849692",
        "studyTitle": "A Prospective, Two-Staged, Single-Masked Study to Evaluate the Effect of ESBA1008 Applied by Microvolume Injection or Infusion in Subjects With Exudative Age-Related Macular Degeneration",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Wet age related macular degeneration (AMD)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20833,
        "nct_id": "NCT02507388",
        "studyTitle": "A Randomized, Double Masked, Three Dose Safety and Pharmacokinetic Study of RTH258 Following Intravitreal (IVT) Injection in Subjects With Neovascular Age-Related Macular Degeneration",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Neovascular Age-Related Macular Degeneration"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20834,
        "nct_id": "NCT02307682",
        "studyTitle": "A two-year, randomized, double-masked, multicenter, three-arm study comparing the efficacy and safety of RTH258 versus aflibercept in subjects with neovascular age-related macular degeneration",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Neovascular Age-Related Macular Degeneration"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20835,
        "nct_id": "NCT03386474",
        "studyTitle": "A 24-week, double-masked, multicenter, two-arm extension study to collect safety and efficacy data on brolucizumab 6 mg drug product intended for commercialization in subjects with neovascular age-related macular degeneration who have completed the CRTH258A2301 study",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Neovascular Age-Related Macular Degeneration"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20836,
        "nct_id": "NCT02434328",
        "studyTitle": "A Two-year, Randomized, Double-masked, Multicenter, Two-arm Study Comparing the Efficacy and Safety of RTH258 6 mg Versus Aflibercept in Subjects With Neovascular Age-related Macular Degeneration",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Neovascular Age-Related Macular Degeneration"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20837,
        "nct_id": "NCT01895361",
        "studyTitle": "A Phase II Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises, (SUSTAIN)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Sickle cell disease"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20838,
        "nct_id": "NCT02555683",
        "studyTitle": "A 52-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "asthma"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20839,
        "nct_id": "NCT02563067",
        "studyTitle": "A 52-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe Asthma.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "asthma"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20843,
        "nct_id": "NCT02868281",
        "studyTitle": "The effectiveness of Asthma Control Test guided treatment compared with usual care in China adult asthma patients",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20846,
        "nct_id": "NCT01953835",
        "studyTitle": "A two-part healthy volunteer study to investigate both the interaction of GSK2586184 with rosuvastatin and simvastatin and to compare the pharmacokinetics of two different formulations of GSK2586184.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Systemic Lupus Erythematosus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20849,
        "nct_id": "NCT02849418",
        "studyTitle": "A phase III study to evaluate the efficacy and safety of GSK1358820 (botulinum toxin type A) in patients with urinary incontinence due to neurogenic detrusor overactivity",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Urinary Bladder",
            "Overactive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20850,
        "nct_id": "NCT03345407",
        "studyTitle": "A Phase IIb, Randomized (Stratified), Double-Blind (Sponsor Open), Parallel-Group, Placebo-Controlled, Dose-Finding Study of Nemiralisib (GSK2269557) Added to Standard of Care (SoC) Versus SoC Alone in Participants Diagnosed with an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20851,
        "nct_id": "NCT03474081",
        "studyTitle": "A Phase IV, 12 week, randomised, double-blind, double-dummy study to compare single inhaler triple therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), with tiotropium monotherapy based on lung function and symptoms in participants with chronic obstructive pulmonary disease",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20852,
        "nct_id": "NCT01262898",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects with Gastroparesis",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Gastroparesis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20853,
        "nct_id": "NCT01638013",
        "studyTitle": "Open-label Extension Study in Rheumatoid Arthritis Patients Who Have Completed Phase 2b Study or Phase 3 Study of ASP015K",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Rheumatoid Arthritis"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2021-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20855,
        "nct_id": "NCT01783444",
        "studyTitle": "A three-arm, randomized, open label, Phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenopausal women with estrogen receptor positive, locally advanced, recurrent, or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Breast Cancer"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20856,
        "nct_id": "NCT00363051",
        "studyTitle": "An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancre-atic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Pancreatic neuroendocrine tumor (PNET)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20857,
        "nct_id": "NCT00412061",
        "studyTitle": "A randomized, double-blind, placebo-controlled, multicenter phase III study in patients with advanced carcinoid tumor receiving Sandostatin LAR\u00ae Depot and RAD001 10 mg/d or San-dostatin LAR\u00ae Depot and placebo",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Carcinoid tumor"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20858,
        "nct_id": "NCT00510068",
        "studyTitle": "A randomized double-blind phase III study of everolimus 10 mg/d plus best supportive care (BSC) versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuro-endocrine tumor (NET)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Pancreatic neuroendocrine tumor (PNET)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20859,
        "nct_id": "NCT02294734",
        "studyTitle": "A randomised, double-blind (sponsor unblinded), placebo-controlled, parallel-group, multicentre study to evaluate the efficacy and safety of GSK2269557 administered in addition to standard of care in adult subjects diagnosed with an acute exacerbation of Chronic Obstructive Pulmonary Disease",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20860,
        "nct_id": "NCT02424799",
        "studyTitle": "A randomised double blind (sponsor unblinded), single and repeat ascending dose First Time in Human study in healthy subjects, cold urticaria and chronic spontaneous urticaria subjects to investigate safety, tolerability, pharmacodynamics and pharmacokinetics of topically applied GSK2646264",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Urticaria"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20861,
        "nct_id": "NCT02522299",
        "studyTitle": "A randomised, double-blind, placebo-controlled study to evaluate the safety, efficacy and changes in induced sputum and blood biomarkers following daily repeat doses of inhaled GSK2269557 for 12 weeks in adult subjects diagnosed with an acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD).",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20862,
        "nct_id": "NCT01632241",
        "studyTitle": "A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race with Systemic Lupus Erythematosus (SLE)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Systemic Lupus Erythematosus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20863,
        "nct_id": "NCT03266172",
        "studyTitle": "A three part, non-randomised, open label study designed to assess the pharmacokinetics of GSK2982772 following administration of minitab modified release formulations in a capsule relative to an immediate release reference tablet formulation (Part A), the pharmacokinetics of escalating, repeat doses of a selected minitab modified release prototype (Part B), and the pharmacokinetics of GSK2982772 following administration of modified release tablet formulations in the fed and fasted state (Part C) in healthy participants",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Autoimmune Diseases"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20864,
        "nct_id": "NCT03674177",
        "studyTitle": "A Phase I/II randomized observer-blind placebo controlled study to evaluate the safety, reactogenicity and immunogenicity of different dose levels of GSK Biologicals\u2019 investigational unadjuvanted RSV Maternal vaccine (GSK3888550A) compared to placebo when administered to healthy non-pregnant women aged 18-45 years",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Respiratory Syncytial Virus Infections"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20865,
        "nct_id": "NCT03807700",
        "studyTitle": "A randomized, single-blind, efficacy study to evaluate oral health and quality of life associated with use of a denture adhesive",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Denture Retention"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20866,
        "nct_id": "NCT04006795",
        "studyTitle": "A Photo-irritation and Photo-sensitisation study in Healthy Subjects for Three Developmental Cosmetic Facial Products",
        "overallStatus": "",
        "phase": NaN,
        "studyType": "",
        "conditions": [
            "Skin Care"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20867,
        "nct_id": "NCT01966445",
        "studyTitle": "A Phase I, First Time in Human, Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Anti-Her3 Monoclonal Antibody GSK2849330 in Subjects with Advanced Her3-Positive Solid Tumors",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Cancer|Neoplasms"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20868,
        "nct_id": "NCT02555371",
        "studyTitle": "A multi-center, randomized, double-blind, placebo controlled, parallel group study to compare cessation versus continuation of long-term mepolizumab treatment in patients with severe eosinophilic asthma (201810)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20869,
        "nct_id": "NCT02719743",
        "studyTitle": "An observer-blind, dose ranging safety and immunogenicity study of GSK Biologicals\u2019 GSK1557484A vaccine in children 6 to less than 36 months of age",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Influenza"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20870,
        "nct_id": "NCT03184987",
        "studyTitle": "A Phase III, 52-week, Open-label Study to Evaluate Long-term Safety of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Patients with Asthma",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20877,
        "nct_id": "NCT02745080",
        "studyTitle": "A randomized, double-blind, active control, multicenter study to evaluate the efficacy at week 52 of secukinumab monotherapy compared with adalimumab monotherapy in patients with active psoriatic arthritis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Psoriatic arthritis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20878,
        "nct_id": "NCT01336634",
        "studyTitle": "A Phase II Study of the BRAF Inhibitor Dabrafenib as a Single Agent and in Combination With the MEK Inhibitor Trametinib in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Cancer"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20880,
        "nct_id": "NCT01245062",
        "studyTitle": "A Phase III Randomized, Open-label Study Comparing GSK1120212 to Chemotherapy in Subjects With Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Melanoma"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20882,
        "nct_id": "NCT02267135",
        "studyTitle": "A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to demonstrate the efficacy of subcutaneous secukinumab 300 mg as assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 weeks of treatment, compared to placebo, and to assess safety and tolerability up to 24 weeks in adult subjects with moderate to severe scalp psoriasis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Moderate to severe scalp psoriasis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20883,
        "nct_id": "NCT01257451",
        "studyTitle": "A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin in type 2 diabetes mellitus patients  70 years (drug-na\u00efve or inadequately controlled on oral agents)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Type 2 Diabetes"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20884,
        "nct_id": "NCT01224366",
        "studyTitle": "A 24-week, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of vildagliptin 50mg bid as an add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Type 2 Diabetes"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20885,
        "nct_id": "NCT00894868",
        "studyTitle": "A multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate the effect of 52 weeks treatment with vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Type 2 Diabetes"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20886,
        "nct_id": "NCT00860288",
        "studyTitle": "A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as add-on therapy to metformin in patients with type 2 diabetes",
        "overallStatus": "",
        "phase": "Phase 2/3",
        "studyType": "",
        "conditions": [
            "Type 2 Diabetes"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20887,
        "nct_id": "NCT00765830",
        "studyTitle": "A 28 week extension to a 24 week multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of vildagliptin (50mg qd) versus placebo in patients with type 2 diabetes and moderate or severe renal insufficiency",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Type 2 Diabetes"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20888,
        "nct_id": "NCT00646542",
        "studyTitle": "A multi-center, randomized, double-blind, clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd) versus placebo in patients with type 2 diabetes and moderate or severe renal insufficiency",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Type 2 Diabetes"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20889,
        "nct_id": "NCT00383578",
        "studyTitle": "A Multi-center, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 24 Weeks Treatment with Vildagliptin 100 mg qd or Metformin 1500 mg daily in Elderly Drug Na\u00efve Patients with Type 2 Diabetes",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Type 2 Diabetes"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20891,
        "nct_id": "NCT00106340",
        "studyTitle": "A multicenter, randomized, double-blind, active controlled study to compare the long-term effect of treatment with LAF237 50 mg bid to glimepiride up to 6 mg daily as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Type 2 Diabetes"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20892,
        "nct_id": "NCT00102388",
        "studyTitle": "A multicenter, double-blind, randomized, active controlled study to compare the effect of long term treatment with LAF237 50 mg bid to gliclazide up to 320 mg daily in drug na\u00efve patients with type 2 diabetes",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Type 2 Diabetes"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20893,
        "nct_id": "NCT00099944",
        "studyTitle": "A multicenter, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment with LAF237 (50 mg qd or bid) to placebo as add-on therapy to glimepiride in patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Type 2 Diabetes"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20894,
        "nct_id": "NCT00099918",
        "studyTitle": "A multicenter, randomized, double-blind, active controlled study to compare the effect of 24 weeks treatment with LAF237 50 mg bid to rosiglitazone 8 mg qd in drug-naive patients with type 2 diabetes",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Type 2 Diabetes"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20895,
        "nct_id": "NCT00099866",
        "studyTitle": "A multicenter, randomized, double-blind, active controlled study to compare the effect of 52 weeks treatment with LAF237 50 mg bid to metformin up to 1000 mg bid in drug na\u00efve patients with type 2 diabetes.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Type 2 Diabetes"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20896,
        "nct_id": "NCT00102466",
        "studyTitle": "A Multicenter, Double-Blind, Randomized, Active Controlled Study to Compare the Effect of 52 Weeks Treatment with LAF237 50 mg bid to Gliclazide up to 320 mg Daily as Add-On Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Type 2 Diabetes"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20897,
        "nct_id": "NCT03245619",
        "studyTitle": "Randomized, Double-blind, Placebo Controlled Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses (Intravenous bolus) and constant intravenous infusion over 7 Days of GSK3335065 in Healthy Adult Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Pancreatitis",
            "Acute Necrotizing"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20898,
        "nct_id": "NCT03287310",
        "studyTitle": "A randomised double-blind (sponsor open), placebo controlled, single ascending dose, First Time in Human study in participants with mild to moderate asthma to assess safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of GSK3511294 administered subcutaneously",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20900,
        "nct_id": "NCT03359850",
        "studyTitle": "An Open-Label, Non-Randomized, Multicenter Study to Determine the Pharmacokinetics and Safety of Niraparib Following a Single Oral Dose in Patients with Advanced Solid Tumors and Either Normal Hepatic Function or Moderate Hepatic Impairment",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Ovarian Neoplasms|Neoplasms|Solid Tumor|Hepatic Impairment"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20901,
        "nct_id": "NCT02141204",
        "studyTitle": "Immunogenicity and safety study of two different formulations of GlaxoSmithKline (GSK) Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine, Rotarix in healthy infants",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Rotavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20902,
        "nct_id": "NCT02215096",
        "studyTitle": "A Phase I, Open-label, Dose-finding Study of GSK2636771 Administered in Combination with Enzalutamide (Xtandi^TM ) in Male Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Neoplasms"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20903,
        "nct_id": "NCT02292784",
        "studyTitle": "Follow-Up Study to Assess Long-Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Obstetric Labour",
            "Premature"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20904,
        "nct_id": "NCT03372603",
        "studyTitle": "A placebo-controlled, double-blind (sponsor open), randomized, crossover study to assess the efficacy, safety, and tolerability of GSK2798745 in participants with chronic cough",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Cough"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20906,
        "nct_id": "NCT02903966",
        "studyTitle": "A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study with open label extension to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with active ulcerative colitis.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Colitis",
            "Ulcerative"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20907,
        "nct_id": "NCT03527173",
        "studyTitle": "A phase IIb randomized, placebo controlled, single centre observer blind, human-challenge study to evaluate the efficacy, safety and immunogenicity of  2 vaccinations with GVGH Shigella sonnei vaccine (1790GAHB) administered by intramuscular route in  healthy non-immune adult population.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Dysentery",
            "Bacillary"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20908,
        "nct_id": "NCT03824236",
        "studyTitle": "A Phase IIa, open-label, non-randomized, controlled, mono-center study to evaluate the efficacy, immunogenicity and safety of a fractional (Fx) booster dose of GlaxoSmithKline Biologicals\u2019 malaria candidate vaccine RTS,S/AS01E when given to healthy adults subjects previously receiving various primary dose schedules in a sporozoite challenge model.",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Malaria"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20909,
        "nct_id": "NCT04136145",
        "studyTitle": "An open-label, randomized, parallel group, single dose study to investigate the PK and safety of belimumab 200 mg intravenous and 200 mg subcutaneous via auto-injector in Chinese healthy participants.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Systemic Lupus Erythematosus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20910,
        "nct_id": "NCT02946385",
        "studyTitle": "A Phase 2b, Open-Label, Multi-Center Study Assessing the Immunological Persistence of Antibodies at Approximately 2 years After the last Meningococcal Vaccination in Study V102_15 and the Response to a Booster dose of GSK MenABCWY or Meningococcal Serogroup B Vaccines, in Healthy Adolescents",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Meningococcal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20911,
        "nct_id": "NCT02212457",
        "studyTitle": "A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of GSK Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to GSK Meningococcal group B vaccine, in Healthy Adolescents",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Infections",
            "Meningococcal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20912,
        "nct_id": "NCT03433482",
        "studyTitle": "A phase 2b, randomized, controlled, observer-blind, multi-center study to evaluate safety and immunogenicity of different formulations of GSK Biologicals\u2019 Meningococcal ACWY conjugate vaccine (GSK3536820A and Menveo) administered to healthy adolescents and young adults 10 to 40 years of age)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Meningitis",
            "Meningococcal"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20919,
        "nct_id": "NCT02853435",
        "studyTitle": "A Phase I; Multi-Center; Open-Label (Parts 1 and 2); Randomized, Double-Blind, Placebo-Controlled (Part 3); Single-Dose; 3-Part Study to Evaluate the Relative Bioavailability of Three Formulations in Healthy Subjects, Food Effect on Tablet Formulation in Healthy Subjects, and Pharmacokinetics of Gepotidacin (GSK2140944) in Japanese Subjects in Fasted and Fed States",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Bacterial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20920,
        "nct_id": "NCT04079790",
        "studyTitle": "A Phase I, Double-Blind, Two-Part, Sequential Study to Evaluate the Pharmacokinetics of Gepotidacin Tablets in Healthy Adult and Adolescent Participants",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Infections",
            "Bacterial"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20921,
        "nct_id": "NCT02981602",
        "studyTitle": "A Phase 2, Double-Blinded, Randomized, Placebo-Controlled, Dose-Escalation Study to Examine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ISIS 505358 in Treatment-Na\u00efve Patients with Chronic HBV Infection",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2021-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20929,
        "nct_id": "NCT01261572",
        "studyTitle": "ASP3550 Phase II Study - A Maintenance-Dose-Finding Study of Three-Month Depot in Patients with Prostate Cancer -",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Prostate Cancer"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2021-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20930,
        "nct_id": "NCT01964170",
        "studyTitle": "Phase III Study of ASP3550 \u2013 An Open-label, Goserelin Acetate-controlled, Parallel Group Study in Patients with Prostate Cancer \u2013",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Prostate Cancer"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2021-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20940,
        "nct_id": "NCT02565511",
        "studyTitle": "A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (GS1)",
        "overallStatus": "",
        "phase": "Phase 2/3",
        "studyType": "",
        "conditions": [
            "Alzheimers Disease"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20941,
        "nct_id": "NCT03131453",
        "studyTitle": "A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (GS2)",
        "overallStatus": "",
        "phase": "Phase 2/3",
        "studyType": "",
        "conditions": [
            "Alzheimers Disease"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20942,
        "nct_id": "NCT02918968",
        "studyTitle": "Postmarketing clinical study on enzalutamide \u2014a randomized phase 4 study comparing enzalutamide versus flutamide in castration-resistant prostate cancer patients who have failed combined androgen blockade therapy with bicalutamide plus androgen deprivation therapy\u2014",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Prostate Cancer"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2022-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20944,
        "nct_id": "NCT02563496",
        "studyTitle": "An Open Label, Non-comparative, Multicenter Study to Assess the Pharmacokinetics, Safety and Efficacy of Tafenoquine (SB-252263, WR238605) in the Treatment of Pediatric Subjects with Plasmodium vivax Malaria",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Malaria",
            "Vivax"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2022-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20945,
        "nct_id": "NCT03258710",
        "studyTitle": "A multi-centre, one-arm prospective study to evaluate efficacy and safety of switching from Entecavir (ETV) to Tenofovir Disoproxil Fumarate (TDF) in Japanese chronic hepatitis B HBeAg-positive and HBV-DNA undetectable subjects",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Hepatitis B",
            "Chronic"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2022-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20947,
        "nct_id": "NCT03308942",
        "studyTitle": "Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination with PD-1 Inhibitor in Patients with Non-Small Cell Lung Cancer",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Neoplasms|Lung Neoplasms"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2022-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20991,
        "nct_id": "NCT04318535",
        "studyTitle": "An open label, randomized, balanced, three treatment, three period, three sequence, single dose, crossover study to evaluate the bioequivalence of test Griseofulvin tablets, 500 mg versus reference Griseofulvin tablets, 500 mg as well as dose proportionality of test Griseofulvin tablets, 250 mg and 500 mg, in healthy, adult participants under fed conditions",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Antifungal Agents"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2022-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20993,
        "nct_id": "NCT03945981",
        "studyTitle": "A Phase 3b multi-center, open label, single arm, 52-week study, evaluating the feasibility, efficacy and safety of rapid Test and Treat intervention in newly diagnosed HIV-1 infected adults using a fixed dose combination of dolutegravir plus lamivudine (DOVATO) as a first line regimen",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "HIV Infections"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2021-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20994,
        "nct_id": "NCT03816696",
        "studyTitle": "An Open-Label Two-way Interaction Clinical Trial to Evaluate the Pharmacokinetic Interactions Between GSK3640254 and Dolutegravir in Healthy Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "HIV Infections"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2021-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20995,
        "nct_id": "NCT03836729",
        "studyTitle": "An Open-Label One-way Interaction Clinical Trial to Evaluate the Pharmacokinetic Interactions Between GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "HIV Infections"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2021-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 20996,
        "nct_id": "NCT03984825",
        "studyTitle": "The Effect of Coadministration of GSK3640254 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "HIV Infections"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2022-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21004,
        "nct_id": "NCT02404350",
        "studyTitle": "Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis (FUTURE5)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Psoriatic Arthritis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21005,
        "nct_id": "NCT03078556",
        "studyTitle": "An Open-label, Randomized, Single dose, Crossover, Pivotal Bioequivalence Study of Fixed-dose Combination Tablets of Dolutegravir and Lamivudine versus Dolutegravir and Lamivudine single entities and Food Effect Assessment in Healthy Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "HIV Infections"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2022-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21006,
        "nct_id": "NCT03095638",
        "studyTitle": "A 2-Part, Phase I, Single Dose, Crossover Relative Bioavailability Study of Both TIVICAY 10 mg Conventional Tablets and 5 mg Dispersible Tablets Compared to Conventional TIVICAY Tablets in Healthy Adult Subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "HIV Infections"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2022-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21007,
        "nct_id": "NCT02738931",
        "studyTitle": "A Phase I, relative oral bioavailability study of different fixed dose combinations of dolutegravir and lamivudine in healthy subjects",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "HIV Infections"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2022-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21008,
        "nct_id": "NCT03441984",
        "studyTitle": "A 2-Part, Phase I, Single-Dose, 3-Period Crossover Relative Bioavailability Study of a Pediatric TRIUMEQ Dispersible Tablet and Pediatric Dolutegravir and Lamivudine (DTG/3TC) Fixed Dose Combination Dispersible Tablet Formulations as Compared With Adult Tablets in Healthy Volunteers",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "HIV Infections"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2022-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21009,
        "nct_id": "NCT02119156",
        "studyTitle": "An Open-label, Non-randomized, 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment With Belimumab 10 mg/kg in Systemic Lupus Erythematosus Subjects",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Systemic Lupus Erythematosus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2022-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21011,
        "nct_id": "NCT03954743",
        "studyTitle": "Safety study of 2 formulations of GSK\u2019s HRV vaccine (444563), in healthy infants starting at age 6-12 weeks",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infections",
            "Rotavirus"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2022-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21012,
        "nct_id": "NCT04090658",
        "studyTitle": "Phase I, observer-blind, safety, reactogenicity and immunogenicity study of GSK\u2019s respiratory syncytial virus (RSV) vaccine GSK3844766A in Japanese subjects aged 60-80 years",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Respiratory Syncytial Virus Infections"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2022-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21018,
        "nct_id": "NCT01961609",
        "studyTitle": "Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants. (SIGNATURE)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Psoriasis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21019,
        "nct_id": "NCT00805480",
        "studyTitle": "Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Chronic Plaque Psoriasis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21020,
        "nct_id": "NCT02559622",
        "studyTitle": "Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab (CARIMA)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Psoriasis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21021,
        "nct_id": "NCT02690701",
        "studyTitle": "Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis (VIP-S)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Chronic Plaque Psoriasis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21022,
        "nct_id": "NCT02748863",
        "studyTitle": "Study of Secukinumab With 2 mL Pre-filled Syringes (ALLURE)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Psoriasis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21023,
        "nct_id": "NCT03066609",
        "studyTitle": "Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Plaque Psoriasis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21024,
        "nct_id": "NCT03055494",
        "studyTitle": "Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients (ObePso-S)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Plaque Psoriasis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21025,
        "nct_id": "NCT03504852",
        "studyTitle": "Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Moderate to Severe Chronic Plaque-type Psoriasis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21026,
        "nct_id": "NCT03589885",
        "studyTitle": "Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis (MATURE)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Plaque Psoriasis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21027,
        "nct_id": "NCT02474082",
        "studyTitle": "Study of Secukinumab Compared to Fumaderm\u00ae in Adults With Moderate to Severe Psoriasis. (PRIME)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Psoriasis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21028,
        "nct_id": "NCT00720941",
        "studyTitle": "Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma (COMPARZ)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Carcinoma",
            "Renal Cell"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21029,
        "nct_id": "NCT02699099",
        "studyTitle": "Phase III randomized, open controlled, multicenter study to evaluate the immunogenicity and safety of the RTS,S/AS01E candidate malaria vaccine, when administered as primary vaccination at 6, 7.5 and 9 months of age with or without co-administration of measles and rubella and yellow fever vaccines to children living in sub-Saharan Africa",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Malaria"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2022-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21030,
        "nct_id": "NCT03275389",
        "studyTitle": "A Phase I/II, randomized, controlled, observer-blind, multi-center study to assess the reactogenicity, safety and immunogenicity of three GlaxoSmithKline (GSK) Biologicals\u2019 investigational supra-seasonal universal influenza vaccines (SUIVs) (unadjuvanted or adjuvanted with AS03 or AS01) administered as a 1 or 2-dose priming schedule followed by a booster dose 12 months post-primary vaccination in 18 to 39 year-old healthy subjects.",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Influenza",
            "Human"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2022-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21031,
        "nct_id": "NCT02177812",
        "studyTitle": "A phase I open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2879552 given orally in subjects with relapsed/refractory acute myeloid leukemia",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Leukaemia",
            "Myelocytic",
            "Acute"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2022-01-06T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21033,
        "nct_id": "NCT02025556",
        "studyTitle": "A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Episodic Migraine Headache"
        ],
        "orgCode": "",
        "orgName": "Teva",
        "status": "",
        "postedDate": "2022-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21036,
        "nct_id": "NCT00202982",
        "studyTitle": "A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone\u00ae Compared to Copaxone\u00ae 20mg, the Currently Approved Dose",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Relapse-Remitting Multiple Sclerosis"
        ],
        "orgCode": "",
        "orgName": "Teva",
        "status": "",
        "postedDate": "2022-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21037,
        "nct_id": "NCT00337779",
        "studyTitle": "Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Relapsing Remitting Multiple Sclerosis"
        ],
        "orgCode": "",
        "orgName": "Teva",
        "status": "",
        "postedDate": "2022-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21038,
        "nct_id": "NCT01874145",
        "studyTitle": "Safety and Tolerability of Glatiramer Acetate (GLACIER)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Relapsing-Remitting Multiple Sclerosis"
        ],
        "orgCode": "",
        "orgName": "Teva",
        "status": "",
        "postedDate": "2022-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21041,
        "nct_id": "NCT01508936",
        "studyTitle": "Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Eosinophilic Asthma"
        ],
        "orgCode": "",
        "orgName": "Teva",
        "status": "",
        "postedDate": "2022-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21042,
        "nct_id": "NCT02696031",
        "studyTitle": "Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis (PREVENT)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Non-radiographic Spondyloarthritis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21043,
        "nct_id": "NCT03136861",
        "studyTitle": "SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis (SKIPPAIN)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Spondyloarthritis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21044,
        "nct_id": "NCT02314442",
        "studyTitle": "A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "Hypercholesterolemia"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21045,
        "nct_id": "NCT01327846",
        "studyTitle": "Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) (CANTOS)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Atherosclerosis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21047,
        "nct_id": "NCT00238485",
        "studyTitle": "An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Bipolar I Disorder"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21048,
        "nct_id": "NCT00107939",
        "studyTitle": "Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Bipolar Disorder"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21053,
        "nct_id": "NCT01227889",
        "studyTitle": "A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Melanoma"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2018-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21055,
        "nct_id": "NCT03020745",
        "studyTitle": "A Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dose and Multiple Doses of GSK3389404 in Chronic Hepatitis B Subjects",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Hepatitis B"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2022-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21056,
        "nct_id": "NCT03422172",
        "studyTitle": "An Open Label, Phase 1 Study to Evaluate the PK, Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, Cabotegravir (CAB; GSK1265744) in HIV Uninfected Chinese Men",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "HIV Infections"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2022-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21057,
        "nct_id": "NCT02603393",
        "studyTitle": "Evaluation of the Efficacy and Safety of QVA149 (110/50 \u03bcg o.d.) vs Tiotropium (18 \u00b5g o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 \u00b5g b.i.d.) in Patients With Moderate to Severe COPD",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Chronic Obstructive Pulmonary Disease (COPD)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21058,
        "nct_id": "NCT01555138",
        "studyTitle": "Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.) (INSTEAD)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Chronic Obstructive Pulmonary Disease (COPD)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21059,
        "nct_id": "NCT00820222",
        "studyTitle": "Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Metastases",
            "Brain"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-09T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21063,
        "nct_id": "NCT01235962",
        "studyTitle": "A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects With Localized or Locally Advanced RCC Following Nephrectomy",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Renal cell carcinoma"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2020-01-05T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21064,
        "nct_id": "NCT02375971",
        "studyTitle": "RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity (RAINBOW)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Retinopathy of Prematurity"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21065,
        "nct_id": "NCT01920711",
        "studyTitle": "Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Heart Failure With Preserved Ejection Fraction"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21066,
        "nct_id": "NCT02227238",
        "studyTitle": "A Phase 3b, randomised, open-label study of the antiviral activity and safety of dolutegravir compared to lopinavir/ritonavir both administered with dual nucleoside reverse transcriptase inhibitor therapy in HIV-1 infected adult subjects with treatment failure on first line therapy",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "HIV Infections"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2022-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21067,
        "nct_id": "NCT03629886",
        "studyTitle": "Safety and protective effect study of GSK Biologicals\u2019 Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in healthy female subjects from the HPV-039 study.",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Cervical Intraepithelial Neoplasia"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2022-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21068,
        "nct_id": "NCT01649375",
        "studyTitle": "16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis (MEASURE2)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Anklyosing Spondylitis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21069,
        "nct_id": "NCT02008916",
        "studyTitle": "16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients (MEASURE 3)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Spondylitis",
            "Ankylosing"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21070,
        "nct_id": "NCT03031782",
        "studyTitle": "Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Juvenile Psoriatic Arthritis",
            "Enthesitis-related Arthritis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2022-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21071,
        "nct_id": "NCT04001803",
        "studyTitle": "A qualitative hybrid III implementation study to identify and evaluate strategies for successful implementation of the cabotegravir + rilpivirine long-acting injectable regimen in the US",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "HIV Infections"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2022-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21072,
        "nct_id": "NCT03984812",
        "studyTitle": "A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK3732394 in Healthy Participants",
        "overallStatus": "",
        "phase": "Phase 1",
        "studyType": "",
        "conditions": [
            "HIV Infections"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2022-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21073,
        "nct_id": "NCT03446573",
        "studyTitle": "A Phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1-infected adults who are virologically suppressed",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "HIV Infections"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2022-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21074,
        "nct_id": "NCT01639339",
        "studyTitle": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active Lupus Nephritis",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Lupus Nephritis"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2022-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21075,
        "nct_id": "NCT03207243",
        "studyTitle": "A randomized, double-blind, parallel group, multicenter, stratified study evaluating the efficacy and safety of repeat doses of GSK3772847 compared with placebo in participants with moderately severe asthma",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Asthma"
        ],
        "orgCode": "",
        "orgName": "GSK",
        "status": "",
        "postedDate": "2022-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21084,
        "nct_id": "NCT03560739",
        "studyTitle": "A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Multiple Sclerosis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21085,
        "nct_id": "NCT02792218",
        "studyTitle": "Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis (ASCLEPIOS I)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Relapsing Multiple Sclerosis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21086,
        "nct_id": "NCT02792231",
        "studyTitle": "Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis. (ASCLEPIOS II)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Relapsing Multiple Sclerosis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21087,
        "nct_id": "NCT02913261",
        "studyTitle": "Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation (REACH2)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Corticosteroid Refractory Acute Graft vs Host Disease"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-02T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21088,
        "nct_id": "NCT02228096",
        "studyTitle": "Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients (ENSIGN)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "B-cell Acute Lymphoblastic Leukemia",
            "\r\nRelapsed B-cell Acute Lymphoblastic Leukemia",
            "\r\nRefractory B-cell Acute Lymphoblastic Leukemia"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21100,
        "nct_id": "NCT02159053",
        "studyTitle": "16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis (MEASURE4)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Anklyosing Spondylitis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21103,
        "nct_id": "NCT01399125",
        "studyTitle": "A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Alzheimer's Disease"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-04T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21106,
        "nct_id": "NCT02039947",
        "studyTitle": "BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Melanoma"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2021-01-03T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21108,
        "nct_id": "NCT00238498",
        "studyTitle": "A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21109,
        "nct_id": "NCT00099957",
        "studyTitle": "A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 Diabetes",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21110,
        "nct_id": "NCT00351832",
        "studyTitle": "A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 12 Weeks Treatment With Vildagliptin (50mg qd, 50mg Bid, 100mg qd) to Placebo in Patients With Type 2 Diabetes",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21111,
        "nct_id": "NCT00099905",
        "studyTitle": "A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21112,
        "nct_id": "NCT00494884",
        "studyTitle": "A Multicenter, Randomized, Double-blind, Parallel-group Study to Investigate the Glucose Lowering Effect, Safety and Tolerability of 24 Weeks Treatment With Vildagliptin 100 mg o.d. Versus Placebo Followed by a 12 Weeks Treatment Period With Open-label Vildagliptin 100 mg o.d. as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21113,
        "nct_id": "NCT01862263",
        "studyTitle": "Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes (VIDA)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21114,
        "nct_id": "NCT00380380",
        "studyTitle": "A Study to Assess the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Diabetes Mellitus",
            "Type 2"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21115,
        "nct_id": "NCT02435849",
        "studyTitle": "Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients (ELIANA)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "B-cell Acute Lymphoblastic Leukemia"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21116,
        "nct_id": "NCT02874794",
        "studyTitle": "Study of Effects of Sacubitril/\u200bValsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction (EVALUATE-HF)",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Heart Failure and Reduced Ejection Fraction"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21117,
        "nct_id": "NCT03205150",
        "studyTitle": "Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Obese Patients With Non-alcoholic Steatohepatitis (NASH)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-07T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21118,
        "nct_id": "NCT02799745",
        "studyTitle": "A Randomized Study of Enzalutamide in Patients with Localized Prostate Cancer Undergoing Active Surveillance (ENACT)",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Prostate Cancer"
        ],
        "orgCode": "",
        "orgName": "Astellas",
        "status": "",
        "postedDate": "2023-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21119,
        "nct_id": "NCT01524783",
        "studyTitle": "A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Advanced NET of GI Origin",
            "Advanced NET of Lung Origin",
            "Neuroendocrine Tumors"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21120,
        "nct_id": "NCT02640664",
        "studyTitle": "RAINBOW Extension Study: an Extension Study to Evaluate the Long Term Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Retinopathy of Prematurity (ROP)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21121,
        "nct_id": "NCT02970669",
        "studyTitle": "Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Ejection Fraction (AWAKE-HF).",
        "overallStatus": "",
        "phase": "Phase 4",
        "studyType": "",
        "conditions": [
            "Heart Failure",
            "Reduced Ejection Fraction"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21122,
        "nct_id": "NCT02900378",
        "studyTitle": "randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure (OUTSTEP-HF)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Chronic Heart Failure With Reduced Ejection Fraction"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-08T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21126,
        "nct_id": "NCT00094367",
        "studyTitle": "A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Infection",
            "Human Immunodeficiency Virus"
        ],
        "orgCode": "",
        "orgName": "ViiV",
        "status": "",
        "postedDate": "2014-01-01T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21127,
        "nct_id": "NCT04072887",
        "studyTitle": "Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Pulmonary Disease",
            "Chronic Obstructive"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21128,
        "nct_id": "NCT00386763",
        "studyTitle": "Efficacy and Safety of the Pediatric Formulation of Artemether- Lumefantrine in Children With Uncomplicated P. Falciparum Malaria.",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Malaria",
            "Falciparum"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-10T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21132,
        "nct_id": "NCT04362137",
        "studyTitle": "Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Cytokine Storm (Covid-19)"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-11T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21133,
        "nct_id": "NCT03399370",
        "studyTitle": "A Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Low-Density Lipoprotein Cholesterol (LDL-C)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "ASCVD;\r\nElevated Cholesterol"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21134,
        "nct_id": "NCT03400800",
        "studyTitle": "A Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Atherosclerotic Cardiovascular Disease (ASCVD) or ACSVD Risk-Equivalents and Elevated Low-Density Lipoprotein Cholesterol (LDL-C)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "ASCVD;\r\nRisk Factor",
            "Cardiovascular;\r\nElevated Cholesterol"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21135,
        "nct_id": "NCT02888080",
        "studyTitle": "A Multiple-dose, Subject and Investigator Blinded, Placebo-controlled, Parallel Design Study to Assess the Efficacy, Safety and Tolerability of ACZ885(Canakinumab) in Patients With Pulmonary Sarcoidosis",
        "overallStatus": "",
        "phase": "Phase 2",
        "studyType": "",
        "conditions": [
            "Pulmonary Sarcoidosis"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21136,
        "nct_id": "NCT03713619",
        "studyTitle": "A Randomized, Double-blind, Multi-center Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNSHINE).",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hidradenitis Suppurativa"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    },
    {
        "study_id": 21137,
        "nct_id": "NCT03713632",
        "studyTitle": "A Randomized, Double-blind, Multicenter Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNRISE)",
        "overallStatus": "",
        "phase": "Phase 3",
        "studyType": "",
        "conditions": [
            "Hidradenitis Suppurativa"
        ],
        "orgCode": "",
        "orgName": "Novartis",
        "status": "",
        "postedDate": "2023-01-12T00:00:00",
        "therapeuticAreas": [],
        "extractedInterventions": [],
        "bulkUploadContentType": "",
        "documentType": ""
    }
]